

SCANNED, # 8

12 FEB 2002

FORM PTO-1390 (Modified) (REV 5-93)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	
TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371		ATTORNEY'S DOCKET NUMBER 065691-0270	
INTERNATIONAL APPLICATION NO. PCT FR00/02319	INTERNATIONAL FILING DATE 08/11/2000	U.S. APPLICATION NO. (If known, see 37 CFR 1.50) Unassigned	107049372
TITLE OF INVENTION Odorant-Binding Human Proteins Fixing Hydrophobic Ligands: Polypeptides and Polynucleotides Coding for said polypeptides and Uses Thereof			
APPLICANT(S) FOR DO/EO/US Gilles PITIOT, Eric LACAZETTE and Francoise GACHON Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:			
<p>1. <input checked="" type="checkbox"/> This is a FIRST submission of items concerning a filing under 35 U.S.C. 371.</p> <p>2. <input type="checkbox"/> This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371.</p> <p>3. <input type="checkbox"/> This express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1).</p> <p>4. <input checked="" type="checkbox"/> A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.</p> <p>5. <input checked="" type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 371(c)(2)). <input type="checkbox"/> is transmitted herewith (required only if not transmitted by the International Bureau). <input checked="" type="checkbox"/> has been transmitted by the International Bureau. <input type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US).</p> <p>6. <input type="checkbox"/> A translation of the International Application into English (35 U.S.C. 371(c)(2)).</p> <p>7. <input checked="" type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)). <input type="checkbox"/> are transmitted herewith (required only if not transmitted by the International Bureau). <input type="checkbox"/> have been transmitted by the International Bureau. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired. <input checked="" type="checkbox"/> have not been made and will not be made.</p> <p>8. <input type="checkbox"/> A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).</p> <p>9. <input type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).</p> <p>10. <input type="checkbox"/> A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).</p> <p>11. <input type="checkbox"/> Applicant claims small entity status under 37 CFR 1.27.</p>			
Items 12. to 17. below concern other document(s) or information included:			
<p>12. <input type="checkbox"/> An Information Disclosure Statement under 37 CFR 1.97 and 1.98.</p> <p>13. <input type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.</p> <p>14. <input type="checkbox"/> A FIRST preliminary amendment. <input type="checkbox"/> A SECOND or SUBSEQUENT preliminary amendment.</p> <p>15. <input type="checkbox"/> A substitute specification.</p> <p>16. <input type="checkbox"/> A change of power of attorney and/or address letter.</p> <p>17. <input checked="" type="checkbox"/> Other items or information: Application Data Sheet, Paper Copy of Sequence Listing, and French Language Patent Application Specification</p>			

SCANNED, # 8

JC13 Rec'd PTO/PTO 12 FEB 2002

U.S. APPLICATION NO. (If known, see 37 C.F.R. 1.50) Unassigned		INTERNATIONAL APPLICATION NO. 107049372 PCT/FR00/02319	ATTORNEY'S DOCKET NUMBER 065691-0270
18. <input checked="" type="checkbox"/> The following fees are submitted:		CALCULATIONS PTO USE ONLY	
Basic National Fee (37 CFR 1.492(a)(1)-(5): Search Report has been prepared by the EPO or JPO.....		\$890.00	
International preliminary examination fee paid to USPTO (37 CFR 1.482).....		\$710.00	
No international preliminary examination fee paid to USPTO (37 CFR 1.482) but international search fee paid to USPTO (37 CFR 1.445(a)(2)).....		\$740.00	
Neither international preliminary examination fee (37 CFR 1.482) nor International search fee (37 CFR 1.445(a)(2)) paid to USPTO.....		\$1,040.00	
International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Article 33(2)-(4)		\$100.00	
ENTER APPROPRIATE BASIC FEE AMOUNT = \$890.00			
Surcharge of \$130.00 for furnishing the oath or declaration later than 20 months from the earliest claimed priority date (37 CFR 1.492(e))			
Months from the earliest claimed priority date (37 CFR 1.492(e))			
Claims	Number Filed	Included in Basic Fee	Extra Claims
Total Claims	51	-	20
		=	31
		x	\$18.00
			\$558.00
Independent Claims	5	-	3
		=	2
		x	\$84.00
			\$168.00
Multiple dependent claim(s) (if applicable)		\$280.00	
		\$280.00	
TOTAL OF ABOVE CALCULATIONS = \$1896.00			
Reduction by 1/2 for filing by small entity, if applicable. \$0.00			
SUBTOTAL = \$1896.00			
Processing fee of \$130.00 for furnishing English translation later the 20 months from the earliest claimed priority date (37 CFR 1.492(f)). +			
TOTAL NATIONAL FEE = \$1896.00			
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property +			
TOTAL FEES ENCLOSED = \$1896.00			
		Amount to be: refunded \$ charged \$	
<p>a. <input checked="" type="checkbox"/> A check in the amount of \$1896.00 to cover the above fees is enclosed.</p> <p>b. <input type="checkbox"/> Please charge my Deposit Account No. 19-0741 in the amount of \$0.00 to the above fees. A duplicate copy of this sheet is enclosed.</p> <p>c. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 19-0741. A duplicate copy of this sheet is enclosed.</p>			
NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.			
SEND ALL CORRESPONDENCE TO:			
<p>Foley & Lardner Customer Number: 22428</p> <p></p> <p>22428</p>			
PATENT TRADEMARK OFFICE			
STEPHEN B. MAEBIUS			
SIGNATURE			
NAME STEPHEN B. MAEBIUS			
REGISTRATION NUMBER 35,264			

15 AUG 2002

#6

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Atty. Docket No: 065691/0270

In re patent application of

PITIOT, GILLES et al.

Serial No. 10/049,372

Filed: February 12, 2002

For: HUMAN ODORANT-BINDING PROTEINS WHICH BIND HYDROPHOBIC LIGANDS:
POLYPEPTIDES AND POLYNUCLEOTIDES ENCODING SAID POLYPEPTIDES, AND USES
THEREOF

STATEMENT TO SUPPORT FILING AND SUBMISSION IN
ACCORDANCE WITH 37 C.F.R. §§ 1.821-1.825

Assistant Commissioner for Patents
Washington, D.C. 20231
Box SEQUENCE

Sir:

In connection with a Sequence Listing submitted concurrently herewith, the undersigned hereby states that:

1. the submission, filed herewith in accordance with 37 C.F.R. § 1.821(g), does not include new matter;

2. the content of the attached paper copy and the attached computer readable copy of the Sequence Listing, submitted in accordance with 37 C.F.R. § 1.821(c) and (e), respectively, are the same; and

3. all statements made herein of their own knowledge are true and that all statements made on information and belief are believed to be true; and further, that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United

Serial No. 10/049,372

States Code and that such willful false statements may jeopardize the validity of the application or any patent resulting therefrom.

Respectfully submitted,

August 6, 2002

Date

James A. Coburn



HARBOR CONSULTING
Intellectual Property Services
1500A Lafayette Road
Suite 262
Portsmouth, N.H.
800-318-3021

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No. :

U.S. National Serial No. :

Filed :

PCT International Application No. : PCT/FR00/02319

VERIFICATION OF A TRANSLATION

I, the below named translator, hereby declare that:

My name and post office address are as stated below;

That I am knowledgeable in the French language in which the below identified international application was filed, and that, to the best of my knowledge and belief, the English translation of the amended sheets of the international application No. PCT/FR00/02319 is a true and complete translation of the amended sheets of the above identified international application as filed.

I hereby declare that all the statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the patent application issued thereon.

Date: February 28, 2002



Full name of the translator :

Elaine Patricia PARRISH

For and on behalf of RWS Group plc

Post Office Address :

Europa House, Marsham Way,

Gerrards Cross, Buckinghamshire,

England.

15 AUG 2002 *JK*

Atty. Dkt. No. 065691/0270

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Gilles PITIOT et al.

Title: HUMAN ODORANT-BINDING PROTEINS WHICH BIND HYDROPHOBIC LIGANDS: POLYPEPTIDES AND POLYNUCLEOTIDES ENCODING SAID POLYPEPTIDES, AND USES THEREOF

Appl. No. 10/049,372

Filing Date: 08/15/2002

Examiner: Unassigned

Art Unit: Unassigned

AMENDMENT IN RESPONSE TO NOTICE UNDER 37 CFR §§1.821-825Commissioner for Patents
Washington, D.C. 20231

Sir:

In response to the Notice to Comply With Requirements for Applications Containing Sequence Disclosures mailed April 16, 2002, please amend the application as follows:

In the Specification:

Please amend the specification as shown:

Please delete the paragraph on page 6, lines 28-30, and replace it with the following paragraph:

The polypeptides according to the invention are characterized in that they preferably comprise the Gly-Thr-Trp-Tyr (SEQ ID NO: 25) domain.

Please delete the paragraph on page 33, lines 6-15, and replace it with the following paragraph:

The upper lines represent the hOBPIIa sequences (SEQ ID NOS 17-19, 21-24) and the lower lines represent the hOBPIIb sequence (SEQ ID NO: 20) for which only the different nucleotides are represented; a dash indicates the absence of corresponding sequences. The shaded capitals are the exon sequences and the lower case letters are the intron sequences. The sizes indicated on the left are indicated in bp. The TATA box is in bold characters and the polyadenylation signal is underlined. The boxes indicate the splice acceptor sites for exons 5, 5b and 5c.

Please delete the paragraph on page 33, lines 35-39 thru page 34 lines 1-4, and replace it with the following paragraph:

FIGURE 5: Alignment of the protein sequences derived from the two human genes hOBPIIa and hOBPIIb (hOBPIIa α = OBP2aaHOMSA (SEQ ID NO: 2), hOBPIIa β = OBP2baHOMSA (SEQ ID NO: 10), hOBPIIb β = OBP2bbHOMSA (residues 15-179 of SEQ ID NO: 12), hOBPIIa γ = OBP2agHOMSA (SEQ ID NO: 6), hOBPIIa δ = OBP2abHOMSA (SEQ ID NO: 4)), of human tear lipocalins (LCN1_HOMSA) (SEQ ID NO: 46), of rat OBPII (OBP2_RATNO) (SEQ ID NO: 47), of bovine lactoglobulin BLG (LACB_BOSTA) (SEQ ID NO: 48), of mouse MUP (MUP6_MUSMU) (SEQ ID NO: 49), of human RBP (RBP_HOMSA) (SEQ ID NO: 50), of bovine OBP (OBP_BOSTA) (SEQ ID NO: 51), of rat MUP (MUP_RATNO) (SEQ ID NO: 52) and of porcine OBP (OBP_SUSSC) (SEQ ID NO: 53).

Please delete the paragraph on page 34, lines 6-16 and replace it with the following paragraph:

The residues in the dark grey boxes are identical and those in the light gray boxes are similar. The elements of secondary structure predicted with the DSC program are underlined and the amino acid residues are in italics. The β -sheets and the α -helices are

numbered for hOPBIIa and b. The anticipated signal peptide cleavage site is indicated with an arrow (AAA₁LS) at position 15. Nonaligned sequences of very divergent forms of spliced genes, hOPBa6 (OPB2adHOMSA) (SEQ ID NO: 8) and hOBPby (OPB2bgHOMSA) (SEQ ID NO: 14) have been added at the bottom of the alignment after the analysis.

Please delete the paragraph on page 39, lines 30-38 thru page 40, lines 1-2, and replace it with the following paragraph:

A Lambda gt11 human testes cDNA library (Clontech) (10^7 p.f.u.) was amplified by 30 polymerase chain reaction (PCR) cycles (94°C 45 sec, 54°C 45 sec, 72°C 1 min 30 sec) with the primer oliEST58 CCTGCAGGTACATGAGCTTCC (SEQ ID NO: 26) and 5' or 3' screening amplimers for inserts located on the arms of the lambda gt11 vectors. A nested PCR was then carried out with oliEST26 CGCTGTATTGCCAGGCTCC (SEQ ID NO: 27) and oligonucleotides specific for the arm of the vector. The PCR products were subcloned into the pGEM-T (r) vector, which made it possible to obtain the 5' end of the hOBPII gene cDNAs.

Please delete the paragraph on page 40, lines 20-39 thru page 41, lines 1-5, and replace it with the following paragraph:

Tissue samples were collected from 45 to 55 year old Caucasian individuals, in agreement with the French regulations in force. The total RNA is extracted according to a single-step method using the RNA NOW® reagent, according to the manufacturer's (Biogentex) instructions. 5 µg of total RNA were reversed-transcribed in a final volume of 20 µl using 0.5 ng of oligonucleotide GACTCGAGTCGACATCGATTTTTTTTTTTTT (SEQ ID NO: 28) with the Superscript® preamplification system (Gibco BRL). Three µl of these reactions were then used for the following PCRs. The expression of the specific mRNAs was determined by PCR using: the primers TL: CCTCTCCCAGCCCCAGCAAG (SEQ ID NO: 29) and AP: GACTCGAGTCGACATCG (SEQ

Atty. Dkt. No. 065691/0270

ID NO: 30) for the LCN1-type genes (LCN1, LCN1b, LCN1c) and, for the hOBPII-type genes, the primers DE: CGCCCAGTGCACCTGCCGAGTC (SEQ ID NO: 31), and FI: CTTTATTGGAGTCAGGTGGGTG (SEQ ID NO: 32). As a quality control for the RNA's the primers G3PDH1: CTCTGCCCTCTGCTGATG (SEQ ID NO: 33) and G3PDH2: CCTGCTTACCCACCTTCTTG (SEQ ID NO: 34) for the G3PDH gene were used; the G3PDH gene is considered to be constitutively expressed in all cell types. 32 PCR cycles (94°C 45 sec, 54°C 45 sec, 72°C 2 min 30 sec) were performed and the amplification products were separated on 1% agarose gel. The DNA was transferred onto a Hybond N+® membrane.

Please delete the paragraph on page 41, lines 7-16, and replace it with the following paragraph:

For the detection of the expression of the various genes, several oligonucleotides specific for the respective genes were synthesized:

- oILCN1: GACTCAGACTCCGGAGATGA (SEQ ID NO: 35),
- oILCN1b: AACTCAGACACCAGAGATGA (SEQ ID NO: 36),
- oILCN1c: GACTCAGATCCCGGAGATGA (SEQ ID NO: 37),
- oI5: CCAGGAGGGACCACTACA (SEQ ID NO: 38) specific for the hOBPIIb gene,
- oI4: CGGGGACGGACGACTACG (SEQ ID NO: 39) specific for the hOBPIIa gene,
- G3PDH3: CTCATGACCACAGTCCATGC (SEQ ID NO: 40).

Please delete the paragraph on page 41, lines 30-39 thru page 42, lines 1-7, and replace it with the following paragraph:

The genotyping is carried out with PCR reactions using 100 ng of genomic DNA originating from 8 CEPH reference families, and using the oligonucleotides oli9 TGTCGGGAACGCAGCTT (SEQ ID NO: 41) and

ol110a TGCCGCTGTCCCCACGTCGG (SEQ ID NO: 42). The thermocycler parameters consist of an initial cycle at 94°C for 10 min followed by 30 cycles at 94°C for 30 sec, 55°C for 30 sec and 70°C for 45 sec, and then a final elongation step of 10 min at 70°C. The PCR products are then analyzed on a 3% agarose gel. The information regarding the markers for chromosome 9 may be obtained at the following internet address (<http://galton.ucl.ac.uk>); the analyses were carried out using the linkage study tools previously described in Lacazette *et al.* (1997). The haplotypes are reconstructed manually according to the recombination events previously described in family 1362 (Attwood *et al.*, 1994).

Please delete the paragraph on page 52, lines 34-39 thru page 54, lines 1-11, and replace it with the following paragraph:

In the case of the hOBPIIb gene, in addition to the hOBPIIb α mRNA previously described, a 106 bp super-numerary exon (exon 3b) between the previous exons 3 and 4 was identified (figure 3). This longer mRNA (782 nucleotides) encodes a 165 amino acid protein hOBPIIb β . From a protein structure point of view, hOBPIIb β is identical to hOBPIIb α up to the 5th putative β -sheet and then differs due to a reading frame shift. The predictions from the computer programs indicate that the motif ALWEALAIIDTRLK (SEQ ID NO: 43) is an α -helix which is just behind the fifth β -sheet. Two additional β -sheets may be present in the long C-terminal portion.

Please delete the paragraph on page 58, lines 36-39 thru page 59, lines 1-23, and replace it with the following paragraph:

A PCR on the plasmid DNA of an hOBPIIb α clone using the primers BIIa/b (5' GTC GGA TCC CTG TCC TTC ACC CTG GAG G 3') (SEQ ID NO: 44), a sense oligonucleotide beginning 45 bases after the protein-initiating ATG, and XIIb (5; GTC CTC GAG GTG TTC GGG AAC GCA GCT TC 3') (SEQ ID NO: 45), an antisense oligonucleotide preceding the stop

codon of the hOBPIIb α protein, made it possible to amplify all of the DNA encoding the secreted hOBPIIb α protein. The *BanH I* and *Xho I* enzymatic restriction sites located at the ends of the two oligonucleotides (bases underlined) were used for directional cloning into a plasmid expression vector pGEX-6P1, followed by transformation by electroporation (1800 V, 200 Ω , 25 μ F) into bacterial strain BL21. Synthesis of the recombinant protein is obtained by adding IPTG, at 5 mM final for 3 h, to 250 ml of culture of the strain in LB medium containing 100 μ g/ml of ampicillin pre-incubated at 37°C for 2 h. The centrifuged cultures are taken up in 25 ml of TENGN buffer. The lysate is sonicated and re-centrifuged. The fusion protein is then purified using 4 ml of beads bearing covalently attached insoluble glutathione (Sigma) per 25 ml of supernatant. After incubation for 4 h, they are washed with 3 volumes of 1M NaCl and then with 10 volumes of 1 X PBS. The elution is obtained by bringing the beads into contact with a glutathione solution (10 mM reduced glutathione, 50 mM Tris-HCl, pH 8.0) for 10 min.

REMARKS

Applicants believe that the present application is now in condition for allowance. Favorable reconsideration of the application as amended is respectfully requested.

The Examiner is invited to contact the undersigned by telephone if it is felt that a telephone interview would advance the prosecution of the present application.

Respectfully submitted,

Date August 14, 2002

FOLEY & LARDNER
Customer Number: 22428



22428

PATENT TRADEMARK OFFICE

Telephone: (202) 672-5407
Facsimile: (202) 672-5399

By Stephen B. Maebius

Stephen Maebius
Attorney for Applicants
Registration No. 35,264

Should additional fees be necessary in connection with the filing of this paper, or if a petition for extension of time is required for timely acceptance of same, the Commissioner is hereby authorized to charge Deposit Account No.19-0741 for any such fees; and applicant(s) hereby petition for any needed extension of time.

MARKED UP VERSION ATTACHED TO AMENDMENT IN

SERIAL NO. 10/049,372

Marked up version of the paragraph on page 6, lines 28-30 is below:

The polypeptides according to the invention are characterized in that they preferably comprise the Gly-Thr-Trp-Tyr (SEQ ID NO: 25) domain.

Marked up version of the paragraph on page 33, lines 6-15, is below:

The upper lines represent the hOBPIIa sequences (SEQ ID NOS 17-19, 21-24) and the lower lines represent the hOBPIIb sequence (SEQ ID NO: 20) for which only the different nucleotides are represented; a dash indicates the absence of corresponding sequences. The shaded capitals are the exon sequences and the lower case letters are the intron sequences. The sizes indicated on the left are indicated in bp. The TATA box is in bold characters and the polyadenylation signal is underlined. The boxes indicate the splice acceptor sites for exons 5, 5b and 5c.

Marked up version of the paragraph on page 33, lines 35-39 thru page 34 lines 1-4, is below:

FIGURE 5: Alignment of the protein sequences derived from the two human genes hOBPIIa and hOBPIIb (hOBPIIa α = OBP2aaHOMSA (SEQ ID NO: 2), hOBPIIa β = OBP2baHOMSA (SEQ ID NO: 10), hOBPIIb β = OBP2bbHOMSA (residues 15-179 of SEQ ID NO: 12), hOBPIIa γ = OBP2agHOMSA (SEQ ID NO: 6), hOBPIIa δ = OBP2abHOMSA (SEQ ID NO: 4)), of human tear lipocalins (LCN1_HOMSA) (SEQ ID NO: 46), of rat OBPII (OBP2_RATNO) (SEQ ID NO: 47), of bovine lactoglobulin BLG (LACB_BOSTA) (SEQ ID NO: 48), of mouse MUP (MUP6_MUSMU) (SEQ ID NO: 49), of human RBP (RBP_HOMSA) (SEQ ID NO: 50), of bovine OBP (OBP_BOSTA) (SEQ ID NO: 51), of rat MUP (MUP_RATNO) (SEQ ID NO: 52) and of porcine OBP (OBP_SUSSC) (SEQ ID NO: 53).

Marked up version of the paragraph on page 34, lines 6-16, is below:

The residues in the dark grey boxes are identical and those in the light gray boxes are similar. The elements of secondary structure predicted with the DSC program are underlined and the amino acid residues are in italics. The β -sheets and the α -helices are numbered for hOPBIIa and b. The anticipated signal peptide cleavage site is indicated with an arrow (AAA;LS) at position 15. Nonaligned sequences of very divergent forms of spliced genes, hOPBa6 (OPB2adHOMSA) (SEQ ID NO: 8) and hOPBby (OPB2bgHOMSA) (SEQ ID NO: 14) have been added at the bottom of the alignment after the analysis.

Marked up version of the paragraph on page 39, lines 30-38 thru page 40, lines 1-2, is below:

A Lambda gt11 human testes cDNA library (Clontech) (10^7 p.f.u.) was amplified by 30 polymerase chain reaction (PCR) cycles (94°C 45 sec, 54°C 45 sec, 72°C 1 min 30 sec) with the primer oliEST58 CCTGCAGGTACATGAGCTTCC (SEQ ID NO: 26) and 5' or 3' screening amplimers for inserts located on the arms of the lambda gt11 vectors. A nested PCR was then carried out with oliEST26 CGCTGTATTGCCAGGCTCC (SEQ ID NO: 27) and oligonucleotides specific for the arm of the vector. The PCR products were subcloned into the pGEM-T (r) vector, which made it possible to obtain the 5' end of the hOPBII gene cDNAs.

Marked up version of the paragraph on page 40, lines 20-39 thru page 41, lines 1-5, is below:

Tissue samples were collected from 45 to 55 year old Caucasian individuals, in agreement with the French regulations in force. The total RNA is extracted according to a single-step method using the

RNA NOW® reagent, according to the manufacturer's (Biogentex) instructions. 5 µg of total RNA were reversed-transcribed in a final volume of 20 µl using 0.5 ng of oligonucleotide GACTCGAGTCGACATCGATTTTTTTTTTTT (SEQ ID NO: 28) with the Superscript® preamplification system (Gibco BRL). Three µl of these reactions were then used for the following PCRs. The expression of the specific mRNAs was determined by PCR using: the primers TL: CCTCTCCCAGCCCCAGCAAG (SEQ ID NO: 29) and AP: GACTCGAGTCGACATCG (SEQ ID NO: 30) for the LCN1-type genes (LCN1, LCN1b, LCN1c) and, for the hOBPII-type genes, the primers DE: CGCCCAGTGACCTGCCGAGGTC (SEQ ID NO: 31), and FI: CTTTATTTGGAGTCAGGTGGGTG (SEQ ID NO: 32). As a quality control for the RNA the primers G3PDH1: CTCTGCCCTCTGCTGATG (SEQ ID NO: 33) and G3PDH2: CCTGCTTACCACTCTCTG (SEQ ID NO: 34) for the G3PDH gene were used; the G3PDH gene is considered to be constitutively expressed in all cell types. 32 PCR cycles (94°C 45 sec, 54°C 45 sec, 72°C 2 min 30 sec) were performed and the amplification products were separated on 1% agarose gel. The DNA was transferred onto a Hybond N+® membrane.

Marked up version of the paragraph on page 41, lines 6-16, is below:

For the detection of the expression of the various genes, several oligonucleotides specific for the respective genes were synthesized:

- o1LCN1 : GACTCAGACTCCGGAGATGA (SEQ ID NO: 35),
- o1LCN1b: AACTCAGACACCAGAGATGA (SEQ ID NO: 36),
- o1LCN1c: GACTCAGATCCCGGAGATGA (SEQ ID NO: 37),
- o15: CCAGGAGGGACCACTACA (SEQ ID NO: 38) specific for the hOBPIIb gene,
- o14: CCGGGACGGACGGACTACG (SEQ ID NO: 39) specific for the hOBPIIa gene,

- G3PDH3: CTCATGACCACAGTCATGC (SEQ ID NO: 40).

Marked up version of the paragraph on page 41, lines 30-39 thru page 42, lines1-7, is below:

The genotyping is carried out with PCR reactions using 100 ng of genomic DNA originating from 8 CEPH reference families, and using the oligonucleotides oli9 TGTTCGGGAACGCAGCTT (SEQ ID NO: 41) and oli10a TGCCCGCTGTCCCCAGTCGG (SEQ ID NO: 42). The thermocycler parameters consist of an initial cycle at 94°C for 10 min followed by 30 cycles at 94°C for 30 sec, 55°C for 30 sec and 70°C for 45 sec, and then a final elongation step of 10 min at 70°C. The PCR products are then analyzed on a 3% agarose gel. The information regarding the markers for chromosome 9 may be obtained at the following internet address (<http://galton.ucl.ac.uk>); the analyses were carried out using the linkage study tools previously described in Lacazette *et al.* (1997). The haplotypes are reconstructed manually according to the recombination events previously described in family 1362 (Attwood *et al.*, 1994).

Marked up version of the paragraph on page 52, lines 34-39 thru page 54, lines1-11, is below:

In the case of the hOBPIIb gene, in addition to the hOBPIIb α mRNA previously described, a 106 bp super-numerary exon (exon 3b) between the previous exons 3 and 4 was identified (figure 3). This longer mRNA (782 nucleotides) encodes a 165 amino acid protein hOBPIIb β . From a protein structure point of view, hOBPIIb β is identical to hOBPIIb α up to the 5th putative β -sheet and then differs due to a reading frame shift. The predictions from the computer programs indicate that the motif ALWEALALIDTRLK (SEQ ID NO: 43) is an α -helix which is just behind the fifth β -sheet. Two additional β -sheets may be present in the long C-terminal portion.

Marked up version of the paragraph on page 58, lines 36-39 thru page 59, lines 1-23, is below:

A PCR on the plasmid DNA of an hOBPIIb α clone using the primers BIIa/b (5' GTC GGA TCC CTG TCC TTC ACC CTG GAG G 3') (SEQ ID NO: 44), a sense oligonucleotide beginning 45 bases after the protein-initiating ATG, and XIIb (5'; GTC CTC GAG GTG TTC GGG AAC GCA GCT TC 3') (SEQ ID NO: 45), an antisense oligonucleotide preceding the stop codon of the hOBPIIb α protein, made it possible to amplify all of the DNA encoding the secreted hOBPIIb α protein. The BanH I and Xho I enzymatic restriction sites located at the ends of the two oligonucleotides (bases underlined) were used for directional cloning into a plasmid expression vector pGEX-6P1, followed by transformation by electroporation (1800 V, 200 Ω , 25 μ F) into bacterial strain BL21. Synthesis of the recombinant protein is obtained by adding IPTG, at 5 mM final for 3 h, to 250 ml of culture of the strain in LB medium containing 100 μ g/ml of ampicillin pre-incubated at 37°C for 2 h. The centrifuged cultures are taken up in 25 ml of TENGN buffer. The lysate is sonicated and recentrifuged. The fusion protein is then purified using 4 ml of beads bearing covalently attached insoluble glutathione (Sigma) per 25 ml of supernatant. After incubation for 4 h, they are washed with 3 volumes of 1M NaCl and then with 10 volumes of 1 X PBS. The elution is obtained by bringing the beads into contact with a glutathione solution (10 mM reduced glutathione, 50 mM Tris-HCl, pH 8.0) for 10 min.

CLAIMS

1. An isolated polypeptide comprising an amino acid sequence having at least 90% identity with the amino acid sequences SEQ ID No. 2, SEQ ID No. 4, SEQ ID No. 6, SEQ ID No. 8, SEQ ID No. 12 or SEQ ID No. 14.

2. An isolated polypeptide, characterized in that it comprises a polypeptide chosen from:

10

a) a polypeptide of sequence SEQ ID No. 2, SEQ ID No. 4, SEQ ID No. 6, SEQ ID No. 8, SEQ ID No. 12 or SEQ ID No. 14;

15

b) a polypeptide which is a variant of a polypeptide of amino acid sequences defined in a);

c) a polypeptide homologous to the polypeptide defined in a) or b) and comprising at least 90% identity with said polypeptide of a);

d) a fragment of at least 15 consecutive amino acids of a polypeptide defined in a), b) or c);

25

e) a biologically active fragment of a polypeptide defined in a), b) or c).

30

3. An isolated polypeptide selected from a polypeptide corresponding to the sequence SEQ ID No. 2 and named OBPII_{αα}, to the sequence SEQ ID No. 4 and named OBPII_{αβ}, to the sequence SEQ ID No. 6 and named OBPII_{αγ}, and to the sequence SEQ ID No. 12 and named OBPII_{ββ}.

35

4. The polypeptide as claimed in any one of claims 1 to 3, characterized in that it comprises at least the Gly-Thr-Trp-Tyr domain.

5. An isolated polynucleotide, characterized in that it encodes a polypeptide as claimed in any one of claims 1 to 4.

5 6. The polynucleotide as claimed in claim 5, of sequence SEQ ID No. 1, SEQ ID No. 3, SEQ ID No. 5, SEQ ID No. 7, SEQ ID No. 11 or SEQ ID No. 13.

10 7. An isolated polynucleotide, characterized in that it comprises a polynucleotide chosen from:

- 15 a) a polynucleotide of sequence SEQ ID No. 1, SEQ ID No. 3, SEQ ID No. 5, SEQ ID No. 7, SEQ ID No. 11 or SEQ ID No. 13, or the sequence of which is that of the RNA corresponding to the sequence SEQ ID No. 1, SEQ ID No. 3, SEQ ID No. 5, SEQ ID No. 7, SEQ ID No. 11 or SEQ ID No. 13;
- 20 b) a polynucleotide, the sequence of which is complementary to the sequence of a polynucleotide defined in a),
- 25 c) a polynucleotide, the sequence of which comprises at least 80% identity with a polynucleotide defined in a) or b),
- 30 d) a fragment of at least 15 consecutive nucleotides, in preference 21 consecutive nucleotides, and preferably 30 consecutive nucleotides, of a polynucleotide defined in a), b), c) or d).

8. The polynucleotide as claimed in claim 7, characterized in that it is labeled directly or indirectly with a radioactive compound or a nonradioactive compound.

35 9. The use of a polynucleotide as claimed in claim 8, as a probe for detecting nucleic acid sequences.

10. The use of a polynucleotide as claimed in any one of claims 5 to 8, as a primer for amplifying or polymerizing nucleic acid sequences.

5

11. The use of a polynucleotide as claimed in claim 8, as a sense or antisense oligonucleotide for controlling the expression of the corresponding protein product.

10 12. A recombinant vector for cloning a polynucleotide as claimed in one of claims 5 to 8 and/or for expressing a polypeptide as claimed in one of claims 1 to 4, characterized in that it contains a polynucleotide as claimed in any one of claims 5 to 8.

15

13. The vector as claimed in claim 12, characterized in that it comprises the elements which allow the expression, optionally the secretion, of said polypeptide in a host cell.

20

14. The vector as claimed in any one of claims 12 to 13, characterized in that the elements which allow the expression of said polypeptide are chosen from:

25 a) the isolated polynucleotide of sequence SEQ ID No. 15 and SEQ ID No. 16;

b) a polynucleotide, the sequence of which is complementary to the sequence of the polynucleotide defined in a);

c) a polynucleotide, the sequence of which comprises at least 80% identity with a polynucleotide defined in a) or in b);

30 d) a polynucleotide which hybridizes, under conditions of high stringency, with a sequence of the polynucleotide defined in a), b) or c).

15. The vector as claimed in claims 13 and 14, for expression in eukaryotic cells, selected from viral DNA and naked DNA.

5

16. A host cell, characterized in that it is transformed with a vector as claimed in one of claims 12 to 15.

10 17. A process for preparing a recombinant polypeptide, characterized in that a host cell as claimed in claim 16 is cultured under conditions which allow the expression and, optionally, the secretion of said recombinant polypeptide, and in that said recombinant polypeptide is recovered.

15

18. A recombinant polypeptide which can be obtained using a process as claimed in claim 17.

20 19. The use of a polypeptide chosen from a polypeptide as claimed in any one of claims 1 to 4 and 18, or a fragment thereof, as a protein which binds to a hydrophobic ligand, preferably an odorous molecule.

25 20. The use of a polypeptide as claimed in any one of claims 1 to 4 and 18, or of the polypeptide hOBPII_{ba} of sequence SEQ ID No. 10, a polypeptide which is a variant of said polypeptide hOBPII_{ba}, a polypeptide homologous to said polypeptide hOBPII_{ba} comprising at 30 least 90% identity with said polypeptide hOBPII_{ba} or a fragment thereof, as a competitive inhibitor, as an agonist or as an antagonist of the cellular receptors for lipocalins.

35 21. A monoclonal or polyclonal antibody, and fragments thereof, characterized in that it is specifically against an isolated polypeptide as claimed in one of claims 1 to 4 and 18.

22. The use of an antibody as claimed in claim 21, for demonstrating the presence of a polypeptide as claimed in one of claims 1 to 4 and 18 in a biological sample.

5

23. A process for detecting an antibody against hOBPII in human serum from an allergic and/or asthmatic patient, using an hOBPII polypeptide.

10 24. A process for controlling the volatilization of an odorant, characterized in that it comprises a step of binding of said odorant with a polypeptide as claimed in any one of claims 1 to 4 and 18, or with the polypeptide hOBPII_{ba} of sequence SEQ ID No. 10, a polypeptide which is a variant of said polypeptide hOBPII_{ba} or a polypeptide homologous to said polypeptide hOBPII_{ba} comprising at least 90% identity with said polypeptide hOBPII_{ba}.

15 20 25. The process as claimed in claim 24, characterized in that the polypeptide is bound to a solid support.

25 26. The process as claimed in claim 24, characterized in that the polypeptide is in a liquid composition.

30 27. The process as claimed in claim 26, characterized in that said composition is a fragranced composition for the skin.

35 28. A process for screening a molecule, preferably odorants or flavors, which comprises passing the molecule over a substrate which comprises a polypeptide as claimed in any one of claims 1 to 4 and 18, or the polypeptide hOBPII_{ba} of sequence SEQ ID No. 10, a polypeptide which is a variant of said polypeptide hOBPII_{ba} or a polypeptide homologous to said polypeptide hOBPII_{ba} comprising at least 90% identity with said polypeptide hOBPII_{ba}, bound to said substrate, said polypeptide

binding said odorant or flavor, and recovering said odorant or flavor from the polypeptide if necessary.

29. The process as claimed in claim 28, characterized
5 in that the molecules are human pheromones.

30. A process for solubilizing lipophilic molecules,
characterized in that it comprises binding said
molecule to a polypeptide as claimed in any one of
10 claims 1 to 4 and 18, or to the polypeptide hOBPII_{ba} of
sequence SEQ ID No. 10, a polypeptide which is a
variant of said polypeptide hOBPII_{ba} or a polypeptide
homologous to said polypeptide hOBPII_{ba} comprising at
least 90% identity with said polypeptide hOBPII_{ba}.

15 31. The application of the polypeptides as claimed in
one of claims 1 to 4 and 18, or of the polypeptide
hOBPII_{ba} of sequence SEQ ID No. 10, of a polypeptide
which is a variant of said polypeptide hOBPII_{ba} or of a
20 polypeptide homologous to said polypeptide hOBPII_{ba}
comprising at least 90% identity with said polypeptide
hOBPII_{ba}, in combination with dietary fatty acids, as a
food supplement.

25 32. The application as claimed in claim 31, for
preparing a medicinal product intended for the
treatment of hyperlipidemias and obesity.

30 33. The application as claimed in claim 31, for
supplementing nonmaternal milks.

34. The polypeptide as claimed in any one of claims 1
to 4 and 18, or the polypeptide hOBPII_{ba} of sequence SEQ
ID No. 10, a polypeptide which is variant of said poly-
35 peptide hOBPII_{ba} or a polypeptide homologous to said
polypeptide hOBPII_{ba} comprising at least 90% identity
with said polypeptide hOBPII_{ba}, as an agent for
targeting a pharmaceutical compound.

35. The polypeptide as claimed in claim 34, characterized in that said polypeptide is expressed in the form of a protein from fusion with a protein which 5 allows specific cellular addressing.

36. The polypeptide as claimed in claim 35, characterized in that said protein which allows specific cellular addressing is chosen from the group composed 10 of interleukins, of cytokines, of lymphokines, of interferons, of growth factors, of hormones and of antibodies.

37. The polypeptide as claimed in claim 34, characterized in that said polypeptide is combined with a 15 molecule which allows specific cellular addressing.

38. The polypeptide as claimed in claim 37, characterized in that said molecule which allows specific 20 cellular addressing is chosen from the group composed of steroids, of interleukins, of cytokines, of lymphokines, of interferons, of growth factors, of hormones and of antibodies.

25 39. The polypeptide as claimed in any one of claims 1 to 4 and 18, or the polypeptide hOBPII_{ba} of sequence SEQ ID No. 10, a polypeptide which is a variant of said polypeptide hOBPII_{ba} or a polypeptide homologous to said 30 polypeptide hOBPII_{ba} comprising at least 90% identity with said polypeptide hOBPII_{ba}, as a pharmaceutical compound transporter.

40. A pharmaceutical composition comprising a pharmaceutical compound bound at least to a polypeptide as 35 claimed in one of claims 34 to 39, and a pharmaceutically acceptable vehicle.

41. The pharmaceutical composition as claimed in

claim 40, characterized in that the pharmaceutical compound is chosen from the group of anticancer agents.

42. The pharmaceutical composition as claimed in
5 claim 41, characterized in that said anticancer agent is a radioactive isotope chosen from the group: iodine¹³¹, yttrium⁹⁰, gold¹⁹⁹, palladium¹⁰⁰, copper⁶⁷, bismuth²¹⁷ and antimony²¹¹.

10 43. The pharmaceutical composition as claimed in any one of claims 40 to 42, characterized in that said polypeptide as claimed in any one of claims 34 to 39 constitutes a delayed form of delivery of said pharmaceutical compound in the body.

15 44. A pharmaceutical composition comprising an expression vector as claimed in claim 12 or 13, and a pharmaceutically acceptable vehicle.

20 45. The pharmaceutical composition as claimed in any one of claims 40 to 44, for treating cancer preferably chosen from breast cancer, uterine cancer, prostate cancer, liver cancer and pulmonary epithelial cell carcinoma.

25 46. The use of a polypeptide chosen from the polypeptide hOBPII_{ba} of sequence SEQ ID No. 10, a polypeptide which is a variant of said polypeptide hOBPII_{ba} and a polypeptide homologous to said polypeptide hOBPII_{ba} comprising at least 90% identity with said polypeptide hOBPII_{ba}, for preparing a medicinal product intended for the treatment of uterine cancer, prostate cancer, liver cancer and pulmonary epithelial cell cancer.

35 47. The use of the polypeptide as claimed in any one of claims 1 to 4 and 18, or the polypeptide hOBPII_{ba} of sequence SEQ ID No. 10, or a polypeptide which is a

variant of said polypeptide hOBPII_{ba} or a polypeptide homologous to said polypeptide hOBPII_{ba} comprising at least 90% identity with said polypeptide hOBPII_{ba}, for preparing a medicinal product intended for the
5 transport of a compound across the placental barrier.

48. The use as claimed in claim 47, characterized in that said transport is carried out from the gestating mother to the fetus, and in that said compound is
10 chosen from hormones, essential fatty acids, lipophilic medicinal products and vitamins.

49. The use as claimed in claim 47, characterized in that said transport is carried out from the fetus to
15 the mother and is intended for the detoxification of the fetus.

50. The polypeptide as claimed in claims 1 to 4 and
18, or the polypeptide hOBPII_{ba} of sequence SEQ ID
20 No. 10, a polypeptide which is a variant of said polypeptide hOBPII_{ba} or a polypeptide homologous to said polypeptide hOBPII_{ba} comprising at least 90% identity with said polypeptide hOBPII_{ba}, as a pregnancy marker.

25 51. The polypeptide as claimed in claims 1 to 4 and
18, or the polypeptide hOBPII_{ba} of sequence SEQ ID
No. 10, a polypeptide which is a variant of said polypeptide hOBPII_{ba} or a polypeptide homologous to said polypeptide hOBPII_{ba} comprising at least 90% identity
30 with said polypeptide hOBPII_{ba}, as a marker for a feto-placental pathological condition

atg agg gag gat cgg tgc atc cag aag aaa atc ctg atg cgg aag acg 294
 Met Arg Glu Asp Arg Cys Ile Gln Lys Lys Ile Leu Met Arg Lys Thr
 70 75 80

gag gag cct ggc aaa ttc acg gcc tat ggg ggc agg aag ctc ata tac 342
 Glu Glu Pro Gly Lys Phe Ser Ala Tyr Gly Gly Arg Lys Leu Ile Tyr
 85 90 95 100

ctg cag gag ctg ccc ggg acg gac gac tac gtc ttt tac tgc aaa gac 390
 Leu Gln Glu Leu Pro Gly Thr Asp Asp Tyr Val Phe Tyr Cys Lys Asp
 105 110 115

cag cgc cgt ggg ggc ctg cgc tac atg gga aag ctt gtc ggt agg aat 438
 Gln Arg Arg Gly Gly Leu Arg Tyr Met Gly Lys Leu Val Gly Arg Asn
 120 125 130

cct aat acc aac ctg gag gcc ctg gaa gaa ttt aag aaa ttg gtc cag 486
 Pro Asn Thr Asn Leu Glu Ala Leu Glu Glu Phe Lys Lys Leu Val Gln
 135 140 145

cac aag gga ctc tcg gag gag gac att ttc atg ccc ctg cag acg gga 534
 His Lys Gly Leu Ser Glu Glu Asp Ile Phe Met Pro Leu Gln Thr Gly
 150 155 160

agc tgc gtt ctc gaa cac taggcagccc ccgggtctgc acctccagag 582
 Ser Cys Val Leu Glu His
 165 170

cccacccatc caccagacac agagcccgaa ccacctggac ctaccctcca gccatgaccc 642
 ttccctgctc ccacccacct gactccaaat aaag 676

<210> 2
 <211> 170
 <212> PRT
 <213> Homo sapiens

<400> 2
 Met Lys Thr Leu Phe Leu Gly Val Thr Leu Gly Leu Ala Ala Leu
 1 5 10 15

Ser Phe Thr Leu Glu Glu Asp Ile Thr Gly Thr Trp Tyr Val Lys
 20 25 30

Ala Met Val Val Asp Lys Asp Phe Pro Glu Asp Arg Arg Pro Arg Lys
 35 40 45

Val Ser Pro Val Lys Val Thr Ala Leu Gly Gly Asn Leu Glu Ala
 50 55 60

Thr Phe Thr Phe Met Arg Glu Asp Arg Cys Ile Gln Lys Lys Ile Leu
 65 70 75 80

Met Arg Lys Thr Glu Glu Pro Gly Lys Phe Ser Ala Tyr Gly Arg
 85 90 95

Lys Leu Ile Tyr Leu Gln Glu Leu Pro Gly Thr Asp Asp Tyr Val Phe
 100 105 110

Tyr Cys Lys Asp Gln Arg Arg Gly Gly Leu Arg Tyr Met Gly Lys Leu
 115 120 125

Val Gly Arg Asn Pro Asn Thr Asn Leu Glu Ala Leu Glu Glu Phe Lys
 130 135 140

Lys Leu Val Gln His Lys Gly Leu Ser Glu Glu Asp Ile Phe Met Pro
 145 150 155 160

Leu Gln Thr Gly Ser Cys Val Leu Glu His
 165 170

<210> 3

<211> 725

<212> DNA

<213> Homo sapiens

<220>

<221> CDS

<222> (43)...(480)

<220>

<223> cDNA396 (725) /SM12 (hOBPIIa-beta)

<400> 3

cccccagtga cctggccgagg tcggcagcac agagctctgg ag atg aag acc ctg
 Met Lys Thr Leu
 1

ttc ctg ggt gtc acg ctc ggc ctg gcc gct gcc ctg tcc ttc acc ctg
 Phe Leu Gly Val Thr Leu Gly Leu Ala Ala Leu Ser Phe Thr Leu
 5 10 15 20

gag gag gag gat atc aca ggg acc ttg tac gtg aag gcc atg gtg gtc
 Glu Glu Glu Asp Ile Thr Gly Thr Trp Tyr Val Lys Ala Met Val Val
 25 30 35

gat aag gac ttt ccg gag gac agg ccc agg aag gtg tcc cca gtg
 Asp Lys Asp Phe Pro Glu Asp Arg Arg Pro Arg Lys Val Ser Pro Val
 40 45 50

aag gtg aca gcc ctg ggc ggt ggg aac ttg gaa gcc acg ttc acc ttc
 Lys Val Thr Ala Leu Gly Gly Asn Leu Glu Ala Thr Phe Thr Phe
 55 60 65

atg agg gag gat cgg tgc atc cag aag aaa atc ctg atg cgg aag acg
 Met Arg Glu Asp Arg Cys Ile Gln Lys Lys Ile Leu Met Arg Lys Thr
 70 75 80

gag gag cct ggc aaa ttc agc gcc tat ggg ggc agg aag ctc ata tac
 Glu Glu Pro Gly Lys Phe Ser Ala Tyr Gly Gly Arg Lys Leu Ile Tyr
 85 90 95 100

<210> 5
 <211> 741
 <212> DNA
 <213> Homo sapiens

<220>
 <221> CDS
 <222> (43) .. (726)

<220>
 <223> cDNA396 (741) /SM4 (hOBPIIa-gamma)

<400> 5
 cgcccaagtga cctggccgagg tcggcagcac agagctctgg ag atg aag acc ctg 54
 Met Lys Thr Leu
 1

ttc ctg ggt gtc acg ctc ggc ctg gcc gct gcc ctg tcc ttc acc ctg 102
 Phe Leu Gly Val Thr Leu Gly Leu Ala Ala Ala Leu Ser Phe Thr Leu
 5 10 15 20

gag gag gag gat atc aca ggg acc tgg tac gtg aag gcc atg gtg gtc 150
 Glu Glu Glu Asp Ile Thr Gly Thr Trp Tyr Val Lys Ala Met Val Val
 25 30 35

gat aag gac ttt ccg gag gac agg agg ccc agg aag gtg tcc cca gtg 198
 Asp Lys Asp Phe Pro Glu Asp Arg Arg Pro Arg Lys Val Ser Pro Val
 40 45 50

aag gtg aca gcc ctg ggc ggt ggg aac ttg gaa gcc acg ttc acc ttc 246
 Lys Val Thr Ala Leu Gly Gly Asn Leu Glu Ala Thr Phe Thr Phe
 55 60 65

atg agg gag gat cgg tgc atc cag aag aaa atc ctg atg cgg aag acg 294
 Met Arg Glu Asp Arg Cys Ile Gln Lys Ile Leu Met Arg Lys Thr
 70 75 80

gag gag cct ggc aaa ttc agc gcc tat ggg ggc agg aag ctc ata tac 342
 Glu Glu Pro Gly Lys Phe Ser Ala Tyr Gly Gly Arg Lys Leu Ile Tyr
 85 90 95 100

ctg cag gag ctg ccc ggg acg gac gac tac gtc ttt tac tgc aaa gac 390
 Leu Gln Glu Leu Pro Gly Thr Asp Asp Tyr Val Phe Tyr Cys Lys Asp
 105 110 115

cag cgc cgt ggg ggc ctg cgc tac atg gga aag ctt gtg gca ttt gct 438
 Gln Arg Arg Gly Gly Leu Arg Tyr Met Gly Lys Leu Val Ala Ser Ala
 120 125 130

ccc tgc agg gcc gtg cgg ctg tcc cca cgt cgg ctc acc tgg cca cct 486
 Pro Cys Arg Ala Val Pro Leu Ser Pro Arg Arg Leu Thr Trp Pro Pro
 135 140 145

cac ctg cag gta gga atc cta ata cca acc tgg agg ccc tgg aag aat	534		
His Leu Gln Val Gly Ile Leu Ile Pro Thr Trp Arg Pro Trp Lys Asn			
150	155	160	
tta aga aat tgg tgc agc aca agg gac tct cgg agg agg aca ttt tca	582		
Leu Arg Asn Trp Cys Ser Thr Arg Asp Ser Arg Arg Arg Thr Phe Ser			
165	170	175	180
tgc ccc tgc aga cgg gaa gct gcg ttc tcg aac act agg cag ccc ccg	630		
Cys Pro Cys Arg Arg Glu Ala Ala Phe Ser Asn Thr Arg Gln Pro Pro			
185	190	195	
ggc ctg cac ctc cag agc cca ccc tac cac cag aca cag agc ccg gac	678		
Gly Leu His Leu Gln Ser Pro Pro Tyr His Gln Thr Gln Ser Pro Asp			
200	205	210	
cac ctg gac cta ccc tcc agc cat gac cct tcc ctc cca ccc acc	726		
His Leu Asp Leu Pro Ser Ser His Asp Pro Ser Leu Leu Pro Pro Thr			
215	220	225	
tgactccaaa taaag	741		
<210> 6			
<211> 228			
<212> PRT			
<213> Homo sapiens			
<400> 6			
Met Lys Thr Leu Phe Leu Gly Val Thr Leu Gly Leu Ala Ala Ala Leu			
1	5	10	15
Ser Phe Thr Leu Glu Glu Asp Ile Thr Gly Thr Trp Tyr Val Lys			
20	25	30	
Ala Met Val Val Asp Lys Asp Phe Pro Glu Asp Arg Arg Pro Arg Lys			
35	40	45	
Val Ser Pro Val Lys Val Thr Ala Leu Gly Gly Asn Leu Glu Ala			
50	55	60	
Thr Phe Thr Phe Met Arg Glu Asp Arg Cys Ile Gln Lys Lys Ile Leu			
65	70	75	80
Met Arg Lys Thr Glu Glu Pro Gly Lys Phe Ser Ala Tyr Gly Arg			
85	90	95	
Lys Leu Ile Tyr Leu Gln Glu Leu Pro Gly Thr Asp Asp Tyr Val Phe			
100	105	110	
Tyr Cys Lys Asp Gln Arg Arg Gly Gly Leu Arg Tyr Met Gly Lys Leu			
115	120	125	
Val Ala Ser Ala Pro Cys Arg Ala Val Pro Leu Ser Pro Arg Arg Leu			
130	135	140	
Thr Trp Pro Pro His Leu Gln Val Gly Ile Leu Ile Pro Thr Trp Arg			
145	150	155	160

Pro Trp Lys Asn Leu Arg Asn Trp Cys Ser Thr Arg Asp Ser Arg Arg
 165 170 175

Arg Thr Phe Ser Cys Pro Cys Arg Arg Glu Ala Ala Phe Ser Asn Thr
 180 185 190

Arg Gln Pro Pro Gly Leu His Leu Gln Ser Pro Pro Tyr His Gln Thr
 195 200 205

Gln Ser Pro Asp His Leu Asp Leu Pro Ser Ser His Asp Pro Ser Leu
 210 215 220

Leu Pro Pro Thr
 225

<210> 7
 <211> 607
 <212> DNA
 <213> Homo sapiens

<220>
 <221> CDS
 <222> (43)..(483)

<220>
 <223> cDNA396 (607) - short form (hOBPIIa-delta)

<400> 7
 cggccaggta cctggcggagg tcggcagcac agagctctgg ag atg aag acc ctg 54
 Met Lys Thr Leu
 1

ttc ctg ggt gtc acg ctc ggc ctg gcc gct gcc ctg tcc ttc acc ctg 102
 Phe Leu Gly Val Thr Leu Gly Leu Ala Ala Leu Ser Phe Thr Leu
 5 10 15 20

gag gag gag gat gag gga gaa tcg gtg cat cca gaa gaa aat cct gat 150
 Glu Glu Glu Asp Glu Gly Glu Ser Val His Pro Glu Glu Asn Pro Asp
 25 30 35

gcg gaa gac gga gga gcc tgg caa att cag cgc cta tgg ggg cag gaa 198
 Ala Glu Asp Gly Gly Ala Trp Gln Ile Gln Arg Leu Trp Gly Gln Glu
 40 45 50

gct cat ata cct gca gga gca gct gcc cgg gac gga cga cta cgt ctt tta 246
 Ala His Ile Pro Ala Gly Ala Ala Arg Asp Gly Arg Leu Arg Leu Leu
 55 60 65

ctg caa aga cca gcg ccc tgg ggg cct gcg cta cat ggg aaa gct tgt 294
 Leu Gln Arg Pro Ala Pro Trp Gly Pro Ala Leu His Gly Lys Ala Cys
 70 75 80

ggc atc tgc tcc ctg cag ggc cgt gcc gct gtc ccc acc ttg gct cac 342
 Gly Ile Cys Ser Leu Gln Gly Arg Ala Ala Val Pro Thr Leu Ala His
 85 90 95 100

ctg gcc acc tca cct gca ggt agg aat cct aat acc aac ctg gag gcc 390
 Leu Ala Thr Ser Pro Ala Gly Arg Asn Pro Asn Thr Asn Leu Glu Ala
 105 110 115

ctg gaa gaa ttt aag aaa ttg gtg cag cgc aag gga ctc tcg gag gag 438
 Leu Glu Glu Phe Lys Lys Leu Val Gln Arg Lys Gly Leu Ser Glu Glu
 120 125 130

gac att ttc atg ccc ctg cag acg gga agc tgc gtt ctc gaa cac 483
 Asp Ile Phe Met Pro Leu Gln Thr Gly Ser Cys Val Leu Glu His
 135 140 145

taggcagccc ccgggtctgc acctccagag cccaccctac caccagacac agagccgga 543

ccacctggac ctaccctcca gccatgaccc ttccctgctc ccacccacct gactccaaat 603

aaag 607

<210> 8

<211> 147

<212> PRT

<213> Homo sapiens

<400> 8
 Met Lys Thr Leu Phe Leu Gly Val Thr Leu Gly Leu Ala Ala Ala Leu
 1 5 10 15

Ser Phe Thr Leu Glu Glu Asp Glu Gly Glu Ser Val His Pro Glu
 20 25 30

Glu Asn Pro Asp Ala Glu Asp Gly Gly Ala Trp Gln Ile Gln Arg Leu
 35 40 45

Trp Gly Gln Glu Ala His Ile Pro Ala Gly Ala Ala Arg Asp Gly Arg
 50 55 60

Leu Arg Leu Leu Leu Gln Arg Pro Ala Pro Trp Gly Pro Ala Leu His
 65 70 75 80

Gly Lys Ala Cys Gly Ile Cys Ser Leu Gln Gly Arg Ala Ala Val Pro
 85 90 95

Thr Leu Ala His Leu Ala Thr Ser Pro Ala Gly Arg Asn Pro Asn Thr
 100 105 110

Asn Leu Glu Ala Leu Glu Glu Phe Lys Lys Leu Val Gln Arg Lys Gly
 115 120 125

Leu Ser Glu Glu Asp Ile Phe Met Pro Leu Gln Thr Gly Ser Cys Val
 130 135 140

Leu Glu His
 145

<210> 9
 <211> 676
 <212> DNA
 <213> Homo sapiens

<220>
 <221> CDS
 <222> (43)..(552)

<220>
 <223> cDNA2098 (676) - conventional form (hOBPIIb-alpha)

<400> 9
 cgcggcgtga cctggccgagg tcggcagcac agagctctgg ag atg aag acc ctg 54
 Met Lys Thr Leu
 1

ttc ctg ggt gtc acg ctc ggc ctg gcc gct gcc ctg tcc acc ctg 102
 Phe Leu Gly Val Thr Leu Gly Leu Ala Ala Ala Leu Ser Phe Thr Leu
 5 10 15 20

gag gag gag gat atc aca ggg acc tgg tac gtg aag gcc atg gtg gtc 150
 Glu Glu Glu Asp Ile Thr Gly Thr Trp Tyr Val Lys Ala Met Val Val
 25 30 35

gat aag gac ttt ccg gag gac agg agg ccc agg aag gtg tcc cca gtg 198
 Asp Lys Asp Phe Pro Glu Asp Arg Arg Pro Arg Lys Val Ser Pro Val
 40 45 50

aag gtg aca gcc ctg ggc ggt ggg aag ttg gaa gcc acg ttc acc 246
 Lys Val Thr Ala Leu Gly Gly Lys Leu Glu Ala Thr Phe Thr Phe
 55 60 65

atg agg gag gat cgg tgc atc cag aag aaa atc ctg atg cgg aag acg 294
 Met Arg Glu Asp Arg Cys Ile Gln Lys Ile Leu Met Arg Lys Thr
 70 75 80

gag gag cct ggc aaa tac agc gcc tat ggg ggc agg aag ctc atg tac 342
 Glu Glu Pro Gly Lys Tyr Ser Ala Tyr Gly Gly Arg Lys Leu Met Tyr
 85 90 95 100

ctg cag gag ctg ccc agg agg gac cac tac atc ttt tac tgc aaa gac 390
 Leu Gln Glu Leu Pro Arg Arg Asp His Tyr Ile Phe Tyr Cys Lys Asp
 105 110 115

cag cac cat ggg ggc ctg ctc cac atg gga aag ctt gtg ggt agg aat 438
 Gln His His Gly Gly Leu Leu His Met Gly Lys Leu Val Gly Arg Asn
 120 125 130

tct gat acc aac cgg gag gcc ctg gaa gaa ttt aag aaa ttg gtg cag 486
 Ser Asp Thr Asn Arg Glu Ala Leu Glu Glu Phe Lys Lys Leu Val Gln
 135 140 145

cgc aag gga ctc tgc gag gag gac att ttc acg ccc ctg cag acg gga 534
 Arg Lys Gly Leu Ser Glu Glu Asp Ile Phe Thr Pro Leu Gln Thr Gly
 150 155 160

agc tgc gtt ccc gaa cac taggcagccc ccgggtctgc acctccagag 582
 Ser Cys Val Pro Glu His
 165 170

cccacccatc caccagacac agagcccgga ccacctggac ctaccctcca gccatgaccc 642
 ttccctgtctc ccacccacct gactccaaat aaag 676

<210> 10
 <211> 170
 <212> PRT
 <213> Homo sapiens

<400> 10
 Met Lys Thr Leu Phe Leu Gly Val Thr Leu Gly Leu Ala Ala Ala Leu
 1 5 10 15

Ser Phe Thr Leu Glu Glu Glu Asp Ile Thr Gly Thr Trp Tyr Val Lys
 20 25 30

Ala Met Val Val Asp Lys Asp Phe Pro Glu Asp Arg Arg Pro Arg Lys
 35 40 45

Val Ser Pro Val Lys Val Thr Ala Leu Gly Gly Lys Leu Glu Ala
 50 55 60

Thr Phe Thr Phe Met Arg Glu Asp Arg Cys Ile Gln Lys Lys Ile Leu
 65 70 75 80

Met Arg Lys Thr Glu Glu Pro Gly Lys Tyr Ser Ala Tyr Gly Gly Arg
 85 90 95

Lys Leu Met Tyr Leu Gln Glu Leu Pro Arg Arg Asp His Tyr Ile Phe
 100 105 110

Tyr Cys Lys Asp Gln His His Gly Gly Leu Leu His Met Gly Lys Leu
 115 120 125

Val Gly Arg Asn Ser Asp Thr Asn Arg Glu Ala Leu Glu Glu Phe Lys
 130 135 140

Lys Leu Val Gln Arg Lys Gly Leu Ser Glu Glu Asp Ile Phe Thr Pro
 145 150 155 160

Leu Gln Thr Gly Ser Cys Val Pro Glu His
 165 170

<210> 11
 <211> 782
 <212> DNA
 <213> Homo sapiens

<220>
 <221> CDS
 <222> (1) .. (537)

<220>
 <223> cDNA2098 (782) - long form (hOBPIIb-beta)

<400> 11 cgc cca gtc acc tgc cga ggt cgg cag cac aga gct ctg gag atg aag Arg Pro Val Thr Cys Arg Gly Arg Gln His Arg Ala Leu Glu Met Lys 1 5 10 15	48
acc ctg ttc ctg ggt gtc acg ctc ggc ctg gcc gct gcc ctg tcc ttc Thr Leu Phe Leu Gly Val Thr Leu Gly Leu Ala Ala Ala Leu Ser Phe 20 25 30	96
acc ctg gag gag gat atc aca ggg acc tgg tac gtg aag gcc atg Thr Leu Glu Glu Asp Ile Thr Gly Thr Trp Tyr Val Lys Ala Met 35 40 45	144
gtg gtc gat aag gac ttt ccg gag gac agg ccc agg aag gtg tcc Val Val Asp Lys Asp Phe Pro Glu Asp Arg Arg Pro Arg Lys Val Ser 50 55 60	192
cca gtg aag gtg aca gcc ctg ggc ggt ggg aag ttg gaa gcc acg ttc Pro Val Lys Val Thr Ala Leu Gly Gly Gly Lys Leu Glu Ala Thr Phe 65 70 75 80	240
acc ttc atg agg gag gat cgg tgc atc cag aag aaa atc ctg atg cgg Thr Phe Met Arg Glu Asp Arg Cys Ile Gln Lys Lys Ile Leu Met Arg 85 90 95	288
aag acg gag gag cct ggc aaa tac acg gcc tgc ttg tcc gca gtc gag Lys Thr Glu Glu Pro Gly Lys Tyr Ser Ala Cys Leu Ser Ala Val Glu 100 105 110	336
atg gac cag atc acg cct gcc ctc tgg gag gcc cta gcc att gac aca Met Asp Gln Ile Thr Pro Ala Leu Trp Glu Ala Leu Ala Ile Asp Thr 115 120 125	384
ttg agg aag ctg agg att ggg aca agg agg cca agg att aca tgg ggg Leu Arg Lys Leu Arg Ile Gly Thr Arg Arg Pro Ile Arg Trp Gly 130 135 140	432
cag gaa gct cat gta cct gca gga gct gcc cag gag gga cca cta cat Gln Glu Ala His Val Pro Ala Gly Ala Ala Gln Glu Gly Pro Leu His 145 150 155 160	480
ctt tta ctg caa aga cca gca cca tgg ggg cct gct cca cat ggg aaa Leu Leu Leu Gln Arg Pro Ala Pro Trp Gly Pro Ala Pro His Gly Lys 165 170 175	528
gct tgt ggg tagaaattct gataccaacc gggaggccct ggaagaattt Ala Cys Gly	577
aagaaatgg tgcagegcaa gggactctcg gaggaggaca ttttcaegcc cctgcagacg 637 ggaagctgctgctgatccaa ctaggcagcc cccgggtctg cacctccaga gcccaccccta 697 ccacccagaca cagagccccgg accacctgga cctacccctcc agccatgacc ctccctgtct 757 cccacccacc tgactccaaa taaag	
782	

<210> 12
<211> 179
<212> PRT
<213> *Homo sapiens*

```

<400> 12
Arg Pro Val Thr Cys Arg Gly Arg Gln His Arg Ala Leu Glu Met Lys
1 5 10 15

Thr Leu Phe Leu Gly Val Thr Leu Gly Leu Ala Ala Ala Leu Ser Phe
20 25 30

Thr Leu Glu Glu Glu Asp Ile Thr Gly Thr Trp Tyr Val Lys Ala Met
35 40 45

Val Val Asp Lys Asp Phe Pro Glu Asp Arg Arg Pro Arg Lys Val Ser
50 55 60

Pro Val Lys Val Thr Ala Leu Gly Gly Lys Leu Glu Ala Thr Phe
65 70 75 80

Thr Phe Met Arg Glu Asp Arg Cys Ile Gln Lys Lys Ile Leu Met Arg
85 90 95

Lys Thr Glu Glu Pro Gly Lys Tyr Ser Ala Cys Leu Ser Ala Val Glu
100 105 110

Met Asp Gln Ile Thr Pro Ala Leu Trp Glu Ala Leu Ala Ile Asp Thr
115 120 125

Leu Arg Lys Leu Arg Ile Gly Thr Arg Arg Pro Arg Ile Arg Trp Gly
130 135 140

Gln Glu Ala His Val Pro Ala Gly Ala Ala Gln Glu Gly Pro Leu His
145 150 155 160

Leu Leu Leu Gln Arg Pro Ala Pro Trp Gly Pro Ala Pro His Gly Lys
165 170 175

Ala Cys Gly

```

<210> 13
<211> 542
<212> DNA
<213> *Homo sapiens*

```
<220>
<221> CDS
<222> (43)..(297)

<220>
<223> cDNA2098 (542) - short form (OBPIIb-gamma)
```

<400> 13
 cggccagtg a cctggccgagg tcggcagcac agagctctgg ag atg aag acc ctg 54
 Met Lys Thr Leu
 1

ttc ctg ggt gtc acg ctc ggc ctg gcc gct gcc ctg tcc acc ctg 102
 Phe Leu Gly Val Thr Leu Gly Leu Ala Ala Ala Leu Ser Phe Thr Leu
 5 10 15 20

gag gag gag gat gag gga gga tcg gtg cat cca gaa gaa aat cct gat 150
 Glu Glu Glu Asp Glu Gly Gly Ser Val His Pro Glu Glu Asn Pro Asp
 25 30 35

gcg gaa gac gga gga gcc tgg caa att cag cgc cta tgg ggg cag gaa 198
 Ala Glu Asp Gly Gly Ala Trp Gln Ile Gln Arg Leu Trp Gly Gln Glu
 40 45 50

gct cat ata cct gca gga gct gcc cag gga cca cta cat ctt tta 246
 Ala His Ile Pro Ala Gly Ala Gln Glu Gly Pro Leu His Leu Leu
 55 60 65

ctg caa aga cca gca cca tgg ggg cct get cca cat ggg aaa gct tgt 294
 Leu Gln Arg Pro Ala Pro Trp Gly Pro Ala Pro His Gly Lys Ala Cys
 70 75 80

ggg taggaattct gataccaacc gggaggccct ggaagaattt aagaatttgg 347
 Gly
 85

tgcagcgcac gggacttcg gaggaggaca ttttcacgcc cctgcagacg ggaagctgcg 407

ttccccaca ctaggcgcac cccgggtctg caccctccaga gcccaccccta ccaccagaca 467

caagccccgg accacctgga cttaccctcc acccatgacc cttccctgtcccacccacc 527

tgactccaaa taaag 542

<210> 14
<211> 85
<212> PRT
<213> Homo sapiens

<400> 14
 Met Lys Thr Leu Phe Leu Gly Val Thr Leu Gly Leu Ala Ala Ala Leu
 1 5 10 15

Ser Phe Thr Leu Glu Glu Asp Glu Gly Gly Ser Val His Pro Glu
 20 25 30

Glu Asn Pro Asp Ala Glu Asp Gly Gly Ala Trp Gln Ile Gln Arg Leu
 35 40 45

Trp Gly Gln Glu Ala His Ile Pro Ala Gly Ala Ala Gln Glu Gly Pro
 50 55 60

Leu His Leu Leu Gln Arg Pro Ala Pro Trp Gly Pro Ala Pro His
 65 70 75 80

Gly Lys Ala Cys Gly
85

gaatgtcgta tattgcatac ataaaaattgt gggattggct tttttttcc tttgtgcggat 1740
 cattctcg agattcatcc tattgtgca tttatcaata gtttattcca ttttacttct 1800
 gagtagtgct ctatggatg gatgtaccac agtctgttta accatttacc tggtggggaa 1860
 agtctgtt tataatgtt ggctatgaca catgtatgg ttttgcgtg gacatcgat 1920
 ttcatatccc tggacaagaag gcccagggtt tttatgtgt gatttcatgc ttgttacagg 1980
 gtcatttttgg ttttgggtt ttttgcgtt ttttgcgtt aacctgtcaaa gccatttcc 2040
 agatccatgt tccatgcata ctcaccaggc ttcaatgtatca tcaatgtatgtt ttatctcg 2100
 ccacccatgtt aggtatgtac tgatataatca tggctttttt ttgcatttca ctgtatgtca 2160
 atgggtgtga gcatctttt atgtgtttt ttgcatttgc tttatctctt ctatgtcaatg 2220
 gtcccttcat gtctttgtt taatgttcatat ttttggaaact ttgtggatgtt gaaaaattct 2280
 ttatataaagaatg taaaatctt ttttgcgtt aatgtatgtt ttgtcaatat ttcttttcag 2340
 tttttgttgcgtt gttttttat ttttgcgtt aatgtatgtt ttgtggatgtt atatttttgg caacatctt 2400
 ttgtatgtatgtt gttttttat ttttgcgtt aatgtatgtt ttgtggatgtt atatttttgg caacatctt 2460
 aaaaatccctt gaccggatc catatgtcaaa agatgttctt gtttttcaaa agtttttag 2520
 tttaatgtt ttttgcgtt aatgtatgtt ttgtggatgtt aattttcaaa cagggtgtga 2580
 gaccatgtt gtttttttgcgtt gtttttttgcgtt ctgtggatgtt ccagtgtttc 2640
 cagccatgtt gtttttttgcgtt ttttgcgtt aatgtatgtt ttgtggatgtt ttttgcgtt 2700
 aatgtatgtt gtttttttgcgtt ttttgcgtt aatgtatgtt ttgtggatgtt ttttgcgtt 2760
 atctatgtatgtt gtttttttgcgtt aatgtatgtt ttgtggatgtt ttttgcgtt 2820
 tggtgtggccg agagccatgtt atcccgatc ttccggaaatg ggaggccggaa gaatcgattt 2880
 aaccatgtt gtttttttgcgtt aatgtatgtt ttgtggatgtt ttttgcgtt 2940
 acagatgtaa ttttgcgtt aaaaataaa aaaaaataaa aatgtatgtt ttgtggatgtt ttttgcgtt 3000
 ctatgtatgtt ttttgcgtt aatgtatgtt ttgtggatgtt ttttgcgtt atataat 3060
 tagatataatc ttttgcgtt aatgtatgtt ttgtggatgtt ttttgcgtt 3120
 acatcttgcgtt atatgtatgtt aatgtatgtt ttgtggatgtt ttttgcgtt 3180
 gatataatgtt ttttgcgtt aatgtatgtt ttgtggatgtt ttttgcgtt 3240
 ttttgcgtt aaaaatccatgtt aatgtatgtt ttgtggatgtt ttttgcgtt 3300
 ttgtatgtatgtt aatgtatgtt ttgtggatgtt aatgtatgtt ttgtggatgtt 3360
 cacaatgtt ttttgcgtt aatgtatgtt ttgtggatgtt ttttgcgtt 3420
 ttctgtatgtt ttttgcgtt aatgtatgtt ttgtggatgtt ttttgcgtt 3480
 agataatataatc ttttgcgtt aatgtatgtt ttgtggatgtt ttttgcgtt 3540
 aatttccctt ttttgcgtt aatgtatgtt ttgtggatgtt ttttgcgtt 3600
 caatgtatgtt aatgtatgtt ttgtggatgtt ttttgcgtt 3660
 tgatgtatgtt aatgtatgtt ttgtggatgtt ttttgcgtt 3720
 aacatataatc ttttgcgtt aatgtatgtt ttgtggatgtt ttttgcgtt 3780
 ttttgcgtt aatgtatgtt ttgtggatgtt ttttgcgtt 3840
 gcaatgtatgtt ttttgcgtt aatgtatgtt ttgtggatgtt ttttgcgtt 3900
 ttttgcgtt aatgtatgtt ttgtggatgtt ttttgcgtt 3960
 ataaccatgtt aatgtatgtt ttgtggatgtt ttttgcgtt 4020
 caccatgtatgtt ttttgcgtt aatgtatgtt ttgtggatgtt ttttgcgtt 4080
 catgtatgtt aatgtatgtt ttgtggatgtt ttttgcgtt 4140
 acctatgtatgtt aatgtatgtt ttgtggatgtt ttttgcgtt 4200
 atctatgtatgtt aatgtatgtt ttgtggatgtt ttttgcgtt 4260
 ttcaatgtatgtt aatgtatgtt ttgtggatgtt ttttgcgtt 4320
 ttgtatgtatgtt aatgtatgtt ttgtggatgtt ttttgcgtt 4380
 gagaatgtatgtt aatgtatgtt ttgtggatgtt ttttgcgtt 4440
 ttttgcgtt aatgtatgtt ttgtggatgtt ttttgcgtt 4500
 caacatgtatgtt aatgtatgtt ttgtggatgtt ttttgcgtt 4560
 ggacaatgtatgtt aatgtatgtt ttgtggatgtt ttttgcgtt 4620
 ctttgcgtt aatgtatgtt ttgtggatgtt ttttgcgtt 4680
 agcaccatgtt aatgtatgtt ttgtggatgtt ttttgcgtt 4740
 ttttgcgtt aatgtatgtt ttgtggatgtt ttttgcgtt 4800
 cggatcaatgtt aatgtatgtt ttgtggatgtt ttttgcgtt 4860
 cttaaaaaatataatc aatgtatgtt ttgtggatgtt ttttgcgtt 4920
 gggaggatgtt aatgtatgtt ttgtggatgtt ttttgcgtt 4980
 ttttgcgtt aatgtatgtt ttgtggatgtt ttttgcgtt 5040
 aaaaaaaaaaaaaatataatc aatgtatgtt ttgtggatgtt ttttgcgtt 5100
 gaaaatgtatgtt aatgtatgtt ttgtggatgtt ttttgcgtt 5160

ttgtcaaggtaaggagggttc tcttttatttc ctactttttctt gagaggttgtt ttccctgaatg 4320
 cgtgatgaat tttagtcaagt actttttctg cattgtatcgat ttagatcatg taatttttct 4380
 tcttaacata ttaatatgtt tgatttttgtt gtattgtacc aggtttccat cccttggaaata 4440
 aactgtttt gggtcatgtt tagaaatttaat ttatattatattttttgtt aatattttttgt 4500
 aaaggattt tggatctata tttcatgggtt atattttttctt ccacgtttcc tttttttgtt 4560
 gtcaaggttt gggttggggat tttttctca tttttttgtt tttttttgtt 4620
 ttatttttt aatgttggat tttttttttt aatggatccat tttttttgtt 4680
 ttggaaatgt tttttttttt aatgttggat tttttttttt aatggatccat tttttttgtt 4740
 tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 4800
 atatgtggga aggttttttc tttttttttt tttttttttt tttttttttt tttttttttt 4860
 tagtgatagt ttctgtttttt tttttttttt tttttttttt tttttttttt tttttttttt 4920
 tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 4980
 tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 5040
 ttatattttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 5100
 tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 5160
 tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 5220
 tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 5280
 tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 5340
 agccccctta tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 5400
 atttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 5460
 acttctgacc tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 5520
 agccactgtt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 5580
 gtggggatgtc agtggatgtt tttttttttt tttttttttt tttttttttt tttttttttt 5640
 tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 5700
 tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 5760
 gatccgaatgt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 5820
 tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 5880
 accttcggc tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 5940
 gaagaagat tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 6000
 agactaccct tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 6060
 ggtatgtt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 6120
 tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 6180
 tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 6240
 caactataat tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 6300
 gcaactatgt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 6360
 acttattttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 6420
 ctgttata tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 6480
 tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 6540
 tagtgatata tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 6600
 tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 6660
 acaaaaatact tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 6720
 cagaagatgt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 6780
 tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 6840
 gaaacatcat tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 6900
 ctatccctat tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 6960
 agactggatgt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 7020
 ggaaggacac tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 7080
 cccaggccat tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 7140
 cttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 7200
 tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 7260
 ggttcatctt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 7320
 tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 7380
 cccggatgtca tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 7440
 aacttcggcc tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 7500
 gcccggatgt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 7560
 gtgtcactgt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 7620
 ggggttggcc tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 7680
 ggggttggatgt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 7740

gcccagcagt ggccgatgtg ggggtgcag agcctggga gggagctgtg gcccggct 11280
 ctgccttacc ctgcagctc cctgacacct gtccttc ccagcacago agccccggg 11340
 tctgcaccc tccatggccac cctaccacca gacacagage cccgaccacc tgacccatc 11400
 ctccagccat gacccttcc tgcctccacc caccgtactc caataaaagt ccttccccc 11460
 cagctctggg caggcttactc tggtgggaca gaggggttgc caccctcc ctgggggtc 11520
 tgctgggggg gggggccacc agggaaactg gggagatgtt ggcacttaga aggggccaaac 11580
 cacaaggcc acgtatcc acaggcttg a gggctgcgt gatgtctgg agggccctc 11640
 gggaaaggcc cccctccggcc tcagggttc ctttaggacag gcaaggccct gggcaggagc 11700
 gtttggaaag ccactggggg ggacaggagc ggggacacgg cgtcagggtt gcaaggatgg 11760
 ggcacccgca gggctccgc ctcagggtc tcagaggat ctcacaactt 11820
 agcagccctgg gtcagtgcc agcaactggg a 11851

<210> 17
 <211> 253
 <212> DNA
 <213> Homo sapiens

<400> 17
 cccggatgtca ggactgggtt ccacatggg ggggggtca ccgtggccacg 60
 tgctcccaagg acactggca gggggctata aagaacatct cgagaggagc cagcacagcc 120
 ttgttcaagac gcccaggatgac ctggccaggat cggcagcaca gagctctgg gatgaagacc 180
 ctgttccctgg gtgtcactgtt cggccgtggc gtcggccctgt ctteacccct ggaggaggag 240
 gatgtcactgtt ggg 253

<210> 18
 <211> 154
 <212> DNA
 <213> Homo sapiens

<400> 18
 cctgtcccaag atcacaggga cctggatcgtt gaaggccatg gtgggtcgata aggactttcc 60
 ggaggacagg agggccaggaa aggtgtcccc agtgaagatg acagccctgg gcgggtggaa 120
 ctggaaagcc acgttccactt tcatgtgtt gttt 154

<210> 19
 <211> 91
 <212> DNA
 <213> Homo sapiens

<400> 19
 tgtttccatc gagggaggat cgggtcatcc agaagaaaaat cctgtatgcgg aagacggagg 60
 agcctggcaaa atacagccgc t tgtagcccc 91

<210> 20
 <211> 126
 <212> DNA
 <213> Homo sapiens

<400> 20
 ggtgtacatc gttgtccgc agtcgatgtt gaccagatca cgcctggccct ctggggggcc 60
 cttagccatc acatggatc gaaatgttggg attggggacaag ggaggccaaag gatttaggtac 120
 ggggg 126

```

<210> 21
<211> 131
<212> DNA
<213> Homo sapiens

<400> 21
tcatctacag atgggggcag gaagctcata tacctgcagg agctgccccg gacggacgac 60
tacgtctttt actgcaaga ccagccgt gggggctgc gtcacatggg aaagtgtg 120
ggtgaggggc c 131

<210> 22
<211> 188
<212> DNA
<213> Homo sapiens

<400> 22
ctcccttttag catctgcctcc ctgcaggccc gtgccgcgtg cccacgcgtc gtcacactgg 60
ccacccatc tgcaaggtagg aatccataa ccaaccttgg ggccttggaa gaatttaaga 120
aattggtgca gcacaaggga ctctcgaggagg aggcacatttt cacgccttgc cagacgggtg 180
aggatcg 188

<210> 23
<211> 44
<212> DNA
<213> Homo sapiens

<400> 23
gtctctgcag gaagctgcgt tctcgaacac tagggtgagt gago 44

<210> 24
<211> 130
<212> DNA
<213> Homo sapiens

<400> 24
cccaagcacag cagccccccg gtctgcacct ccagagccca ccctaccacc agacacagag 60
cccgacaccat ctggacccatc cttccagcca tgaccccttc ctgtccccac ccacccgtact 120
ccaaataaaag 130

<210> 25
<211> 4
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      peptide

<400> 25
Gly Thr Trp Tyr
1

```

23

<210> 26
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Primer

<400> 26
cctgcaggta catgagcttc c

21

<210> 27
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Primer

<400> 27
cgctgtattt gccaggctcc

20

<210> 28
<211> 35
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 28
gactcgagtc gacatcgatt tttttttttt ttttt

35

<210> 29
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Primer

<400> 29
cctctcccaag ccccagcaag

20

<210> 30
<211> 17
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Primer

24

<400> 30
gactcgagtc gacatcg

17

<210> 31
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Primer

<400> 31
cgccccatgtga cctgccgagg tc

22

<210> 32
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Primer

<400> 32
cttttatttgg agtcaggtgg gtg

23

<210> 33
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Primer

<400> 33
ctctgcccccc tctgtgtatg

20

<210> 34
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Primer

<400> 34
cctgcttccac caccttcttg

20

<210> 35
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 35
gactcagact ccggagatga

20

<210> 36
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 36
aactcagaca ccagagatga

20

<210> 37
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 37
gactcagatc ccggagatga

20

<210> 38
<211> 18
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 38
ccaggaggga ccactaca

18

<210> 39
<211> 18
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 39
ccggggacgga cgactacg

18

<210> 40
 <211> 20
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

<400> 40
 ctcatgacca cagtccatgc

20

<210> 41
 <211> 18
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

<400> 41
 tgttcggaa cgcagctt

18

<210> 42
 <211> 20
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

<400> 42
 tgccgctgtc cccacgtcgg

20

<210> 43
 <211> 13
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic
 motif

<400> 43
 Ala Leu Trp Glu Ala Leu Ala Ile Asp Thr Arg Leu Lys
 1 5 10

<210> 44
 <211> 28

<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Primer

<400> 44
gtcggatccc tgccttac cctggagg

28

<210> 45
<211> 29
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Primer

<400> 45
gtcctcgagg tggcggaa cgcagttc

29

<210> 46
<211> 176
<212> PRT
<213> Homo sapiens

<400> 46
Met Lys Pro Leu Leu Leu Ala Val Ser Leu Gly Leu Ile Ala Ala Leu
1 5 10 15

Gln Ala His His Leu Leu Ala Ser Asp Glu Glu Ile Gln Asp Val Ser
20 25 30

Gly Thr Trp Tyr Leu Lys Ala Met Thr Val Asp Arg Glu Phe Pro Glu
35 40 45

Met Asn Leu Glu Ser Val Thr Pro Met Thr Leu Thr Thr Leu Glu Gly
50 55 60

Gly Asn Leu Glu Ala Lys Val Thr Met Leu Ile Ser Gly Arg Cys Gln
65 70 75 80

Glu Val Lys Ala Val Leu Glu Lys Thr Asp Glu Pro Gly Lys Tyr Thr
85 90 95

Ala Asp Gly Gly Lys His Val Ala Tyr Ile Ile Arg Ser His Val Lys
100 105 110

Asp His Tyr Ile Phe Tyr Cys Glu Gly Glu Leu His Gly Lys Pro Val
115 120 125

Arg Gly Val Lys Leu Val Gly Arg Asp Pro Lys Asn Asn Leu Glu Ala
130 135 140

Leu Glu Asp Phe Glu Lys Ala Ala Gly Ala Arg Gly Leu Ser Thr Glu
145 150 155 160

Ser Ile Leu Ile Pro Arg Gln Ser Glu Thr Cys Ser Pro Gly Ser Asp
 165 170 175

<210> 47
 <211> 176
 <212> PRT
 <213> Rattus sp.

<400> 47
 Met Lys Ser Arg Leu Leu Thr Val Leu Leu Leu Gly Leu Met Ala Val
 1 5 10 15

Leu Lys Ala Gln Glu Ala Pro Pro Asp Asp Gln Glu Asp Phe Ser Gly
 20 25 30

Lys Trp Tyr Thr Lys Ala Thr Val Cys Asp Arg Asn His Thr Asp Gly
 35 40 45

Lys Arg Pro Met Lys Val Phe Pro Met Thr Val Thr Ala Leu Glu Gly
 50 55 60

Gly Asp Leu Glu Val Arg Ile Thr Phe Arg Gly Lys Gly His Cys His
 65 70 75 80

Leu Arg Arg Ile Thr Met His Lys Thr Asp Glu Pro Gly Lys Tyr Thr
 85 90 95

Thr Phe Lys Gly Lys Lys Thr Phe Tyr Thr Lys Glu Ile Pro Val Lys
 100 105 110

Asp His Tyr Ile Phe Tyr Ile Lys Gly Gln Arg His Gly Lys Ser Tyr
 115 120 125

Leu Lys Gly Lys Leu Val Gly Arg Asp Ser Lys Asp Asn Pro Glu Ala
 130 135 140

Met Glu Glu Phe Lys Lys Phe Val Lys Ser Lys Gly Phe Arg Glu Glu
 145 150 155 160

Asn Ile Thr Val Pro Glu Leu Leu Asp Glu Cys Val Pro Gly Ser Asp
 165 170 175

<210> 48
 <211> 178
 <212> PRT
 <213> Bovine sp.

<400> 48
 Met Lys Cys Leu Leu Ala Leu Ala Leu Thr Cys Gly Ala Gln Ala
 1 5 10 15

Leu Ile Val Thr Gln Thr Met Lys Gly Leu Asp Ile Gln Lys Val Ala
 20 25 30

Gly Thr Trp Tyr Ser Leu Ala Met Ala Ala Ser Asp Ile Ser Leu Leu
 35 40 45

Asp Ala Gln Ser Ala Pro Leu Arg Val Tyr Val Glu Glu Leu Lys Pro
 50 55 60

Thr Pro Glu Gly Asp Leu Glu Ile Leu Leu Gln Lys Trp Glu Asn Gly
 65 70 75 80

Glu Cys Ala Gln Lys Lys Ile Ile Ala Glu Lys Thr Lys Ile Pro Ala
 85 90 95

Val Phe Lys Ile Asp Ala Leu Asn Glu Asn Lys Val Leu Val Leu Asp
 100 105 110

Thr Asp Tyr Lys Lys Tyr Leu Leu Phe Cys Met Glu Asn Ser Ala Glu
 115 120 125

Pro Glu Gln Ser Leu Ala Cys Gln Cys Leu Val Arg Thr Pro Glu Val
 130 135 140

Asp Asp Glu Ala Leu Glu Lys Phe Asp Lys Ala Leu Lys Ala Leu Pro
 145 150 155 160

Met His Ile Arg Leu Ser Phe Asn Pro Thr Gln Leu Glu Glu Gln Cys
 165 170 175

His Ile

<210> 49

<211> 180

<212> PRT

<213> Murine sp.

<400> 49

Met Lys Met Leu Leu Leu Cys Leu Gly Leu Thr Leu Val Cys Val
 1 5 10 15

His Ala Glu Glu Ala Ser Ser Thr Gly Arg Asn Phe Asn Val Glu Lys
 20 25 30

Ile Asn Gly Glu Trp His Thr Ile Ile Leu Ala Ser Asp Lys Arg Glu
 35 40 45

Lys Ile Glu Asp Asn Gly Asn Phe Arg Leu Phe Leu Glu Gln Ile His
 50 55 60

Val Leu Glu Asn Ser Leu Val Leu Lys Phe His Thr Val Arg Asp Glu
 65 70 75 80

Glu Cys Ser Glu Leu Ser Met Val Ala Asp Lys Thr Glu Lys Ala Gly
 85 90 95

Glu Tyr Ser Val Thr Tyr Asp Gly Phe Asn Thr Phe Thr Ile Pro Lys
 100 105 110

Thr Asp Tyr Asp Asn Phe Leu Met Ala His Leu Ile Asn Glu Lys Asp
 115 120 125

Gly Glu Thr Phe Gln Leu Met Gly Leu Tyr Gly Arg Glu Pro Asp Leu
 130 135 140

Met Ser Asp Ile Lys Glu Arg Phe Ala Gln Leu Cys Glu Glu His Gly
 145 150 155 160

Ile Leu Arg Glu Asn Ile Ile Asp Leu Ser Asn Ala Asn Arg Cys Leu
 165 170 175

Gln Ala Arg Glu
 180

<210> 50

<211> 199

<212> PRT

<213> Homo sapiens

<400> 50

Met Lys Trp Val Trp Ala Leu Leu Leu Ala Ala Trp Ala Ala Ala
 1 5 10 15

Glu Arg Asp Cys Arg Val Ser Ser Phe Arg Val Lys Glu Asn Phe Asp
 20 25 30

Lys Ala Arg Phe Ser Gly Thr Trp Tyr Ala Met Ala Lys Lys Asp Pro
 35 40 45

Glu Gly Leu Phe Leu Gln Asp Asn Ile Val Ala Glu Phe Ser Val Asp
 50 55 60

Glu Thr Gly Gln Met Ser Ala Thr Ala Lys Gly Arg Val Arg Leu Leu
 65 70 75 80

Asn Asn Trp Asp Val Cys Ala Asp Met Val Gly Thr Phe Thr Asp Thr
 85 90 95

Glu Asp Pro Ala Lys Phe Lys Met Lys Tyr Trp Gly Val Ala Ser Phe
 100 105 110

Leu Gln Lys Gly Asn Asp Asp His Trp Ile Val Asp Thr Asp Tyr Asp
 115 120 125

Thr Tyr Ala Val Gln Tyr Ser Cys Arg Leu Leu Asn Leu Asp Gly Thr
 130 135 140

Cys Ala Asp Ser Tyr Ser Phe Val Phe Ser Arg Asp Pro Asn Gly Leu
 145 150 155 160

Pro Pro Glu Ala Gln Lys Ile Val Arg Gln Arg Gln Glu Glu Leu Cys
 165 170 175

Leu Ala Arg Gln Tyr Arg Leu Ile Val His Asn Gly Tyr Cys Asp Gly
 180 185 190

Arg Ser Glu Arg Asn Leu Leu
195

<210> 51
<211> 159
<212> PRT
<213> Bovine sp.

<400> 51
Ala Gln Glu Glu Glu Ala Glu Gln Asn Leu Ser Glu Leu Ser Gly Pro
1 5 10 15

Trp Arg Thr Val Tyr Ile Gly Ser Thr Asn Pro Glu Lys Ile Gln Glu
20 25 30

Asn Gly Pro Phe Arg Thr Tyr Phe Arg Glu Leu Val Phe Asp Asp Glu
35 40 45

Lys Gly Thr Val Asp Phe Tyr Phe Ser Val Lys Arg Asp Gly Lys Trp
50 55 60

Lys Asn Val His Val Lys Ala Thr Lys Gln Asp Asp Gly Thr Tyr Val
65 70 75 80

Ala Asp Tyr Glu Gly Gln Asn Val Phe Lys Ile Val Ser Leu Ser Arg
85 90 95

Thr His Leu Val Ala His Asn Ile Asn Val Asp Lys His Gly Gln Thr
100 105 110

Thr Glu Leu Thr Glu Leu Phe Val Lys Leu Asn Val Glu Asp Glu Asp
115 120 125

Leu Glu Lys Phe Trp Lys Leu Thr Glu Asp Lys Gly Ile Asp Lys Lys
130 135 140

Asn Val Val Asn Phe Leu Glu Asn Glu Asp His Pro His Pro Glu
145 150 155

<210> 52
<211> 181
<212> PRT
<213> Rattus sp.

<400> 52
Met Lys Leu Leu Leu Leu Leu Cys Leu Gly Leu Thr Leu Val Cys
1 5 10 15

Gly His Ala Glu Glu Ala Ser Ser Thr Arg Gly Asn Leu Asp Val Ala
20 25 30

Lys Leu Asn Gly Asp Trp Phe Ser Ile Val Val Ala Ser Asn Lys Arg
35 40 45

Glu Lys Ile Glu Glu Asn Gly Ser Met Arg Val Phe Met Gln His Ile
50 55 60

Asp Val Leu Glu Asn Ser Leu Gly Phe Lys Phe Arg Ile Lys Glu Asn
 65 70 75 80

Gly Glu Cys Arg Glu Leu Tyr Leu Val Ala Tyr Lys Thr Pro Glu Asp
 85 90 95

Gly Glu Tyr Phe Val Glu Tyr Asp Gly Gly Asn Thr Phe Thr Ile Leu
 100 105 110

Lys Thr Asp Tyr Asp Arg Tyr Val Met Phe His Leu Ile Asn Phe Lys
 115 120 125

Asn Gly Glu Thr Phe Gln Leu Met Val Leu Tyr Gly Arg Thr Lys Asp
 130 135 140

Leu Ser Ser Asp Ile Lys Glu Lys Phe Ala Lys Leu Cys Glu Ala His
 145 150 155 160

Gly Ile Thr Arg Asp Asn Ile Ile Asp Leu Thr Lys Thr Asp Arg Cys
 165 170 175

Leu Gln Ala Arg Gly
 180

<210> 53
 <211> 157
 <212> PRT
 <213> Sus scrofa

<400> 53
 Gln Glu Pro Gln Pro Glu Gln Asp Pro Phe Glu Leu Ser Gly Lys Trp
 1 5 10 15

Ile Thr Ser Tyr Ile Gly Ser Ser Asp Leu Glu Lys Ile Gly Glu Asn
 20 25 30

Ala Pro Phe Gln Val Phe Met Arg Ser Ile Glu Phe Asp Asp Lys Glu
 35 40 45

Ser Lys Val Tyr Leu Asn Phe Phe Ser Lys Glu Asn Gly Ile Cys Glu
 50 55 60

Glu Phe Ser Leu Ile Gly Thr Lys Gln Glu Gly Asn Thr Tyr Asp Val
 65 70 75 80

Asn Tyr Ala Gly Asn Asn Lys Phe Val Val Ser Tyr Ala Ser Glu Thr
 85 90 95

Ala Leu Ile Ile Ser Asn Ile Asn Val Asp Glu Glu Gly Asp Lys Thr
 100 105 110

Ile Met Thr Gly Leu Leu Gly Lys Gly Thr Asp Ile Glu Asp Gln Asp
 115 120 125

Leu Glu Lys Phe Lys Glu Val Thr Arg Glu Asn Gly Ile Pro Glu Glu
130 135 140

Asn Ile Val Asn Ile Ile Glu Arg Asp Asp Cys Pro Ala
145 150 155

HUMAN ODORANT-BINDING PROTEINS WHICH BIND HYDROPHOBIC
LIGANDS: POLYPEPTIDES AND POLYNUCLEOTIDES ENCODING
SAID POLYPEPTIDES, AND APPLICATIONS THEREOF

5 The present invention relates to the demonstration of novel human odorant-binding proteins, hereafter named "OBPs", and also to the applications thereof, both therapeutically and non-therapeutically.

10 The present invention is based on the identification of a family of lipocalin genes, composed of three genes and two pseudogenes, on human chromosome 9q34; the three genes correspond to the LCN1 gene which has already been described and to two novel genes which are 15 the subject of the present invention and are called hOBPIIa and hOBPIIb. In addition, the invention is based on the attribution of novel functions to already known human lipocalins, through the demonstration of new areas of expression.

20 Although a certain number of OBPs have already been demonstrated (Pelosi et al., 1996), such as the rat OBP for example (see in particular patent EP-0 335 654), the OBPs according to the present invention are human

25 OBPs which have a very large number of advantages, as will emerge from the remainder of the text, compared to the murine proteins.

These OBP proteins of the lipocalin family have, as far 30 as some of them are concerned, been mentioned indirectly in patent WO 99/07740, but their OBP function has never been described to date; the same is also true of the proteins LCN1, retinol-binding protein (RBP) and apo-lipoprotein D (ApoD), as will be more fully explained 35 hereinafter.

Historically, the lipocalin family (Pervaiz and Brew, 1987), has been defined based on the human retinol-

binding protein (RBP) and on 3 other proteins: bovine β -lactoglobulin, rat $\alpha 2\mu$ -globulin and human $\alpha 1$ -micro-globulin. From these reference proteins, and using sequence homologies, the lipocalin family has increased

5 in size so as to now incorporate a large number of proteins, more than about 100, both in eukaryotes and in prokaryotes (Flower et al., 1995, 1996). This family consists of small proteins (160-190 amino acids) which contain a hydrophobic pocket and are generally secreted

10 (Bocskei et al., 1992; Senoo et al., 1990, Zeng et al., 1996; Miller, 1998), although, in certain cases, they are proteins which remain associated with the membrane (Nagata et al., 1991). In vertebrates, the sequence identities between the various lipocalins are in the

15 region of 20%; however, the sequence identities are greater for the orthologous proteins, and also for the recent paralogous genes described (Igarashi et al., 1992; Dewald et al., 1992).

20 The present invention relates to the isolated OBPII polypeptides encoded by the two new isolated human genes, OBPIIa and OBPIIb, located at the 9q34 locus; the invention also relates to the corresponding polynucleotide sequences, the corresponding mRNAs and also

25 the regulatory promoter sequences which determine the expression profile in the various tissues and in particular in the secretory tissues. These two genes encode at least seven different polypeptides given the existence of alternative splicing of the transcripts.

30 The OBPIIa gene encodes at least 4 different polypeptides, named OBPII_{a α} , OBPII_{a β} , OBPII_{a γ} and OBPII_{a δ} , and the OBPIIb gene encodes three different polypeptides, named OBPII_{b α} , OBPII_{b β} and OBPII_{b δ} . Even though one gene is mainly expressed, all the messenger forms are found

35 in the nasal structure.

The subject of the present invention is therefore an isolated polypeptide comprising an amino acid sequence having at least 90% identity with the amino acid

sequences SEQ ID No. 2, SEQ ID No. 4, SEQ ID No. 6, SEQ ID No. 8, SEQ ID No. 10, SEQ ID No. 12 or SEQ ID No. 14, and LCN1, ApoD and RBP.

5 It should be understood that the invention relates to the polypeptides obtained by purification from natural sources or obtained using recombinant techniques, as will be described subsequently; the invention also relates to the polypeptides obtained by chemical 10 synthesis, which may then comprise unnatural amino acids. In the present description, the term "polypeptide" will be used to denote equally a protein or a peptide.

15 The expression "percentage identity between the sequences" is intended to denote the percentage of amino acids which are identical between the sequences, obtained with the best possible sequence alignment, this percentage being purely statistical and the 20 differences between the polypeptides being distributed randomly and over the entire length.

The present invention also relates to an isolated polypeptide, characterized in that it comprises a polypeptide chosen from:

30 a) a polypeptide of sequence SEQ ID No. 2, SEQ ID No. 4, SEQ ID No. 6, SEQ ID No. 8, SEQ ID No. 10, SEQ ID No. 12 or SEQ ID No. 14;

b) a polypeptide which is a variant of a polypeptide of amino acid sequences defined in a);

35 c) a polypeptide homologous to the polypeptide defined in a) or b) and comprising at least 90% identity with said polypeptide of a);

d) a fragment of at least 15 consecutive amino acids of a polypeptide defined in a), b) or c);

e) a biologically active fragment of a polypeptide defined in a), b) or c).

5 The term "variant polypeptide" will be intended to mean all the mutated polypeptides which may exist naturally, in particular in humans, and which correspond in particular to truncations, substitutions, deletions and/or additions of amino acid residues. The variant
10 polypeptides according to the invention conserve at least one hydrophobic ligand-binding domain.

The term "homologous polypeptide" will be intended to denote the polypeptides exhibiting, compared to the
15 polypeptides of SEQ ID No. 2, SEQ ID No. 4, SEQ ID No. 6, SEQ ID No. 8, SEQ ID No. 10, SEQ ID No. 12 and SEQ ID No. 14, certain modifications, such as in particular a deletion, addition or substitution of at least one amino acid, a truncation, an extension and/or
20 a chimeric fusion. Among the homologous polypeptides, preference is given to those in which the amino acid sequence exhibits at least 90% identity, in preference 95%, preferably 97%, and even more preferably 99% identity with the amino acid sequences of the polypeptides according to the invention. In the case of a substitution, one or more amino acids, which may or may not be consecutive, are replaced with "equivalent amino acids". The expression "equivalent amino acid" is herein aimed at denoting any amino acid which can be
25 substituted for one of the amino acids of the basic structure, without however modifying the essential functional properties or characteristics of the corresponding polypeptides, their biological activities, such as for example the *in vivo* induction of antibodies
30 capable of recognizing the polypeptide, the amino acid sequence of which is included in the amino acid sequence SEQ ID No. 2, SEQ ID No. 4, SEQ ID No. 6, SEQ ID No. 8, SEQ ID No. 10, SEQ ID No. 12 or SEQ ID No. 14, or a fragment thereof. These equivalent amino
35

- 5 -

acids may be determined either based on their structural homology with the amino acids for which they substitute, or based on the results of cross biological assays which the various polypeptides may produce. By way of 5 example, mention will be made of the possibilities of substitutions which can be made without their being, as a result of this, an extensive modification of the biological activities of the correspondingly modified polypeptides; for example, replacing leucine with 10 valine or isoleucine, aspartic acid with glutamic acid, glutamine with asparagine, arginine with lysine, etc., it naturally being possible to envision the reverse substitutions under the same conditions. Thus, it is possible to envision introducing certain modifications, 15 such as in particular a deletion, addition or substitution of at least one amino acid, into the alpha-helices of the protein without destroying the calyx formed by the structure composed of the beta-sheets; similarly, it is possible to introduce equivalent amino 20 acids which make it possible to conserve the hydrophobic nature of the beta-sheets. It may also be advantageous to introduce modifications into the sequence of the polypeptides of the invention in order to generate homologous polypeptides lacking protease sites.

25 The term "biologically active fragment" will be intended to denote, in particular, a fragment of amino acid sequence of a polypeptide according to the invention, exhibiting at least one of the functional properties or 30 characteristics of the polypeptides according to the invention, in particular in that: (i) it is capable of being recognized by an antibody specific for a polypeptide according to the invention or by antibodies produced by patients during an immune reaction; (ii) it 35 has at least one of the domains or regions as defined below; (iii) it is capable of binding a hydrophobic ligand and in particular odorous molecules, preferably pheromones; (iv) it is capable of specifically binding a receptor.

The term "polypeptide fragment" is intended to denote a polypeptide comprising a minimum of 15 amino acids, in preference 18 amino acids, preferably 25 amino acids
5 and even more preferably 50 amino acids. The polypeptide fragments according to the invention, obtained by cleavage of said polypeptide with a proteolytic enzyme, or with a chemical reagent, or by placing said polypeptide in a very acid environment, are also part
10 of the invention. When the intention is to use a sequence of 15, 18, 25 or 50 amino acids, this, of course, preferably involves the portions corresponding to functional epitopes of the above polypeptides, which may be integrated into a polypeptide with a longer
15 structure, for example in the form of a fusion protein; this will depend on the intended uses of these polypeptides.

According to a preferred embodiment, the present
20 invention relates to an isolated polypeptide selected from a polypeptide corresponding to the sequence SEQ ID No. 2 and named OBPII_{αα}, to the sequence SEQ ID No. 4 and named OBPII_{αβ}, to the sequence SEQ ID No. 6 and named OBPII_{αγ}, to the sequence SEQ ID No. 10 and named
25 OBPII_{βα}, and to the sequence SEQ ID No. 12 and named OBPII_{ββ}.

The polypeptides according to the invention are characterized in that they preferably comprise the
30 Gly-Thr-Trp-Tyr domain.

The invention also relates to the isolated polynucleotide characterized in that it encodes a polypeptide as described above. The polynucleotide according to the
35 invention is chosen from the polynucleotide of sequence SEQ ID No. 1, SEQ ID No. 3, SEQ ID No. 5, SEQ ID No. 7, SEQ ID No. 9, SEQ ID No. 11 or SEQ ID No. 13.

The invention also relates to an isolated polynucleotide, characterized in that it comprises a polynucleotide chosen from:

- 5 a) a polynucleotide of sequence SEQ ID No. 1, SEQ ID No. 3, SEQ ID No. 5, SEQ ID No. 7, SEQ ID No. 9, SEQ ID No. 11 or SEQ ID No. 13, or the sequence of which is that of the RNA corresponding to the sequence SEQ ID No. 1, SEQ ID No. 3, SEQ ID No. 5, SEQ ID No. 7, 10 SEQ ID No. 9, SEQ ID No. 11 or SEQ ID No. 13;
- 15 b) a polynucleotide, the sequence of which is complementary to the sequence of a polynucleotide defined in a),
- 15 c) a polynucleotide, the sequence of which comprises at least 80% identity, in preference 90%, preferably 95%, and even more preferably 97% identity with a polynucleotide defined in a) or b),
- 20 d) a polynucleotide which hybridizes, under conditions of high stringency, with a sequence of a polynucleotide defined in a), b) or c),
- 25 e) a fragment of at least 15 consecutive nucleotides, in preference 21 consecutive nucleotides, and preferably 30 consecutive nucleotides, of a polynucleotide defined in a), b), c) or d).
- 30 In the present description, the terms "polynucleotide", "oligonucleotide", "polynucleotide sequence", "nucleotide sequence" or "nucleic acid" will be intended to denote a DNA fragment, both a double-stranded DNA, a single-stranded DNA and products for transcription of 35 said DNAs, and/or an RNA fragment, said synthetic or isolated natural fragments, possibly comprising unnatural nucleotides, denoting a precise chain of nucleotides, which may or may not be modified, making

it possible to define a fragment or a region of a nucleic acid.

The expression "polynucleotide of complementary sequence" is intended to denote any DNA, the nucleotides of which are complementary to those of SEQ ID No. 1, SEQ ID No. 3, SEQ ID No. 5, SEQ ID No. 7, SEQ ID No. 9, SEQ ID No. 11 or SEQ ID No. 13, or a portion of SEQ ID No. 1, SEQ ID No. 3, SEQ ID No. 5, SEQ ID No. 7, SEQ ID No. 9, SEQ ID No. 11 or SEQ ID No. 13, and the orientation of which is reversed.

For the purpose of the present invention, the term "percentage identity" is intended to mean a percentage of bases which are identical between the polynucleotides, obtained after the best alignment, this percentage being purely statistical and the differences between the two polynucleotides being distributed randomly and over their entire length.

For the purpose of the present invention, the expression "hybridization under conditions of high stringency" means that the conditions of temperature and ionic strength are chosen such that they allow the hybridization between two complementary DNA fragments to be maintained. By way of illustration, conditions of high stringency for the hybridization step for the purposes of defining the polynucleotide fragments described above are advantageously as follows:

The DNA-DNA or DNA-RNA hybridization is carried out in two steps: (1) prehybridization at 42°C for 3 hours in phosphate buffer (20 mM, pH 7.5) containing 5 × SSC (1 × SSC corresponds to a solution of 0.15 M NaCl + 0.015 M sodium citrate), 50% of formamide, 7% of sodium dodecyl sulfate (SDS), 10 × Denhardt's, 5% of dextran sulfate and 100 µg/ml of salmon sperm DNA; (2) actual hybridization for 20 hours at a temperature which depends on the length of the probe (i.e.: 42°C for a

probe of length > 100 nucleotides), followed by 2 washes for 20 minutes at 20°C in 2 × SSC + 2% SDS, 1 wash for 20 minutes at 20°C in 0.1 × SSC + 0.1% SDS. The final wash is carried out in 0.1 × SSC + 0.1% SDS for 5 30 minutes at 60°C for a probe of length > 100 nucleotides. The high stringency hybridization conditions described above for a nucleotide of defined length will be adjusted by those skilled in the art for longer or shorter oligonucleotides, according to the teaching of 10 Sambrook et al. (1989).

Advantageously, a nucleotide fragment corresponding to the above definition will have at least 15 consecutive nucleotides, preferably at least 21 nucleotides, and 15 even more preferentially at least 30 consecutive nucleotides, of the sequence from which it is derived.

According to one embodiment of the invention, the polynucleotide according to the invention is characterized 20 in that it is directly or indirectly labeled with a radioactive compound or a nonradioactive compound. The polynucleotide according to the invention is used as a primer for amplifying or polymerizing nucleic acid sequences; the invention also relates to the use of a 25 polynucleotide according to the invention as a probe for detecting nucleic acid sequences. According to the invention, the polynucleotide fragments which may be used as a probe or as a primer in processes for detecting, identifying, titering or amplifying nucleic 30 acid sequence will have a minimum length of 9 bases, preferably 18 bases, and even more preferably 36 bases. Finally, the invention relates to the use of a polynucleotide according to the invention as a sense or 35 antisense oligonucleotide for controlling the expression of the corresponding protein product, in this case a polypeptide according to the invention.

The unlabeled polynucleotide sequences according to the invention may be used directly as a probe, primer or

oligonucleotide; however, the sequences used are generally labeled so as to obtain sequences which can be used for many applications. The primers, probes and oligonucleotides according to the invention are labeled 5 with radioactive elements or with nonradioactive molecules; among the radioactive isotopes used, mention may be made of ^{32}P , ^{33}P , ^{35}S , ^3H or ^{125}I . The nonradioactive entities are selected from ligands, such as biotin, avidin, streptavidin or digoxigenin, haptens, 10 dyes and luminescent agents, such as radioluminescent, chemiluminescent, bioluminescent, fluorescent or phosphorescent agents.

The invention also comprises a method for detecting 15 and/or titering nucleic acid according to the invention, in a biological sample, characterized in that it comprises the following steps: (i) isolating the DNA from the biological sample to be analyzed, or obtaining a cDNA from the RNA of the biological sample; (ii) 20 specifically amplifying the DNA encoding the polypeptide according to the invention using primers; (iii) analyzing the amplification products.

The invention also comprises a kit for detecting and/or 25 titering a nucleic acid according to the invention, in a biological sample, characterized in that it comprises the following elements: (i) a pair of nucleic acid primers according to the invention, (ii) the reagents required to perform a DNA amplification reaction and, 30 optionally, (iii) a component for verifying the sequence of the amplified fragment, more particularly a probe according to the invention.

The invention also comprises a method for detecting 35 and/or titering nucleic acid according to the invention, in a biological sample, characterized in that it comprises the following steps: (i) bringing a probe according to the invention into contact with a biological sample; (ii) detecting and/or titering the

hybrid formed between said probe and the DNA of the biological sample.

The invention also comprises a kit for detecting and/or 5 titering nucleic acid according to the invention, in a biological sample, characterized in that it comprises the following elements: (i) a probe according to the invention, (ii) the reagents required to carry out a hybridization reaction and, where appropriate, (iii) a 10 pair of primers according to the invention, and also the reagents required for a DNA amplification reaction.

The invention in particular relates to the methods 15 according to the invention described above, for detecting and diagnosing cells of cancerous origin, and mainly breast, uterine, ovarian, prostate and lung cancers.

The polynucleotides according to the invention may thus 20 be used as a primer and/or probe in processes using in particular the PCR (polymerase chain reaction) technique (Erlich, 1989; Innis et al., 1990, and Rolfs et al., 1991). This technique requires choosing pairs of oligonucleotide primers which border the fragment which must 25 be amplified. Reference may, for example, be made to the technique described in American patent U.S. No. 4 683 202. The amplified fragments can be identified, for example after agarose or polyacrylamide gel electrophoresis or after a chromatography technique 30 such as gel filtration or ion-exchange chromatography. The specificity of the amplification can be controlled by molecular hybridization using, as a probe, the nucleotide sequences polynucleotides of the invention, plasmids containing these sequences or products of 35 amplification thereof. The amplified nucleotide fragments may be used as reagents in hybridization reactions in order to demonstrate the presence, in a biological sample, of a target nucleic acid of sequence

complementary to that of said amplified nucleotide fragments.

The invention is also directed toward the nucleotide 5 fragments which can be obtained by amplification using primers according to the invention.

Other techniques for amplifying target nucleic acid may advantageously be used as an alternative to PCR (PCR-like), using pairs of primers of nucleotide sequences 10 according to the invention. The term "PCR-like" will be intended to denote all methods using direct or indirect reproductions of nucleic acid sequences, or in which the labeling systems have been amplified; these 15 techniques are of course known; in general, this involves amplifying the DNA with a polymerase; when the sample of origin is an RNA, a reverse transcription should be performed beforehand. There are currently a large number of processes for this amplification, such 20 as for example the SDA (strand displacement amplification) technique (Walker *et al.*, 1992), the TAS (transcription-based amplification system) technique described by Kwok *et al.* in 1989, the 3SR (self-sustained sequence replication) technique described by 25 Guatelli *et al.* in 1990, the NASBA (nucleic acid sequence based amplification) technique described by Kievitis *et al.* in 1991, the TMA (transcription mediated amplification) technique, the LCR (ligase chain reaction) technique described by Landegren *et al.* 30 in 1988 and improved by Barany *et al.* in 1991, which uses a heat-stable ligase, the RCR (repair chain reaction) technique described by Segev in 1992, the CPR (cycling probe reaction) technique described by Duck *et al.* in 1990, and the Q-beta-replicase amplification 35 technique described by Miele *et al.* in 1983 and improved in particular by Chu *et al.* in 1986 and Lizardi *et al.* in 1988, and then by Burg *et al.* (1996) and also by Stone *et al.* (1996).

When the target polynucleotide to be detected is an RNA, for example an mRNA, use will advantageously be made, prior to carrying out an amplification reaction using the primers according to the invention or to 5 carrying out a detection process using the probes of the invention, of an enzyme of the reverse transcriptase type in order to obtain a cDNA from the RNA contained in the biological sample. The cDNA obtained will then be used as a target for the primers or the probes used 10 in the amplification or detection process according to the invention.

The nucleotide probes according to the invention hybridize specifically with a DNA or RNA molecule of a 15 polynucleotide according to the invention, more particularly with the sequences SEQ ID No. 1, SEQ ID No. 3, SEQ ID No. 5, SEQ ID No. 7, SEQ ID No. 9, SEQ ID No. 11 and SEQ ID No. 13, under high stringency hybridization conditions as given in the form of a 20 previous example.

The hybridization technique may be carried out in diverse ways (Matthews et al., 1988). The most general method consists in immobilizing the nucleic acid 25 extracted from the cells of various tissues or from cells in culture, on a support (such as nitrocellulose, nylon or polystyrene), and in incubating the immobilized target nucleic acid with the probe, under well-defined conditions. After hybridization, the 30 excess probe is removed and the hybrid molecules formed are detected by the suitable method (measurement of the radioactivity, of the fluorescence or of the enzymatic activity linked to the probe).

35 According to another embodiment of the nucleic acid probes according to the invention, they may be used as a capture probe. In this case, a probe, termed "capture probe", is immobilized on a support and is used to capture, by specific hybridization, the target nucleic

acid obtained from the biological sample to be tested, and the target nucleic acid is then detected using a second probe, termed "detection probe", labeled with an easily detectable element.

5

In a preferred embodiment, the invention comprises the use of a sense or antisense oligonucleotide for controlling the expression of the corresponding protein product. Among the advantageous nucleic acid fragments, 10 mention should in particular be made of the antisense oligonucleotides the structure of which ensures, by hybridization with the target sequence, inhibition of the expression of the corresponding product. Mention should also be made of the sense oligonucleotides 15 which, by interaction with proteins involved in regulating the expression of the corresponding product, will induce either inhibition or activation of this expression. The oligonucleotides according to the invention have a minimum length of 9 bases, preferably 20 of 18 bases, and even more preferably 36 bases.

The invention relates to a recombinant vector for cloning a polynucleotide according to the invention and/or for expressing a polynucleotide according to the 25 invention, characterized in that it contains a polynucleotide according to the invention as described above. The vector according to the invention is characterized in that it comprises the elements which allow the expression of said sequences in a host cell 30 and, optionally, the secretion of said sequences out of the host cell.

The term "expression vector" is intended to mean both autonomously replicating expression vectors of the 35 plasmid type and systems intended to ensure integration in the cells, but these expression vectors may also be expression vectors of the viral type or even, when the intention is to perform, for example, gene therapy, naked DNA. Among the viral vectors, preference is given

to those derived from adenoviruses, from adenovirus-associated viruses (AAVs), from retroviruses, from lentiviruses, and preferably HIV derivatives, from poxviruses and from the herpesvirus, for expression in 5 a eukaryotic system. Among the nonviral vectors, preference is given to naked polynucleotides, such as naked DNA or naked RNA according to the technique developed by the company VICAL, yeast artificial chromosomes (YACs) for expression in yeast, mouse 10 artificial chromosomes (MACs) for expression in murine cells and, preferably, human artificial chromosomes (HACs) for expression in human cells.

According to a particular embodiment, the vector 15 according to the invention comprises elements for controlling the expression of the polypeptides; these control elements are preferably chosen from (i) the promoter sequence of the hOBPIIa gene according to the invention, which corresponds to the sequence SEQ ID 20 No. 15 and/or from the promoter sequence of the hOBPIIb gene according to the invention, which corresponds to the sequence SEQ ID No. 16; (ii) a polynucleotide, the sequence of which is complementary to the sequence SEQ ID No. 15 and SEQ ID No. 16; (iii) a polynucleotide, 25 the sequence of which comprises at least 80% identity with a polynucleotide defined in (i) or (ii); (iv) a polynucleotide which hybridizes, under conditions of high stringency, with the polynucleotide sequence defined in (i), (ii) or (iii).

30 The computer tools available to those skilled in the art allow them to easily identify the regulatory promoter boxes required and sufficient to control the gene expression, in particular the TATA, CCAAT and GC 35 boxes, and also the stimulatory (enhancer) or inhibitory (silencer) regulatory sequences which control, in CIS, the expression of the genes according to the invention; among these regulatory sequences, mention should be made of IRE, MRE and CRE.

It is also within the scope of the invention to use the elements defined above and chosen from the sequence SEQ ID No. 15 and SEQ ID No. 16, for controlling the expression of heterologous polypeptides other than those of the invention, and in particular for directing the expression of heterologous polypeptides in the cell types in which the polypeptides according to the invention are normally expressed.

The invention also comprises the host cells, in particular the eukaryotic and prokaryotic cells, characterized in that they are transformed with the vectors according to the invention. The host cells are preferably transformed under conditions which allow the expression of a recombinant polypeptide according to the invention. The host cell may be chosen from bacterial cells, but also from yeast cells and from plant and animal cells; the host cell is preferably a mammalian cell (Edwards and Aruffo, 1993), but also an insect cell in which it is possible to use processes which use baculoviruses for example (Luckow, 1993). These cells may be obtained by introducing into host cells a nucleotide sequence inserted into a vector as defined above, and then culturing said cells under conditions which allow the replication and/or expression of the transfected nucleotide sequence.

According to a particular embodiment, the invention also relates to a transgenic animal or plant which comprises host cells according to the invention.

The invention also relates to a method for preparing a polypeptide, characterized in that it uses a vector according to the invention. More particularly, the invention relates to a method for preparing a recombinant polypeptide, characterized in that transformed cells according to the invention are cultured under conditions which allow the expression of said

- 17 -

recombinant polypeptide, and in that said recombinant polypeptide is recovered.

The polypeptide according to the invention can be obtained according to a process of the invention and according to the techniques for producing recombinant polypeptides known to those skilled in the art. The present invention therefore relates to the recombinant polypeptide which can be obtained using the method presented above. In this case, the nucleic acid sequence used is placed under the control of signals which allow its expression in a host cell. An effective system for producing a recombinant polypeptide requires a vector, for example of plasmid or viral origin, and a compatible host cell. The vector must comprise a promoter, translation initiation and termination signals, and also suitable regions for regulating transcription. It must be possible for it to be maintained stably in the cell and it may, optionally, contain particular signals which specify secretion of the translated polypeptide. These various control signals are chosen as a function of the host cell used. To this effect, the nucleic acid sequences according to the invention may be inserted into vectors which replicate autonomously in the host chosen, or vectors which integrate in the host chosen. Such vectors will be prepared according to the methods commonly used by those skilled in the art, and the clones resulting therefrom may be introduced into a suitable host using standard methods, such as for example transfection by calcium phosphate precipitation, lipofection, electroporation or heat shock.

The recombinant polypeptides obtained as indicated above may be both in the glycosylated form and nonglycosylated form, and may or may not have the natural tertiary structure.

The polypeptides obtained by chemical synthesis and possibly comprising unnatural amino acids, corresponding to said recombinant polypeptides, are also included in the invention. The peptides according to the invention 5 may also be prepared using techniques which are conventional in the domain of peptide synthesis. This synthesis may be performed in homogeneous solution or in solid phase.

10 The recombinant polypeptide purification processes used are known to those skilled in the art. The recombinant polypeptide may be purified from cell lysates and extracts, and/or from the culture medium supernatant, by methods used individually or in combination, such as 15 fractionation, chromatography methods, immunoaffinity techniques using specific monoclonal or polyclonal antibodies, etc. A preferred variant consists in producing a recombinant polypeptide fused to a "carrier" protein (chimeric protein). The advantage of 20 this system is that it allows stabilization and a decrease in the proteolysis of the recombinant product, an increase in solubility during the *in vitro* renaturation and/or simplification of the purification when the fusion partner has affinity for a specific 25 ligand.

The present invention relates to the use of a polypeptide chosen from an hOBPIIa and hOBPIIb polypeptide according to the invention, or a fragment thereof, and 30 from LCN1, retinol-binding protein (RBP) and apolipoprotein D (ApoD), as a protein which binds to a hydrophobic ligand, preferably an odorous molecule. In fact, besides the OBP function of the lipocalins LCN1, RBP and ApoD 35 has never been suggested. Specifically, while the presence of LCN1 in the nasal mucus has been described (Redl et al., 1992), it was, in fact, attributed another function, namely an antiprotease function, whereas the main function of the LCN1 protein purely

appears to be the transport of hydrophobic ligands; moreover, the tests carried out in the context of the present invention with a recombinant LCN1 protein have not made it possible to demonstrate antiprotease 5 activity. The same is true for retinol-binding protein and apolipoprotein D, which have never been presented as having OBP function.

10 The present invention also relates to the use of a polypeptide according to the invention or a fragment thereof, LCN1, RBP and apolipoprotein D as a competitive inhibitor, as an agonist or as an antagonist of the cellular receptors for lipocalins. The use of an inhibitor of the binding of lipocalins to their 15 receptor may be employed in an anticancer strategy; specifically, a certain number of tumors are hormone-dependent: thus, breast tumors are sensitive to steroids; since the steroids are transported by lipocalins, it is within the scope of the invention to 20 provide inhibitors of binding to the polypeptides according to the invention and LCN1, OBP or APO-D to avoid the binding of steroid hormones to the receptors of tumor cells.

25 The invention also relates to a monoclonal or polyclonal antibody and fragments thereof, characterized in that they specifically bind a polypeptide according to the invention. Chimeric antibodies, humanized antibodies and single-chain antibodies are also part of the 30 invention. The antibody fragments according to the invention are preferably Fab or F(ab')2 fragments.

35 The polypeptides according to the invention make it possible to prepare monoclonal or polyclonal antibodies. The monoclonal antibodies may advantageously be prepared from hybridomas according to the technique described by Kohler and Milstein in 1975. The polyclonal antibodies may be prepared for example by immunizing an animal, in particular a mouse, with a

polypeptide according to the invention combined with an adjuvant of the immune response, and then purifying the specific antibodies contained in the serum of the immunized animals on an affinity column to which the 5 polypeptide having been used as the antigen has been attached beforehand. The polyclonal antibodies according to the invention may also be prepared by purification on an affinity column on which a polypeptide according to the invention has been immobilized beforehand.

10 The invention also relates to a monoclonal antibody specific for a polypeptide according to the invention and capable of inhibiting the interaction between said polypeptide and the cellular receptor to which said 15 polypeptide specifically binds. According to another embodiment, the monoclonal antibody according to the invention is capable of inhibiting the interaction between said polypeptide and its hydrophobic ligands, in preference the odorous molecules, and preferably the 20 pheromones, to which said polypeptide binds.

The antibodies of the invention may also be labeled in the same way as described previously for the nucleic acid probes of the invention, and preferably with 25 labeling of the enzymatic, fluorescent or radioactive type. Such labeled antibodies may be used to detect these polypeptides in a biological sample. The biological sample preferably consists of a fluid, for example human biopsies, serum or blood. They thus 30 constitute a means for analyzing the expression of the polypeptide according to the invention, for example by immunofluorescence and/or gold-labeling, and/or with enzymatic immunoconjugates.

35 More generally, the antibodies of the invention may advantageously be used in any situation in which the expression of a polypeptide according to the invention is to be observed, and more particularly in immuno-cytochemistry, in immunohistochemistry or in Western

blotting experiments, or in ELISA and RIA techniques. It is thus within the scope of the invention to provide a method for detecting and/or titering a polypeptide according to the invention, in a biological sample,

5 characterized in that it comprises the steps of bringing the biological sample into contact with antibodies according to the invention, and then revealing the antigen-antibody complex formed.

10 Also falling within the context of the invention is a kit for detecting and/or titering a polypeptide according to the invention, in a biological sample, characterized in that it comprises the following elements: (i) a monoclonal or polyclonal antibody as

15 described above; (ii) where appropriate, the reagents for constituting the medium suitable for the immunological reaction; (iii) the reagents for detecting the antigen-antibody complexes produced by the immunological reaction. This kit is in particular useful for

20 carrying out Western blotting experiments and for immunoprecipitation experiments.

The hOBPIIs according to the present invention may be used in many applications.

25 The first applications of the OBPs lie in the control of odorants; these applications essentially concern personal hygiene (perfumery, cosmetology, pharmacy) or general hygiene.

30 They may be used in a process for controlling the volatilization of an odorant; such a process is characterized in that it comprises a step of binding of said odorant with a polypeptide according to the

35 invention or with the LCN1, RBP or apolipoprotein D proteins.

It is also possible to bind the odorant to a solid support using an OBPII according to the invention

- 22 -

attached to said support, it being possible for this binding to be both covalent binding and noncovalent binding, for example by adsorption or by binding of the avidin-biotin type, if necessary. Under these 5 conditions, a fragranced support is obtained which retains the odorants for a longer period of time, gradually releasing them and possibly being used both in the cosmetics domain and in the domain of maintenance products in general. The supports used may be supports 10 of the block type or of the ball type, for example. Of course, the OBPIIs according to the present invention may be more particularly used in the perfumery and cosmetics industry, in which the OBPs will be used in the form of a liquid mixture intended to control the 15 volatilization of the odorants after the composition has been spread on human skin. This makes it possible to prolong the "staying-power" of fragrances or to form part of the composition of body deodorants in particular. Of course, the term "fragrance" generally 20 encompasses the mixtures known in perfumery, based on alcohol or in aqueous form, and containing in particular essential oils. The polypeptide according to the invention may also form part of the composition of retinol-based creams, as an agent for transporting and 25 protecting said retinol, for cosmetological applications, and in particular for preventing, smoothing out and treating wrinkles and fine lines of the skin, and combating cutaneous and/or subcutaneous loosening.

30 Among the applications relating to general hygiene, the process according to the invention may be used in a device directed toward deodorizing premises, such as for example animal houses or cowsheds. Such a device may also be envisioned for deodorizing the flow of air 35 entering an air conditioning machine; such a device would be very useful in geographical regions which are polluted.

The invention also relates to a process for screening a molecule, preferably odorants or flavors, which comprises passing the molecule over a substrate which comprises a polypeptide according to the invention or 5 LCN1, RBP and apolipoprotein D, bound to said substrate, said polypeptide binding said odorant or flavor, and recovering said odorant or flavor from the polypeptide if necessary. The OBPs according to the invention may thus make it possible to isolate odorants 10 or fragrances, by binding them to a support as described above but which, in this case, may be, for example, a chromatography column, by passing over this column the product from which it is desired to capture the odorants. It is, of course, possible, still in this 15 same type of application, to carry out an analysis of a complex fragrance using the differences in retention of the various products by the OBPs.

The isolation process described above may also be used 20 to separate particular "odorants", especially human pheromones.

The hOBPIIs according to the present invention may be used for agrofoods or industrial applications.

25 The OBPs according to the present invention, by virtue of their characteristics, may make it possible to solubilize certain lipophilic molecules by associating them with said OBPs. Thus, the polypeptides according 30 to the invention may be used in combination with dietary fatty acids by way of a food supplement. The present invention relates to a process for solubilizing lipophilic molecules, characterized in that it comprises binding said lipophilic molecule to a 35 polypeptide according to the invention, to LCN1, to RBP or to apoD.

The OBPIIs, like LCN1, RBP and ApoD, may be involved in the transport of fatty acids and in the biological

mechanisms for detecting the fatty acid load of the food intake, in particular in the buccal region. The invention therefore also relates to the use of the polypeptides above, in combination with fatty acids,
5 for decreasing the consumption of fatty acids, in particular in hyperlipidemias or in obesity. The polypeptides above may therefore be used for treating hyperlipidemias and obesity. Specifically, these proteins contribute to the detection of the fatty acid
10 content in the food taken in (Gilbertson, 1998); an excess of these proteins should lead to the physiological system which detects the fatty load of a food intake being deceived. Thus, a food portion which is low in fat but supplemented with OBP, ApoD, RBP or LCN1
15 pre-loaded with fatty acid will be falsely identified as being rich in fat.

Another application is to supplement a nonmaternal milk with one or more of the polypeptides described above.
20

The OBPs according to the present invention may be used in preventive and curative therapy.

Thus, a lack of detection of this type of protein in a
25 biological specimen using an antibody, a primer and/or a probe according to the invention may be an element for the diagnosis of anosmia.

Similarly, it is possible to envision the detection of
30 anti-OBPII antibodies in a biological sample of human origin; the presence or the titer of these antibodies may be related to certain types of allergy, in particular in asthmatics. In this case, it may be possible to treat this type of allergy by administering
35 polypeptide fragments as described, which would decrease the immune reactions to the external allergies.

The invention therefore relates to a process for detecting antibodies against human OBPIIs (hOBPIIs) in human serum from an allergic and/or asthmatic patient using an hOBPII polypeptide according to the invention.

5

According to another embodiment, the invention relates to a process for detecting antibodies against human OBPIIs (hOBPIIs) in a biological fluid from a patient suffering from a cancer, and in particular from prostate cancer and/or from breast cancer and/or from uterine cancer and/or from ovarian cancer and/or from lung cancer. Specifically, the proteins according to the invention are overexpressed in tumors, and in particular in prostate cancer (US 5804368, WO 97 10503, 10 CS 84 02898, CS 83 02012, CS 82 08506, CS 82 08215), 15 breast cancer (Stoeicz and Gould, 1995; Simard *et al.*, 1992), uterine cancer, ovarian cancer and lung cancer.

20 The OBPs according to the present invention may also be used in pharmaceutical compositions, this being in particular in order to deliver certain drugs.

In fact, lipocalins are used by mammals to transport hydrophobic molecules in biological fluids. It even 25 appears that they are the natural transporters of xenobiotics *in vivo*. For example, an experimental overload of xenobiotics creates, in male rats, tumors in the proximal convoluted tube (PCT) of the nephron (Borghoff *et al.*, 1990). Specifically, the MUP proteins, 30 only produced in male rats, are reabsorbed by the PCT cells; after lysosomal degradation, the MUP proteins release the xenobiotics which they were transporting. These xenobiotics accumulate in these cells and lead them toward a tumor pathway by mutagenesis. Lipocalins 35 therefore appear to be the ideal structure to trap, in their calyx, a molecule used as a medicinal product, thus avoiding a general distribution thereof. Thus, G. Beste *et al.* (1999) and application WO 99 16873 describe a strategy of mutagenesis and screening

variants of a lipocalin having optimum affinity for a given ligand. It is therefore possible to create a highly specific "medicinal product cage".

5 The present invention therefore relates to a polypeptide according to the invention, as an agent for targeting a pharmaceutical compound. The expression "agent for targeting" is intended to denote the polypeptides of the invention capable of transporting and releasing the
10 ligand to which they are bound, at the level of certain target tissues or cells which have, at their surface, receptors for said polypeptides. Thus, the invention relates to the transport of a medicinal product in the cage of a polypeptide according to the invention, and
15 targeting cells through the ability of the OBPII to bind to a specific receptor.

It is also within the scope of the invention to develop fusion proteins or chimeric proteins comprising the
20 cage corresponding to the lipocalins according to the invention combined with a protein which allows specific cellular addressing, generally different from that which is natural for the OBPIIs. A subject of the present invention is therefore a polypeptide, characterized in that said polypeptide is expressed in the form of a protein from fusion with a protein which allows specific cellular addressing. Among the proteins which allow specific cellular addressing, mention should be made of interleukins, of cytokines, of
25 lymphokines, of chemokines, of growth factors, of hormones, and of monoclonal or polyclonal antibodies. The interleukins, cytokines and lymphokines are chosen from a group preferably composed of the interleukins II-1 to II-20, and the interferons α -IFN, β -IFN and
30 γ -IFN. The growth factors are preferably chosen from the colony stimulating factors G-CSF, GM-CSF, M-CSF, and erythropoietin. The hormones are preferably chosen from steroid hormones.

According to another embodiment, the polypeptide according to the invention, as an agent for targeting a pharmaceutical compound, is combined with a molecule which allows specific cellular addressing. Among the 5 molecules which allow specific cellular addressing, mention should be made of the group of steroids, of interleukins, of cytokines, of lymphokines, of interferons, of growth factors, of hormones and of antibodies. The molecule is preferably a steroid. The 10 combination of the polypeptide according to the invention and said molecule is produced either via a noncovalent attachment, using for example the avidin-biotin system, or via a covalent attachment, using for example chemical bridging agents.

15 Among the pharmaceutical compounds which the polypeptide according to the invention may transport and target, mention should be made of medicinal products, and in particular anticancer agents. The anticancer 20 agents are selected from the group of antiproliferative, antineoplastic or cytotoxic agents, and are used to arrest the development of cancers and to induce regression and/or elimination of the tumor mass. These anticancer agents are preferably radioisotopes, and 25 even more preferably gamma-ray-emitting radioisotopes, such as iodine¹³¹, yttrium⁹⁰, gold¹⁹⁹, palladium¹⁰⁰, copper⁶⁷, bismuth²¹⁷ and antimony²¹¹. Beta- and alpha-ray-emitting radioisotopes may also be used for the therapy. The non-isotopic anticancer agents bound to 30 the polypeptide according to the invention are many and varied; mention may be made of: (i) antimetabolites, such as antifolate agents, methotrexate, (ii) purine and pyrimidine analogs (mercaptopurine, fluorouracil, 5-azacytidine), (iii) antibiotics, (iv) lectins (ricin, 35 abrin) and (iv) bacterial toxins (diphtheria toxin); the toxins are preferably chosen from *Pseudomonas* exotoxin A, diphtheria toxin, cholera toxin, *Bacillus* anthrox toxin, Pertussis toxin, *Shigella* Shiga toxin,

Shiga-like toxin, *Escherichia coli* toxins, colicin A, d-endotoxin and *Haemophilus A* hemagglutinin.

The invention also relates to a pharmaceutical composition comprising a pharmaceutical compound bound to at least one polypeptide according to the invention, and a pharmaceutically acceptable vehicle. It is also within the scope of the invention to increase the binding capacity by mutagenesis of this same protein. The invention also relates to a pharmaceutical composition as defined above, for treating cancer, and in particular prostate cancer, breast cancer, uterine cancer, ovarian cancer, liver cancer and pulmonary epithelial cell carcinoma. Given that the OBP named hOBPIIb, apolipoprotein D, RBP and α -1-acid glycoprotein are expressed in the prostate, the pharmaceutical composition according to the invention is intended for the treatment of prostate cancer. Similarly, given that it has been demonstrated that the mRNA of the ApoD, RBP and LCN1 proteins is produced in the mammary gland, in addition to the production of hOBPIIb already described in application WO 99 07740, the pharmaceutical composition according to the invention is intended for the treatment of breast cancer.

The invention also relates to a polypeptide according to the invention, as a pharmaceutical compound transporter. The term "transporter" is intended to denote polypeptides according to the invention capable of vehiciling a pharmaceutical compound, in the body, without said compound being released at a preferred site in the body. Such a polypeptide constitutes a means for delivering said pharmaceutical compound in the body.

The present invention also relates to a pharmaceutical composition according to the invention, characterized

in that said polypeptide constitutes a delayed form of delivery of said pharmaceutical compound in the body.

Specifically, the pharmaceutical compound of interest
5 bound to the OBPII polypeptide according to the invention gradually diffuses in the body as said transporter polypeptide is catabolized in the body. The use of recombinant DNA techniques allows those skilled in the art to modify the half-life duration of the
10 OBPII polypeptide in the body by introducing modifications into said polypeptide. Thus, it may be advantageous to develop a homologous polypeptide according to the invention, for which the protease cleavage sites have been mutated in order to increase
15 the half-life of said polypeptide in the body. It may also be advantageous to develop a multimeric polypeptide, expressed for example in the form of a fusion protein, in order to avoid a "glomerular escape" (renal clearance) and thus to increase the half-life of said
20 polypeptide in the body.

According to another aspect, the invention relates to a compound characterized in that it is chosen from an antibody, a polypeptide, a ligand, a polynucleotide, an
25 oligonucleotide and a vector according to the invention, as a medicinal product, and in particular as active principles of a medicinal product; these compounds will preferentially be in soluble form, and combined with a pharmaceutically acceptable vehicle.
30 The term "pharmaceutically acceptable vehicle" is intended to denote any type of vehicle conventionally used in the preparation of injectable compositions, i.e. a diluent and/or a suspending agent, such as an isotonic or buffered saline solution. These compounds
35 will preferably be administered systemically, in particular intravenously, intramuscularly, intradermally or orally. Their optimal methods of administration, doses and pharmaceutical forms may be determined according to the criteria generally taken into account

in establishing a treatment suitable for a patient, such as for example the age or bodyweight of the patient, the seriousness of his or her general condition, the tolerance to the treatment and the side 5 effects observed, etc.

The invention also relates to a pharmaceutical composition comprising an expression vector according to the invention and a pharmaceutically acceptable 10 vehicle.

It is also possible to use the property of expression in particular sites of these proteins in order to provide imaging and/or a diagnosis of certain types of 15 cancer.

Finally, given the high expression of the polypeptides according to the invention in the placenta (cf. figure 10), the present invention provides various 20 therapeutic applications intended to treat pathological conditions of gestation in women.

Thus, one of the objects of the present invention is to use the polypeptide according to the invention for 25 preparing a medicinal product intended to transport compounds across the placental barrier. These compounds are preferably lipophilic molecules. The polypeptide according to the invention may be used to transport compounds from the gestating mother to the fetus; the 30 compounds possibly being chosen from the molecules of therapeutic interest, which are preferably lipophilic, essential fatty acids, hormones, vitamins and, more generally, small lipophilic molecules.

35 In fact, it has been demonstrated that the cells of the placental villi secrete massive amounts of the polypeptide according to the invention, in particular the OBPIIs. These polypeptides then spread through the

fetal blood and to the general blood circulation of the fetus.

In addition, the polypeptide according to the invention
5 may be used to transport a compound from the fetus to
the gestating mother. Specifically, the fetus secretes,
via the villi of the nasal structures, polypeptides
according to the invention which participate in
molecule exchanges between the fetus and the mother at
10 the amniotic membrane. An object of the present
invention is therefore also to provide the fetus with
polypeptides according to the invention so as to allow
the transport of compounds present in the fetus, for
example xenobiotics, to the placenta and/or to the
15 amniotic membrane, in order to allow the detoxification
of the fetus.

According to another aspect of the invention, the polypeptide according to the invention may be used as a
20 pregnancy marker. Specifically, the polypeptide according to the invention is present in various biological liquids of the mother, such as the urine or blood; measuring the concentration thereof and/or the presence thereof constitutes a pregnancy marker. In
25 this capacity, this marker may be used with, or in place of, or in addition to the pregnancy marker constituted by human choriogonadotrophin, hCG; the polypeptide according to the invention and hCG are, in fact, molecules which are secreted by the trophoblastic
30 placental cells.

Finally, according to another aspect of the invention, the polypeptide may be used as a marker for feto-placental pathological conditions. It may constitute a
35 marker for the rupture of the amniotic sack membrane.

Other characteristics and advantages of the invention appear in the remainder of the description with the

examples and the figures, the legends of which are represented below.

FIGURE 1: Genomic organization of the LCN1/hOBPII locus

5

The top line represents the region of chromosome 9q34. The double-headed arrow indicates the gap between the location of the polymorphic markers D9S1811 and D9S67; the relative position of the markers D9S67 and D9S1826 10 is uncertain.

The middle level indicates the partial organization of the cosmids at 3 different loci: LCN1c, LCN1b-hOBPIIb, LCN1-hOBPIIa. The cosmids (approximately 40 kb) are 15 represented by horizontal lines with their name and the arms of the T3 and T7 vectors noted below the line. The arrows represent the various genes or pseudogenes with their respective orientation. In the cosmids, the vertical dotted lines represent the EcoRI sites. The symbol \otimes indicates an uncertain orientation of the 20 locus.

The bottom level shows the intron/exon structures of the LCN1 and hOBPII genes: the black boxes represent the 25 exons; the arrows represent the transcription initiation site; o11 to o15 represent the oligonucleotide probes used to screen the cosmids; Alu represents the presence of repeat sequences.

30 **FIGURE 2: Dot Plot Analysis of:**

- (A) sequence of the LCN1-hOBPIIa locus (AC000396+ACXXXXXX) versus the LCN1b-hOBPIIb locus (AC002098);
- (B) sequence of the LCN1-hOBPIIa locus (AC000396+ACXXXXXX) versus the sequence of the LCN1c locus;
- 35 (C) sequence of the LCN1b-hOBPIIb locus (AC002098) versus the sequence of the LCN1c locus (AC002106).

Genomic sequences were filtered for the repetitive sequences using "Repeatmasker" (REF), and then compared

and dotplotted with the program gcg using a window size of 25, and a criterion of 20 with an 80% homology.

FIGURE 3: Nucleotide sequence of hOBPII genes

5

The upper lines represent the hOBPIIa sequence and the lower lines represent the hOBPIIb sequence for which only the different nucleotides are represented; a dash indicates the absence of corresponding sequences. The 10 shaded capitals are the exon sequences and the lower case letters are the intron sequences. The sizes indicated on the left are indicated in bp. The TATA box is in bold characters and the polyadenylation signal is underlined. The boxes indicate the splice acceptor 15 sites for exons 5, 5b and 5c.

FIGURE 4: Diagrammatic representation of the two hOBPII genes and of their corresponding mRNAs

20 The horizontal lines represent the exon/intron organization with sizes indicated in bp. The shaded boxes numbered from 1 to 7 are the coding exon sequences of the main transcripts; the letters b and c refer to supernumerary exons. The various transcripts 25 are represented using assembled boxes: the first, hOBPIIa α and hOBPIIb α , correspond to the main transcripts, the others correspond to the forms derived from alternate splicing. ↓ indicates a shift in the reading frame resulting from the insertion or from the 30 deletion of an exon and ' represents a stop codon. The letter "a" represents an α -helix and "b" β -sheets predicted by the DSC program. The letters in italics are predictions obtained with the "Predator" program.

35 **FIGURE 5: Alignment of the protein sequences derived from the two human genes hOBPIIa and hOBPIIb (hOBPIIa α = OBP2aaHOMS, hOBPIIb α = OBP2baHOMSA, hOBPIIb β = OBP2bbHOMSA, hOBPIIa γ = OBP2agHOMSA, hOBPIIa β = OBP2abHOMSA), of human tear lipocalins (LCN1_HOMSA), of**

rat OBPII (OBP2_RATNO), of bovine lactoglobulin BLG (LACB_BOSTA), of mouse MUP (MUP6_MUSMU), of human RBP (RBP_HOMSA), of bovine OBP (OBP_BOSTA), of rat MUP (MUP_RATNO) and of porcine OBP (OBP_SUSSC).

5

The residues in the dark gray boxes are identical and those in the light gray boxes are similar. The elements of secondary structure predicted with the DSC program are underlined and the amino acid residues are in 10 italics. The β -sheets and the α -helices are numbered for hOBPIIa and b. The anticipated signal peptide cleavage site is indicated with an arrow (AAA \downarrow LS) at position 15. Nonaligned sequences of very divergent 15 forms of spliced genes, hOBP α δ (OBP2adHOMSA) and hOBP β y (OBP2bgHOMSA) have been added at the bottom of the alignment after the analysis.

FIGURE 6: RT-PCR analysis

20 (A) Detection of the LCN1, LCN1b and LCN1c RT-PCR products with their specific probes, and (B) detection of the hOBPIIa and hOBPIIb RT-PCR products with their specific probes. (C) Control G3PDH RNA. The sizes are indicated in bp.

25

FIGURE 7: Tissue location of the hOBP mRNAs

Sections of the middle meatus (A, B), of the conchae (C, D), of the prostate (E, F), of the vas deferens (G, 30 H), and of the mammary glands (I, J) were hybridized with digoxigenin-11-UTP-labeled hOBP riboprobes. The hybridization with a sense hOBP riboprobe did not reveal any signal (B, D, F, H, J). A specific 35 hybridization signal is obtained with an antisense riboprobe (A, C, E, G, I). The arrows indicate different structures: AC: acinar cells, EC: epithelial cells, GC: glandular cells, SD: secretory duct and L: lumen (X200).

FIGURE 8: Phylogenetic distance tree for vertebrate lipocalins

The usual abbreviations for lipocalins were used.
5 Indicated after the symbol "_" are the first three letters of the genus followed by the first two letters of the species.

FIGURE 9: Scheme of the evolution of the LCN1-OBPII gene subfamily during evolution

The boxes indicate the exons arranged on a line representing the genomic DNA. The "://" between the lines indicate that the loci are not consecutive,
15 without it being possible to determine the order. The large cross under the symbol "?" illustrates a partial duplication or complete duplication event with a subsequent genomic deletion for the LCN1c locus (choice indicated by the symbol "*"). The smallest cross
20 indicates the removal of the seventh exon which appears to be specific for humans because of the numerous repeat sequences Alu present in this genomic region and because the rat has two VEGP genes. The symbol "*" marks the exon recruitment step based on the data
25 present and those of the literature; this step may have appeared at any time after the duplications of the loci and may have been sequential.

FIGURE 10: RT-PCR analysis, in the oral sphere and the genital sphere, of the expression of the other known human lipocalins

Definition of novel OBP and VEGP functions for the RBP (retinol-binding protein) and ApoD (apolipoprotein D)
35 proteins.

FIGURE 11: Study of the polyclonal antibody against the hOBPII proteins

5 The fusion protein is loaded in wells 1 and 3. A sample
of human nasal mucus is loaded in wells 2 and 4. The
proteins contained in wells 1 and 2 were revealed with
10 Coomassie blue staining. The antibody hybridized on the
membrane obtained by Western blotting specifically
reveals the GST-hOBPIIb protein between 30 and 42 kDa
15 (well 3) and the 18 kDa hOBPIIa and hOBPIIb (well 4) in
the human nasal mucus.

FIGURE 12: Immunohistochemistry on the tissues of the olfactory apparatus

15 Strong immunoreactivity can be observed on the section
of septum (green staining, A) on the two sections of
concha (C and D) and on the section of middle meatus
(F). The negative controls prepared for the septum (B),
20 for the concha (E) and for the middle meatus (G) show
no reactivity. The cell nuclei are located by DAPI
staining (blue staining). The magnifications used are
X 100 for the sections A, B, C, E and G, and X 200 for
the sections D and F.

25 **FIGURE 13: Immunohistochemistry on tissues of the oral sphere**

These two tissues, lacrymal glands (A, B) and von
30 Ebner's glands (E, F) show strong immunoreactivity
compared to the results obtained with the pre-immune
serum (C for the lacrymal glands and D for the von
Ebner's glands). Magnification X 200.

35 **FIGURE 14: Immunohistochemistry on the mammary glands and lung**

Strong immunoreactivity is visible on the sections of
mammary glands (A and B) compared to the negative

- 37 -

control (C) prepared using pre-immune serum. Strong immunoreactivity is also observed on the sections of lung (E and F), again compared to the negative control (D). Each observation is made at a magnification of 5 X 100 for A and C and at a magnification of X 200 for B, D, E and F.

FIGURE 15: Demonstration of the hOBPII proteins in various nasal structures: concha (A: 200x, B: 400x), 10 septum (C: 300x, D: 600x), middle meatus (E: 400x, F: 600x)

Detection of the hOBPII proteins with a rabbit polyclonal serum revealed by peroxidase activity detected by DAB. AC: secretory acinar cell, P: DAB precipitate (hOBPII detection). 15

FIGURE 16: Demonstration of the LCN1 protein in various nasal structures: concha (A: 200x, B: 500x), septum (C: 20 100x, D: 500x), middle meatus (E: 200x, F: 600x)

Detection of the LCN1 protein with a rabbit polyclonal serum revealed by peroxidase activity detected by DAB. AC: secretory acinar cells, P: DAB precipitate (LCN1 25 detection).

FIGURE 17: Demonstration of the ApoD protein in various nasal structures: concha (A: 500x, B: 700x), septum (C: 300x), middle meatus (D: 400x)

Detection of the ApoD protein with a mouse monoclonal antibody revealed by peroxidase activity detected by DAB. AC: secretory acinar cell, P: DAB precipitate (ApoD detection). 35

FIGURE 18: Demonstration of the hOBPII protein in various structures of the oral sphere: lacrymal gland (A: 200x, B: 600x), von Ebner's glands (C: 100x, D: 400x), lung (E: 200x, 800x)

5

Detection of the hOBPII protein with a rabbit polyclonal serum revealed by peroxidase activity detected by DAB. AC: secretory acinar cell, P: DAB precipitate (hOBPII detection).

10

FIGURE 19: Demonstration of the hOBPII proteins in various placental structures: chorionic villi (A: 300x, B: 800x), amniotic membrane (C: 800x), cord (D: 600x)

15

Detection of the hOBPII proteins with a rabbit polyclonal serum revealed by peroxidase activity detected by DAB. L: lacuna (contains maternal blood), C: fetal capillary, Am: amniotic membrane, E: epithelial cells derived from the extra-embryonic ectoblast, MB: 20 basement membrane, M: mesenchymal layer, P: DAB precipitate (hOBPII detection).

25

FIGURE 20: Demonstration of the LCN1 protein in various placental structures: chorionic villi (A: 200x, B: 800x), amniotic membrane (C: 600x), cord (D: 500x)

30

Detection of the LCN1 protein with a rabbit polyclonal serum revealed by peroxidase activity detected by DAB. L: lacuna (contains maternal blood), C: fetal capillary, Am: amniotic membrane, E: epithelial cells derived from the extra-embryonic ectoblast, MB: basement membrane, M: mesenchymal layer, P: DAB precipitate (LCN1 detection).

FIGURE 21: Demonstration of the ApoD protein in various placental structures: chorionic villi (A: 100x, B: 500x), amniotic membrane (C: 400x), cord (D: 400x)

5 Detection of the ApoD protein with a mouse monoclonal antibody revealed by peroxidase activity detected by DAB. L: lacuna (contains maternal blood), C: fetal capillary, Am: amniotic membrane, E: epithelial cells derived from the extra-embryonic ectoblast, MB: basement
10 membrane, M: mesenchymal layer, P: DAB precipitate (ApoD detection).

EXAMPLES

15 **EXAMPLE 1: MATERIALS AND METHODS**

1.A. Human chromosome 9 cosmid library

20 A copy of the library of cosmids specific for human chromosome 9, LL09NC01P, constructed by Dr. J. Allmeman (Biochemical Sciences Division, Lawrence Livermore National Library, Livermore, CA USA) under the aegis of the National Gene Library Project, supported financially by the American Department of Energy, was used. The 25 library was screened and the clones analyzed as previously described (Lacazette et al., 1997).

1.B. Cloning and sequence analysis

30 A Lambda gt11 human testes cDNA library (Clontech) (10^7 p.f.u.) was amplified by 30 polymerase chain reaction (PCR) cycles (94°C 45 sec, 54°C 45 sec, 72°C 1 min 30 sec) with the primer oliEST58 CCTGCAGGTACATGAGCTTC and 5' or 3' screening amplimers for inserts located on 35 the arms of the lambda gt11 vectors. A nested PCR was then carried out with oliEST26 CGCTGTATTGCCAGGCTCC and oligonucleotides specific for the arm of the vector. The PCR products were subcloned into the pGEM-T(r)

vector, which made it possible to obtain the 5' end of the hOBPII gene cDNAs.

The sequences obtained using the standard oligonucleotide pGEM-T(r) and a dye terminator-based sequencing ready reaction mix (Applied Biosystems) were separated by electrophoresis using an ABI PRISM 377 automatic sequencer (Perkin Elmer) and were then analyzed with the sequence navigator 1.0.1. software (Perkin Elmer).
5 Full length cDNA clones of hOBPII α (hOBPII α , hOBPII α β , hOBPII α δ , hOBPII α γ) and hOBPII β (hOBPII β α , hOBPII β β , hOBPII β γ) were obtained from the RT-PCR by purifying the bands of interest according to the manufacturer's instructions (Qiagen gel extraction kit) or, for the
10 weakly expressed alternative forms, by subcloning the nested PCR products into a pGEM-T(r) vector.
15

1.C. RT-PCR analysis

20 Tissue samples were collected from 45 to 55 year old Caucasian individuals, in agreement with the French regulations in force. The total RNA is extracted according to a single-step method using the RNA NOW[®] reagent, according to the manufacturer's (Biogentex) instructions. 5 μ g of total RNA were reverse-transcribed in a final volume of 20 μ l using 0.5 ng of oligonucleotide GACTCGAGTCGACATCGATTTTTTTTTTTTT with the Superscript[®] preamplification system (Gibco BRL). Three μ l of these reactions were then used for the
25 following PCRs. The expression of the specific mRNAs was determined by PCR using: the primers TL: CCTCTCCCAGCCCCAGCAAG and AP: GACTCGAGTCGACATCG for the LCN1-type genes (LCN1, LCN1b, LCN1c) and, for the hOBPII-type genes, the primers DE:
30 CGCCCAAGTGACCTGCGAGGTC, and FI: CTTTATTGAGTCAGGTGGGTG. As a quality control for the RNAs the primers G3PDH1: CTCTGCCCTCTGCTGATG and G3PDH2: CCTGCTTCAACCACCTTCTTG for the G3PDH gene were used; the G3PDH gene is considered to be constitutively
35

expressed in all cell types. 32 PCR cycles (94°C 45 sec, 54°C 45 sec, 72°C 2 min 30 sec) were performed and the amplification products were separated on 1% agarose gel. The DNA was transferred onto a Hybond N+®
5 membrane.

For the detection of the expression of the various genes, several oligonucleotides specific for the respective genes were synthesized:
10

- oLLCN1: GACTCAGACTCCGGAGATGA,
- oLLCN1b: AACTCAGACACCGAGAGATGA,
- oLLCN1c: GACTCAGATCCCGGAGATGA,
- o15: CCAGGGAGGGACCACTACA specific for the hOBPIIb gene,
15
- o14: CCCGGGACGGACGACTACG specific for the hOBPIIa gene,
- G3PDH3: CTCATGACCACAGTCCATGC.

The oligonucleotides are labeled with γ^{32} P-ATP using T4 kinase (Applied Biosystem); the labeled oligonucleotide hybridizations are performed at 42°C. The final wash is performed in a solution of 0.1 X SSC, 0.1% SDS at 48°C for 20 min. The specificity of the oligonucleotide hybridization reactions is controlled using samples of digested cosmid DNA (p233G2 for LCN1 and hOBPIIa, P19E7
20

25 for LCN1b and hOBPIIb, and P181A9 for LCN1c) loaded onto the gel with RT-PCR products.

1.D. Genotyping and linkage analysis

30 The genotyping is carried out with PCR reactions using 100 ng of genomic DNA originating from 8 CEPH reference families, and using the oligonucleotides o119 TGTTCCGGAACGCAGCTT and o110a TGCCGCTGCCCCACGTCGG. The thermocycler parameters consist of an initial cycle at
35 94°C for 10 min followed by 30 cycles at 94°C for 30 sec, 55°C for 30 sec and 70°C for 45 sec, and then a final elongation step of 10 min at 70°C. The PCR products are then analyzed on a 3% agarose gel. The information regarding the markers for chromosome 9 may
30

be obtained at the following internet address (h_TT_P://galton.ucl.ac.uk); the analyses were carried out using the linkage study tools previously described in Lacazette *et al.* (1997). The haplotypes are 5 reconstructed manually according to the recombination events previously described in family 1362 (Attwood *et al.*, 1994).

1.E. Secondary structure predictions

10

A multiple alignment of the lipocalin proteins for which the crystallographic structures have already been described (Monaco *et al.*, 1992; Spinelli *et al.*, 1998), with the hOBPIIA and hOBPIIB proteins, was obtained 15 using the Clustalx software (ftp.infobiogen.fr). The putative secondary structures were determined with the DSC (Discrimination of protein Secondary structure Class) program developed by R.D. King and M.J.E. Sternberg (<http://bioweb.pasteur.fr/seqanal/interfaces/dsc-simple.html>). The secondary structures of the 20 proteins corresponding to the alternatively spliced forms are presumed to be identical to the conventional forms before the reading frame shift; after the shift, the structural prediction is made with a single 25 sequence and is performed using the Predator software (<http://pbil.ibcp.fr/cgi-bin>).

1.F. Phylogenetic analysis

30

The lipocalin proteins, the sequences of which are entirely known, were aligned three times consecutively using the Clustalx software ([ftp://ftp.infobiogen.fr](http://ftp.infobiogen.fr)). Distances in the phylogenetic tree were calculated with Clustalx and plotted with Njplot.

35

1.G. In situ hybridization

Serial sections cut on a cryostat (8 μ m thick) are collected on SuperFrost[®] Plus slides (Menzel Glazer)

and stored at -80°C. Antisense and sense RNA probes are obtained according to standard techniques using T7 or SP6 polymerase, from a matrix obtained by digestion of the phOBPIIaP2 cDNA clone with NcoI or PstI restriction enzymes, and using DIG-11-UTP (Boehringer Mannheim) (the probe is approximately 150 nucleotides long). The matrices digested with PstI and transcribed with T7 RNA polymerase correspond to the antisense probe and the matrices digested with NcoI and transcribed with the SP6 RNA polymerase correspond to the sense probe. Tissue sections are fixed in 4% paraformaldehyde for 15 min and then rinsed for 5 min in 2 X PBS. After acetylation (2 x 5 min in a triethanolamine (TEA) buffer, pH 8, containing 0.25%, v/v, of acetic anhydride), the tissue sections are prehybridized at 60°C for 15 min in 50% formamide/1 X SSC. The labeled probes are applied to each of the sections in 50 µl of hybridization buffer (50% formamide, 1 X Denhardt's, 500 µg/ml total tRNA, 10% Dextran sulfate, 10 mM dithiothreitol). The sections are covered and then incubated in humid chambers at 50°C overnight. After hybridization, the slides are immersed at 55°C in a washing buffer (50% formamide, 1 X SSC) for 2 hours. Each slide is then rinsed twice 5 min in 2 X SSC at ambient temperature, and then treated for 30 min with 10 mg/ml of RNase at 37°C and, finally, immersed in a washing solution (50% formamide, 2 X SSC) for 2 hours at 55°C. The slides are then placed in 0.1 X SSC for 15 min at 55°C. The immunodetection is performed using an alkaline phosphatase-conjugated anti-DIG antibody (Fab fragments) according to the Boehringer Mannheim protocol. The sections are examined at different magnifications using an Axiophot microscope (Zeiss).

35 1.H. Production of a monoclonal antibody against the
hOBPII proteins

Two hundred and fifty µl of fusion proteins were given to the company Agro-Bio for the production of

antibodies. Rabbits (New Zealand White SPF) are injected on days 0, 14, 28 and 42. The sera are taken on days 0, 35, 49 and 63. In order to test the antibody, the fusion protein is loaded in lanes 1 and 3 (figure 11),
5 while human nasal mucus is loaded in lanes 2 and 4. Lanes 1 and 2, and also the lane corresponding to the molecular weight ladder, correspond to revelation with Coomassie blue. Lanes 3 and 4 correspond to detection of the proteins recognized by the antibody using the
10 Western blot technique. Lanes 1 and 3 show the presence of a series of truncated recombinant proteins between 30 and 42 kDa derived from a relatively inefficient synthesis due to the presence of many codons which are rare in the bacterium, within the hOBPIIb sequence.
15 However, this production of recombinant protein was sufficient to produce a polyclonal antibody of good quality, as indicated by the revelation, in lane 4 corresponding to the nasal mucus, of an 18 kDa band specific for the hOBPII proteins.
20

1.1. Immunohistochemistry

1.1.1. 8 μ m serial sections of various tissues are fixed with paraformaldehyde (5 min) and rinsed three
25 times with 1 X PBS (15 min) then incubated for 30 min in a 3% solution of BSA in 1 X PBS, before being incubated overnight in the presence of the anti-fusion protein antibody in a 1 X PBS solution. After three rinses in 1 X PBS (15 min), a rabbit anti-IgG antibody
30 coupled to FITC (green staining by fluorescence) in a 1 X PBS solution is placed in contact with the slides for 3 hours. After rinsing in 1 X PBS, a solution of DAPI (100 ng/ μ l in 1 X PBS) is applied for 10 min (counterstaining of the cell nuclei in blue). After
35 three rinses in 1 X PBS (15 min) the slides are mounted in water-glycerol (50/50). The analysis is carried out in the presence of DAPI and FITC filters with the aid of a CDD camera using an integration time of between 4 and 32 ms.

1.1.2. The tissues are frozen at -80°C in the presence of OCT. 7 micrometer serial sections are cut using a microtome. The tissues are then fixed with 4% para-
5 formaldehyde in PBS. The slides are incubated for 10 min in a solution of methanol in the presence of 4.5% of H₂O₂, and then rinsed three times in PBS for 5 min. After incubation for 30 min in a 3% bovine serum
10 albumin solution, the first antibody (diluted to 1/350) is incubated overnight at ambient temperature (rabbit polyclonal antibodies for hOBPII and LCN1, and mouse monoclonal antibody for ApoD). Then, after three 15 min rinses in PBS, the second antibody (diluted to 1/300) (anti-rabbit for hOBPII and LCN1, and anti-mouse for
15 ApoD) is incubated for 3 h at ambient temperature. After three rinses in PBS for 15 min, peroxidase revelation with DAB is carried out for 2 to 10 min, using the "Vector" kit. The slides are then rinsed with water and counterstained with Mayer's hematoxylin for
20 2 min. After two rinses with water, the slides are dehydrated by passing them successively through baths containing 70°, 95°, 100° and 100° ethanol solutions and, finally, two baths of toluene. The slides are then mounted in Canada balsam and observed using a Zeiss
25 microscope.

EXAMPLE 2: IDENTIFICATION OF A GENE HOMOLOGOUS TO LCN1 LOCATED ON HUMAN CHROMOSOME 9

30 The identification of the LCN1 complementary DNA encoding the lipocalin from human tears (Lassagne and Gachon, 1993) has previously been reported, as has the location of the gene on chromosome 9q34 (Lassagne et al, 1993; Lacazette et al, 1997). The two genes
35 encoding the von Ebner's gland proteins 1 and 2 (Kock et al, 1994) correspond to the proteins homologous to LCN1 in rats; this poses the question of whether other genes encoding an LCN1 protein exist in the human genome. *In situ* hybridization experiments (Lassagne et

al, 1993) and also analyses with somatic hybrids (Lassagne et al, 1995) indicate that, if they exist, these additional human genes must be located in chromosomal region 9q34.

5

A library of cosmids specific for human chromosome 9 (LL09NP01) was screened with the human LCN1 cDNA probe; 26 cosmids were identified; they were digested with EcoRI or PvuII, and then hybridized successively with 10 the LCN1 DNA and various oligonucleotides (figure 1).

The cosmids are divided into 3 groups. The first group (clones P32H3, P41B5, P63B6, P92H20, P109C6, P145H6, P195B4, P233G2, P233F2, P265D4 and P276H8) correspond 15 to the cosmids containing a sequence of the previously isolated LCN1 gene (accession number: L14927) made up of 7 exons (Holzfeind and Redl, 1994). The second group (clone P19E4, P19E7, P42H9, P98H5 and P142H8) corresponds to the sequence LCN1b homologous to LCN1 (clone 20 P19E4) (accession number: Y10826) from the promoter up to the 6th exon, which then diverges. A third group of cosmids (clone P110C1, P174E4, P174E5, P181A9, P181B6, P211A7, P238C6 and P291E1) contains a region LCN1c, established from the partial sequencing of the clone 25 P181A9 (accession number Y10827), which is highly homologous to LCN1 only from the promoter up to exon 2. Thus, LCN1 is the only gene which contains the 7th and last exon. In addition, the TATA boxes are degenerate in the promoters of the LCN1b and LCN1c genes.

30

**EXAMPLE 3: IDENTIFICATION OF GENOMIC DUPLICATIONS
CONTAINING THE LIPOCALIN GENES AND MAPPING
OF CHROMOSOME REGION 9Q34**

35 During the period in time over which the LCN1 gene family was identified, a vast project of physical mapping led to the identification of cosmid contigs partially covering chromosome region 9q34 (Nahmias et al, 1994, Van Slegtenhorst et al., 1995, Hornigold et

al, 1997); the sequencing of the corresponding clones was performed by a group from the Massachusetts Institute of Technology (Boston, USA).

5 Analyses comparing sequences in the database, for LCN1, LCN1b and LCN1c, revealed strong homologies between the previously described LCN1 gene (accession number L14927) and the three cosmid sequences: P161A1 having the accession number AC002098, P203H12 with the accession 10 number AC000396 and P161G2 with the accession number AC002106.

15 A very fine analysis, in particular of the 3' region of the LCN1 genes, revealed that the LCN1c sequence corresponded to the clone having the accession number AC002106, LCN1b to the number AC002098 and LCN1 to the number AC000396; there is, however, an insertion of 60 base pairs at position 12360 of the clone having the accession number AC000396 compared to that having the number L14927. Additional analyses revealed that these sequences are homologous over a region which is much larger than the LCN1 genes. As illustrated by the dot plot analyses (figure 2), these three cosmids correspond to duplicated genomic regions; the cosmids P161A1 20 (AC002098) and P203H12 (AC000396) are homologous over their entire sequences; the cosmid P161G2 (AC002106) is homologous to the sequence only for sequences located 25 upstream of intron 3 of the LCN1 gene.

30 The relative positions of these duplicated regions of human chromosome 9 were analyzed. The results were compared with the physical map established in the context of the physical mapping project by restriction analyses of the cosmids (Hornigold et al, 1997) using 35 the same library LIN09NC01P. Approximately the same cosmids were found in the two searches for the LCN1c locus; the sequence comparison for the cosmid P181A9 reveals that its T3 end contains the Surf 5 gene (figure 1). In addition, AC002106 is located in a

- 48 -

sequence contig between ABO and the Surfeit locus, confirming the location of LCN1c. P161A1 and P203H12 have less precise locations using the data from Hornigold and from his collaborators because of the 5 limit of the restriction mapping strategy for the duplicated regions. P203H12 (AC000396) appears to correspond to the LCN1 gene which was previously located close to the D9S1826 marker (Lacazette et al., 1997), with the exception of a 60 base pair insertion.

10 In order to test whether P203H12 may correspond to a 4th duplicated region, the region was tested by PCR on genomic DNA from 150 unrelated individuals using primers specific for AC000396 and L14927. A single band 15 corresponding to the length of the AC000396 sequence was detected (data not shown), thus proving that P203H12 contains the previously described LCN1 gene. The LCN1b locus was not positioned precisely in the region, as demonstrated by the fact that the AC002098 20 ends and also the ends of the cosmids containing LCN1b detect no homologous sequence in the databanks.

25 The sequence analysis made it possible to identify a putative minisatellite at position 3177-3724 of the cosmid corresponding to AC002098 (figure 1); a rare polymorphism was thus demonstrated in a population of 20 unrelated individuals (PIC = 0.05). This new polymorphic marker is informative only in family 1362 of the 8 CEPH reference families tested.

30 The linkage analysis revealed two-point lod scores greater than 3 at theta = 0 for the D9S275 and D9S1818 35 markers. The reconstruction of the haplotype confirmed the location of the LCN1b gene between the D9S1811 and D9S67 markers in chromosome 9q34 (figure 1).

EXAMPLE 4: IDENTIFICATION OF TWO NEW LIPOCALIN GENES

The sequence analyses revealed new data.

The comparison of AC002098 to the databank revealed similarities between this sequence and the lipocalin genes. In addition to the region 21000 to 27000, which 5 contains the LCN1b gene, the region around position 2150 contains sequences which exhibit similarities with the sequences encoding the rat type II odorant-binding proteins, lipocalins from tears and also the EST AA460385.

10 In parallel, the comparison of the AC000396 sequence to the databank revealed, in addition to the region 11100 to 17100 containing the LCN1 gene, similarities for the same group of sequences in the region 36600 to 37800.

15 The EST AA460385 expressed in human testes corresponds to 4 exons of the new lipocalin gene present in the clone P161A1 (AC002098). A putative 50 base pair exon similar to the EST sequence is also present at the end 20 of the clone P203H12 (AC000396).

The inventors have therefore concluded that a new lipocalin gene exists at a position distal to LCN1b. The inventors have put forward the hypothesis that, 25 subsequent to a genomic duplication, a second gene orthologous to the gene encoding the EST is present in the 3' region of LCN1.

30 The sequencing of the cosmid P233G2 containing this region (figure 1) with oligonucleotides defined from the EST in fact revealed the presence of another lipocalin gene at a locus 20 kb distal to the LCN1 gene. In order to identify the first exons of the two new genes, nested PCRs on cDNA clones originating from a testes 35 library were carried out between the oligonucleotides located in the 5' region of the EST and the arms of the vector. The PCR products were cloned and their sequence revealed three additional exons going by the genomic sequence (figure 1). A TATA box is present upstream of

the first exon in both cases (figure 3). The two mRNAs, hOBPIIa corresponding to the gene located downstream of LCN1 and hOBPIIb located downstream of LCN1b (figures 3 and 4), are 97.5% and 63% identical to those corresponding to the LCN1 gene. The intron/exon organizations of these two genes are consistent with the lipocalin family.

In addition, the deduced protein sequences (170 amino acids) confirm that they belong to the lipocalin family. The two putative mature proteins hOBPIIa (MW = 17.8 kDa) and hOBPIIb (MW = 18.0 kDa) are 89% identical. These two novel proteins contain a putative signal peptide of 15 amino acids (figure 5), the conserved residues GXWY at position 27 to 30, and two cysteines which may be involved in a disulfide bridge (position 74 to 166).

However, the paired sequence comparisons with the other lipocalins indicate weak conservation of the amino acid residues (15 to 25%), with the exception of human TL/VEG encoded by the LCN1 gene (mean value 43% over 155 amino acids) and rat OBPII (mean value 45.5%). Moreover, the calculated isoelectric points of hOBPIIa and of hOBPIIb are 7.85 and 8.72, respectively, whereas those of the lipocalins are acid (in the region of 4.5), with the exception of rat OBPII (PI = 9.01). The prediction for the secondary structures of the hOBPIIa and hOBPIIb proteins with the DSC program, by carrying out multiple alignments with the sequences of lipocalins of known structures, indicates the presence of 8 strands of antiparallel β -sheets which may allow the formation of a calyx, followed by an α -helix and a final β -sheet, in agreement with the known data for the structures of the lipocalins (figure 5).

EXAMPLE 5: STUDY OF THE EXPRESSION OF THE LIPOCALIN GENES IDENTIFIED

5 In order to specify whether LCN1b, LCN1c, hOBPIIa and hOBPIIb are expressed genes, RT-PCR analyses were carried out on 18 different human tissues known to produce lipocalins (figure 6).

10 Two pairs of primers were synthesized; one recognizes the LCN1-type mRNAs and the other the hOBPII-type mRNAs. The hybridization of the oligonucleotides specific for the genes, on membranes on which the RT-PCR products are immobilized after transfer via the Southern technique, and then the subcloning of the 15 hybridized products revealed that LCN1b and LCN1c are not expressed in any of the products tested, whereas the LCN1 mRNAs are detected in the lacrymal gland, the sweat gland, the von Ebner's glands, the nasal septum, the epithelium of the nasal concha, as well as the 20 placenta and mammary glands (figure 6A). These data and the sequence information, which indicates that the TATA box and the last exon have been lost, make it possible to affirm that LCN1b and LCN1c are pseudogenes which do not contribute to the formation of the human LCN1 25 proteins.

30 On the other hand, the hOBPIIa and hOBPIIb genes are expressed, which confirms the previous detection thereof in the cDNA libraries. Surprisingly, although 35 both proteins hOBPIIa and hOBPIIb are very similar over their entire sequence, including in the 1.5 kb promoter region, their expression profiles are different (figure 6B). The hOBPIIa protein is strongly expressed in the nasal septum, the middle meatus, the nasal concha, the testes and the placenta, and more weakly in the mammary glands, the lacrymal glands, the sweat glands, the von Ebner's glands and the lung. On the other hand, the hOBPIIb protein is expressed predominantly in the prostate, the testes and the

mammary glands, and more weakly in the submaxillary glands, the nasal septum and the middle meatus.

In addition, the RT-PCR analyses revealed the existence
5 of alternative splicing of the product of transcription
of the hOBPIIa gene and of the hOBPIIb gene, which
generates, respectively, four and three mRNAs
(figures 3, 4, 5 and 6).

10 The transcription of the hOBPIIa gene generates at
least four mRNAs which encode four different proteins;
the first mRNA encodes the hOBPIIa α protein which
corresponds to the hOBPIIa protein described above. In
the hOBPIIa gene, three different splice acceptor sites
15 have been identified for exon 5 (figures 3 and 4), thus
forming two other splice variants. A first splice
variant has an acceptor site for exon 5 located 49 bp
before the previous one (exon 5b); this generates a
725 nucleotide mRNA which encodes the 146 amino acid
20 protein hOBPIIa β . This protein is identical up to the
8th putative β -sheet and then different with only 16
additional amino acids. A second splice variant has an
acceptor site for exon 5 located 65 bp before the
previous one (exon 5c); this generates a 741 nucleotide
25 mRNA which encodes a 228 amino acid protein hOBPIIa γ .
This protein has the first eight putative β -sheets
identical to those of hOBPIIa α , and is then different
in the C-terminal region (figure 5) due to a reading
frame shift generated by this alternative splicing
30 event; the structure of this C-terminal region
predicted by the Predator program is a long bent region
containing a 9th β -sheet.

In the case of the hOBPIIb gene, in addition to the
35 hOBPIIb α mRNA previously described, a 106 bp super-
numerary exon (exon 3b) between the previous exons 3
and 4 was identified (figure 3). This longer mRNA
(782 nucleotides) encodes a 165 amino acid protein
hOBPIIb β . From a protein structure point of view,

hOBPIIb β is identical to hOBPIIb α up to the 5th putative β -sheet and then differs due to a reading frame shift. The predictions from the computer programs indicate that the motif ALWEALAIIDTRLK is an α -helix 5 which is just behind the fifth β -sheet. Two additional β -sheets may be present in the long C-terminal portion.

None of the alternative splicing variants for one gene 10 is detected symmetrically for the other gene, although the putative splice acceptor and donor sites may be present (figure 3). In addition to these protein motifs which conserve the conventional structure of a 15 lipocalin, we have demonstrated, for the two genes hOBPIIa and hOBPIIb, the existence of a small amount of mRNA which has undergone alternative splicing and encodes proteins, the sequence of which is not directly 20 related to the lipocalins. mRNAs encoding hOBPIIa δ and hOBPIIb γ , which lack the sequence encoding exon 2 and which have, respectively, exon 5b and exon 5, encode putative secreted proteins of 147 and 85 amino acids, respectively (figures 4 and 5); these proteins diverge 25 from the previous proteins from the 24th amino acid.

In order to identify the cells expressing the hOBPII 25 genes, the inventors hybridized digoxigenin-labeled sense and antisense ribonucleic acid probes on tissue sections (figure 7). The hOBPII mRNAs are detected in the acinar cells of the middle meatus and of the nasal conchae, and also epithelial cells of the conchae; this 30 supports the idea that the hOBPII proteins are involved in olfactory function. In addition to the production in the oral sphere, mRNAs encoding hOBPII were detected in the genital sphere, in particular in the glandular cells of the prostate, and in the secretory epithelial 35 cells of the vas deferens. No signal was detected in the male gonads, which suggests that the expression of the hOBPII genes detected in the RT-PCR experiments corresponded to the presence of additional ducts in the tissue preparation (rete testis and lobuli

epididymidis). In combining these results from the detection of all of the mRNAs encoding hOBPII with those of the RT-PCR approach, it appeared that five hOBPII proteins (hOBPIIa α , hOBPIIa β , hOBPIIa γ , 5 hOBPIIb α , hOBPIIb β) are secreted by the epithelial cells of the ducts of the male gonads, and also acinar cells of the middle meatus and of the nasal conchae; in these cells, the mRNAs encoding hOBPIIa are highly predominant. Only the two hOBPIIb proteins (hOBPIIb α 10 and hOBPIIb β) are secreted by the epithelial-glandular cells of the prostate and of the mammary glands.

EXAMPLE 6: PHYLOGENETIC ANALYSIS AND CLASSIFICATION OF THE LIPOCALINS

15 The dotplot analysis (figure 2) and also the genomic duplications which we revealed indicate a common origin for the LCN1 and hOBPII genes. To clarify the relationships between the members of the lipocalin family and 20 to verify that we identified the human gene orthologous to rat OBPII (Dear et al., 1991), we constructed a phylogenetic distance tree with the vertebrate lipocalins (figure 8).

25 The inventors demonstrated nine main groups of lipocalins derived from a common precursor:

- the apolipoprotein and retinol binding protein (RBP) family (group 1);
- 30 - the prostaglandin D synthase and neutrophil gelatinase-associated lipocalin precursor group (group 2);
- the alpha-1-microglobulin/bikunin (protein HC) subfamily (group 3);
- 35 - the orosomucoid subfamily (A1AG, A1AH, A1AI) (group 4);
- the oral sphere subfamily 1 (OBPII-type-LCN1/VEGP, VNSP I and II, LALP, CanF1) (group 5);
- the lactoglobulin subfamily (group 6);

- the subfamily of proteins secreted by the lizard epididymis (group 7);
- the oral sphere subfamily 2 (mouse major urinary proteins (MUP)) (group 8);
- 5 - the oral sphere subfamily 3 (OBP1, mouse OBPII, aphrodisin, probasin, BD20) (group 9).

The present invention relates more particularly to groups 5, 8 and 9.

10 Group 5 contains the hOBPII proteins which are closely related from an evolutionary point of view to rat OBPII. Taken together, the present results indicate that the human hOBPII genes are orthologs of the rat 15 OBPII gene. This group also contains the LCN1-VEGP proteins of various species. Taking into consideration the genomic organization of the hOBPII-LCN1 genes, the data from the tree illustrate the duplication event (arrow) which gives rise to the ancestral hOBPII and 20 LCN1 genes from their common lipocalin precursor (figure 9). More recently, the original duplications of the 50 kb region containing hOBPII-LCN1 (arrow) generated, in humans, the two hOBPII genes and the LCN1 gene and its pseudogene LCN1b. The additional duplication 25 which gave rise to the LCN1c pseudogene is partial in the human genome and does not produce a functional protein, and is therefore absent from the present tree. In addition, the two rat VEG proteins are more closely related to one another in the phylogenetic tree than to 30 the human LCN1 protein. The situation is identical for the two human OBPII proteins compared to the rat OBPII protein. These results are in favor of a process of gene conversion for at least some lipocalin genes. This may also be correlated to the fact that these genes are 35 located on the same chromosomal arm.

Group 9 corresponds to the oral sphere family 3 and contains OBPs which have already been described. The aphrodisin protein has already been described as a

pheromone transporter (Henzel et al., 1988) and appears to be orthologous to the rat and mouse OBP1 protein, with two paralogous OBP1 genes. Finally, the olfactory lipocalins produced by the Bowman's glands of *rana pipiens* (OLFA RANPI), which are considered to be potential odorant transporters in frog mucus, are not related to any putative OBP group (groups 5, 8 and 9), thus suggesting the existence of other OBP categories.

Some lipocalins have been described as being allergens. The major allergen of dogs, the CanF1 protein, mainly expressed in the von Ebner's glands (Konieczny et al., 1997), appears in the tree to be the dog VEG protein. This result, which shows that LCN1 may be allergenic, prompts the inventors to propose that the OBPII proteins are involved in allergic processes. Similarly, the major allergen of horses, EquC1, expressed in the liver and the salivary glands (Grégoire et al., 1996), appears to be orthologous to an MUP protein member (group 3). The major allergen of cows (BD20 BOSTA), which is present in the oral sphere family 2 (group 4) is more closely related to probasin. CanF2, which is mainly expressed in the parotid gland (Konieczny et al., 1997), does not appear to be orthologous to a previously described lipocalin.

The present invention has made it possible to reveal the existence of a genomic duplication at the q34 locus of human chromosome 9, which harbors a gene family of the LCN1 type; this family comprises, besides the LCN1 gene, which has been previously described, two pseudogenes and also two hOBPII genes which are paralogous to LCN1. The inventors have revealed that the hOBPII-LCN1 family results from consecutive genomic duplication events. The sequences and also the genomic organization revealed that the LCN1 and hOBPII genes derive from a common ancestor and were generated by means of tandem duplication. The sequence comparisons demonstrated that the hOBPIIa α and hOBPIIb α proteins are the hOBPII

protein forms closest to LCN1; this is corroborated by the fact that the size of exon 5 of LCN1 is 121 bp, which corresponds to the size of exon 5a of the hOBPII protein, and by the fact that no exon 3b was found in 5 the LCN1 protein. Similar results are obtained when this comparison is carried out with the other seven exons of the lipocalins. These data are in favor of the diversity of the hOBPII proteins being acquired through the integration of surrounding additional genomic DNA 10 at the upstream splice acceptor site for exon 5 of hOBPIIa or through the recruitment of a supernumerary exon (exon 3b) for the hOBPIIb protein. The hypothesis of a recruitment of exons rather than a decrease in the size of the exons or than a loss of exons is more 15 probable.

The inventors showed that the hOBPII and LCN1 genes encode proteins involved in various functions, as shown by the expression of these genes in both the oral 20 sphere and the genital sphere. In addition, the inventors showed, by the phylogenetic analysis (example 6), that several different proteins could contribute to the same odorant-binding protein function; thus, three lipocalin subfamilies (groups 5, 25 8 and 9) corresponding to several proteins are found expressed in the oral sphere, and in particular in the nasal and buccal glands.

This analysis, showing that several lipocalins 30 contribute to the same physiological function and that the same protein could contribute to various functions, led the inventors to analyze the expression of the other human lipocalins in all of the tissues studied (figure 10). This led to the demonstration that the 35 gene encoding apolipoprotein D is expressed in the glands of the nasal concha and of the middle meatus, thus making it a potential odorant-binding protein. Similarly, retinol binding protein (RBP) is expressed

by the nasal epithelium and may also contribute to this function.

The inventors therefore propose the inclusion of the
5 ApoD and RBP proteins in the human OBP family and
include them in all the claims relating to these human
OBPs.

The inventors have demonstrated that the transcription
10 of the two hOBPII genes generates many alternative
transcripts which encode different proteins, the
structure of which is compatible with that of a hydro-
phobic ligand transporter.

15 The inventors have demonstrated the expression of the
two hOBPII genes in the oral sphere (nasal glands, von
Ebner's glands, submaxillary glands, lacrymal glands,
lung). The inventors have also demonstrated that the
hOBPII proteins according to the invention are produced
20 by the cells of the genital sphere; the hOBPII gene is
mainly expressed in the prostate, the vas deferens and
the mammary glands, while the expression of the hOBPIIa
gene is restricted to the vas deferens. The in situ
analyses have revealed that the mRNA is produced by the
25 glandular cells of the prostate and epithelial
secretory cells of the vas deferens, supporting the
idea that the corresponding proteins are secreted into
the seminal fluid. The proteins according to the
invention may therefore be involved in the reproductive
30 function, but also in all the other functions usually
attributed to lipocalins.

**EXAMPLE 7: PRODUCTION OF A RECOMBINANT HOBPIIb α PROTEIN
IN A PROKARYOTIC SYSTEM**

35 A PCR on the plasmid DNA of an hOBPIIb α clone using the
primers BIIa/b (5' GTC GGA TCC CTG TCC TTC ACC CTG GAG
G 3'), a sense oligonucleotide beginning 45 bases after
the protein-initiating ATG, and XIIb (5' GTC CTC GAG

GTG TTC GGG AAC GCA GCT TC 3'), an antisense oligonucleotide preceding the stop codon of the hOBPII β protein, made it possible to amplify all of the DNA encoding the secreted hOBPII β protein. The BamH I and 5 Xho I enzymatic restriction sites located at the ends of the two oligonucleotides (bases underlined) were used for directional cloning into a plasmid expression vector pGEX-6P1, followed by transformation by electroporation (1800 V, 200 Ω , 25 μ F) into a bacterial strain 10 BL21. Synthesis of the recombinant protein is obtained by adding IPTG, at 5 mM final for 3 h, to 250 ml of culture of the strain in LB medium containing 100 μ g/ml of ampicillin pre-incubated at 37°C for 2 h. The centrifuged cultures are taken up in 25 ml of TENGN 15 buffer. The lysate is sonicated and re-centrifuged. The fusion protein is then purified using 4 ml of beads bearing covalently attached insoluble glutathione (Sigma) per 25 ml of supernatant. After incubation for 4 h, they are washed with 3 volumes of 1M NaCl and then 20 with 10 volumes of 1 X PBS. The elution is obtained by bringing the beads into contact with a glutathione solution (10 mM reduced glutathione, 50 mM Tris-HCl, pH 8.0) for 10 min.

25 The amount of recombinant protein produced is estimated by migration on polyacrylamide gel and staining with Coomassie blue (figure 11). The specificity of induction of a recombinant protein is tested by Western blot using a goat anti-GST antibody (figure 11), revealed 30 with a peroxidase-coupled goat anti-IgG antibody, using an ECL-plus kit (Amersham). The separation of the fusion protein into two proteins is obtained by proteolysis of 100 μ g of pre-dialyzed recombinant protein with 2U of preScission™ protease (Pharmacia 35 Biotech) in 10 μ l final containing 1 X enzyme buffer, for 4 h at 5°C.

**EXAMPLE 8: DETECTION OF THE hOBPIIS IN VARIOUS TISSUES
BY IMMUNOHISTOCHEMISTRY**

5 The location of the hOBPII proteins in the nasal structures (figures 12 and 15), the buccal structures and the lacrymal glands (figures 13 and 18), the mammary glands and the lungs (figures 14 and 18) is revealed by immunohistochemistry.

10 **EXAMPLE 9: DETECTION OF THE hOBPIIS, LCN1 and ApoD IN
THE NASAL STRUCTURES BY RT-PCR AND BY
IMMUNOHISTOCHEMISTRY**

15 The RT-PCRs carried out using the sets of primers for the hOBPIIs and for LCN1 reveal the presence of the corresponding mRNAs in at least one of the nasal structures. The techniques of immunohistochemical detection both by fluorescence detection and by revelation using peroxidase and DAB reveal the presence 20 of the hOBPII (figure 15) and LCN1 (figure 16) proteins in the epithelial cells of the acini of the nasal glands, and also in the lumina of the secretory ducts. Some can also be detected on mucus attached to the tissues.

25 The RT-PCRs carried out using the sets of primers for apolipoprotein D reveal the presence of the corresponding mRNAs in at least one of the nasal structures. The techniques of immunohistochemical detection by 30 revelation using peroxidase and DAB reveal the presence of the ApoD protein (figure 17) in the epithelial cells of the acini of the nasal glands, and also in the lumina of the secretory ducts, although the expression appears to be weaker and in fewer acini than for the 35 hOBPIIs.

**EXAMPLE 10: DETECTION OF THE hOBPIIs, LCN1 and ApoD IN
THE PLACENTA BY RT-PCR AND BY IMMUNOHISTO-
CHEMISTRY**

5 The RT-PCRs carried out using the sets of primers for
the hOBPIIs and for LCN1 reveal the presence of the
corresponding mRNAs in the placenta. The techniques of
immunohistochemical detection by revelation using
10 peroxidase and DAB reveal the presence of the hOBPII
(figure 19) and LCN1 (figure 20) proteins very strongly
in the lacunae of the placental villi and much more
weakly, and very diffusely, in the epithelial cells of
the amniotic membrane and in subjacent cells, both for
the amniotic membrane and for the cord. The expression
15 of the mRNAs detected by RT-PCR in the placental villi
indicates that these hOBPII proteins are produced by
the placenta in order to transfer lipophilic molecules
(hormones, fatty acids, vitamins, etc.) to the fetus
via the fetal blood circulation. The proteins detected
20 in the amniotic membrane may correspond to the
absorption of these proteins from the amniotic fluid,
since it is known that the nasal structures of the
fetus are bathed in this amniotic fluid. The hOBPII and
LCN1 proteins would thus contribute to the transport of
25 lipophilic substances which are small in size from the
mother to the fetus in the chorionic villi via the
fetal blood, and from the fetus to the mother via the
amniotic fluid.

30 The RT-PCRs carried out using the sets of primers for
the ApoD protein reveal the presence of the
corresponding mRNAs in the placenta. The techniques of
immunohistochemical detection by revelation using
35 peroxidase and DAB reveal the presence of the ApoD
protein very strongly in the lacunae of the placental
villi (figure 21). The ApoD protein is not detected in
the cells of the amniotic membrane nor in subjacent
cells, both for the amniotic membrane and for the
cord. The expression of the mRNAs detected by RT-PCR

in the placenta indicates that the ApoD protein is produced by the placenta in order to transfer lipophilic molecules (hormones, fatty acids, vitamins, etc.) to the fetus via the fetal blood circulation. The ApoD 5 protein may also be produced by the fetal liver. The ApoD protein would thus contribute to the transport of lipophilic substances which are small in size from the mother to the fetus in the chorionic villi via the fetal blood.

10 More generally, the expression of lipocalins by the placenta, such as alpha-1-acid glycoprotein (A1AG), prostaglandin D synthase (PGDS), PP14 and RBP, as revealed by the RT-PCR techniques, indicates that these 15 proteins, which have hydrophobic molecule-transporting properties, are recruited in massive amounts for mother-child connections, for transporting these molecules which may be steroid hormones, fatty acids, vitamins or xenobiotics, and more generally metabolism-derived detoxification products.

20

- 63 -
REFERENCES

Attwood, J. et al. (1994) *Genomics* **19**, 203-214.

5 Barany, F., (1991), *Proc. Natl. Acad. Sci. USA*, **88**, 189-193.

Beste et al. (1999), *Proc. Natl. Acad. Sci. USA*, **96**, 1898-1903.

10 Bocskei, Z. et al. (1992) *Nature* **360**, 186-188.

Borghoff S.J. et al. (1990) *Annu. Rev. pharmacol. Toxicol.* **30**, 349-367

15 Burg, J.L. et al. (1996), *Mol. and Cell. Probes*, **10**, 257-271.

20 Chu, B.C.F. et al. (1986), *Nucleic Acids Res.*, **14**, 5591-5603.

Dear, T.N. et al. (1991) *Biochemistry* **30**, 10376-10382.

Dewald, G. et al. (1996) *Ann Hum Genet* **60**, 281-291.

25 Duck, P. et al. (1990), *Biotechniques*, **9**, 142-147.

Edwards, C.P., and Aruffo, A., (1993), *Curr. Op. Biotechnology* **4**, 558-563.

30 Erlich, H.A., (1989), New York: Stockton Press.

Flower, D.R. (1995) *J Mol Recognit* **8**, 185-195.

35 Flower, D.R. (1996) *Biochem J* **318**, 1-14.

Gilbertson T.A. (1998) *Cur. Op. Neurobiology* **8**, 447-452.

Gregoire, C. et al. (1996) J Biol Chem 271, 32951-32959.

5 Guatelli J.C. et al. (1990), Proc. Natl. Acad. Sci. USA, 87, 1874-1878.

Henzel, W.J. et al. (1988) J Biol Chem 263, 16682-16687.

10 Holzfeind, P. and Redl, B. (1994) Gene 139, 177-183.

Hornigold, N. et al. (1997) Genomics 41, 385-389.

Innis, M.A. et al. (1990), Academic Press.

15 Igarashi, M. et al. (1992) Proc Natl Acad Sci USA 89, 5376-2380.

Kievitis, T. et al. (1991), J. Virol. Methods, 35, 273-286.

20 Kock, K. et al. (1994) Eur J Biochem 221, 905-916.

Kohler, G. et al. (1975), Nature, 256 (5517), 495-497.

25 Konieczny, A. et al. (1997) Immunology 92, 577-586.

Kwoh, D.Y. et al. (1989), Proc. Natl. Acad. Sci. USA, 86, 1173-1177.

30 Lacazette, E. et al. (1997) Ann Hum Genet 61, 449-455.

Landegren, U. et al. (1988), Science, 241, 1077-1080.

Lassagne, H. and Gachon, A.M. (1993) Exp Eye Res 56, 605-609.

35 Lassagne, H. et al. (1993) Genomics 18, 160-161.

Lassagne, H. et al. (1995) Cytogenet Cell Genet 71, 104.

Lizardi, P.M. et al. (1988) *Biotechnology* 6, 1197-1202.

5 Luckow, V.A. (1993) *Curr. Op. Biotechnology* 4, 564-572.

Matthews, J.A. et al. (1988), *Anal. Biochem.* 169: 1-25.

10 Miele, E.A. et al. (1983) *J. Mol. Biol.* 171: 281-295.

Miller, W.L. (1998) *Clin Perinatol* 25, 799-817, v.

Monaco, H.L. and Zanotti, G. (1992) *Biopolymers* 32, 457-465.

15 Nagata, A. et al. (1991) *Proc Natl Acad Sci USA* 88, 4020-4024.

Nahmias, J. et al. (1995) *Eur J Hum Genet* 3, 65-77.

20 Pelosi, P. (1996) *J Neurobiol* 30, 3-19.

Pervaiz, S. and Brew, K. (1987) *Faseb J* 1, 209-214.

25 Redl, B. et al. (1992) *J Biol Chem* 267, 20282-20287.

Rolfs, A. et al. (1991), Berlin: Springer-Verlag.

30 Sambrook, J. et al. (1989), T. Sec. Ed. Cold Spring Harbor Lab., Cold Spring Harbor, New York.

Segev, D., (1992), Kessler C. Springer Verlag, Berlin, New York, 197-205.

35 Senoo, H. et al. (1990) *J Lipid Res* 31, 1229-1239.

Shaw, P.H. et al. (1983) *Cell* 32, 755-761.

Simard et al. (1992) *Endocrinology* 133, 1115-1121.

Spinelli, S. et al. (1998) Biochemistry 37, 7913-7918.

Stoesz S.P. and Gould M.N. (1995) Oncogene 11: 2233-2241.

5

Stone, B.B. et al. (1996) Mol. and Cell. Probes 10: 359-370.

10 van Slegtenhorst, M. et al. (1995) Eur J Hum Genet 3, 78-86.

Walker, G.T. et al. (1992) Nucleic Acids Res. 20: 1691-1696.

15 Zeng, C. et al. (1996) Proc Natl Acad Sci USA 93, 6626-6630.

CLAIMS

1. An isolated polypeptide comprising an amino acid sequence having at least 90% identity with the amino acid sequences SEQ ID No. 2, SEQ ID No. 4, SEQ ID No. 6, SEQ ID No. 8, SEQ ID No. 12 or SEQ ID No. 14.
5
2. An isolated polypeptide, characterized in that it comprises a polypeptide chosen from:
10
 - a) a polypeptide of sequence SEQ ID No. 2, SEQ ID No. 4, SEQ ID No. 6, SEQ ID No. 8, SEQ ID No. 12 or SEQ ID No. 14;
 - 15 b) a polypeptide which is a variant of a polypeptide of amino acid sequences defined in a);
 - c) a polypeptide homologous to the polypeptide defined in a) or b) and comprising at least 90% identity 20 with said polypeptide of a);
 - d) a fragment of at least 15 consecutive amino acids of a polypeptide defined in a), b) or c);
 - 25 e) a biologically active fragment of a polypeptide defined in a), b) or c).
3. An isolated polypeptide selected from a polypeptide corresponding to the sequence SEQ ID No. 2 and 30 named OBPII_{αα}, to the sequence SEQ ID No. 4 and named OBPII_{αβ}, to the sequence SEQ ID No. 6 and named OBPII_{αγ}, and to the sequence SEQ ID No. 12 and named OBPII_{ββ}.
4. The polypeptide as claimed in any one of claims 1 35 to 3, characterized in that it comprises at least the Gly-Thr-Trp-Tyr domain.

5. An isolated polynucleotide, characterized in that it encodes a polypeptide as claimed in any one of claims 1 to 4.

5 6. The polynucleotide as claimed in claim 5, of sequence SEQ ID No. 1, SEQ ID No. 3, SEQ ID No. 5, SEQ ID No. 7, SEQ ID No. 11 or SEQ ID No. 13.

10 7. An isolated polynucleotide, characterized in that it comprises a polynucleotide chosen from:

- 15 a) a polynucleotide of sequence SEQ ID No. 1, SEQ ID No. 3, SEQ ID No. 5, SEQ ID No. 7, SEQ ID No. 11 or SEQ ID No. 13, or the sequence of which is that of the RNA corresponding to the sequence SEQ ID No. 1, SEQ ID No. 3, SEQ ID No. 5, SEQ ID No. 7, SEQ ID No. 11 or SEQ ID No. 13;
- 20 b) a polynucleotide, the sequence of which is complementary to the sequence of a polynucleotide defined in a),
- 25 c) a polynucleotide, the sequence of which comprises at least 80% identity with a polynucleotide defined in a) or b),
- 30 d) a fragment of at least 15 consecutive nucleotides, in preference 21 consecutive nucleotides, and preferably 30 consecutive nucleotides, of a polynucleotide defined in a), b), c) or d).

8. The polynucleotide as claimed in claim 7, characterized in that it is labeled directly or indirectly with a radioactive compound or a nonradioactive compound.

35 9. The use of a polynucleotide as claimed in claim 8, as a probe for detecting nucleic acid sequences.

10. The use of a polynucleotide as claimed in any one of claims 5 to 8, as a primer for amplifying or polymerizing nucleic acid sequences.

5

11. The use of a polynucleotide as claimed in claim 8, as a sense or antisense oligonucleotide for controlling the expression of the corresponding protein product.

10 12. A recombinant vector for cloning a polynucleotide as claimed in one of claims 5 to 8 and/or for expressing a polypeptide as claimed in one of claims 1 to 4, characterized in that it contains a polynucleotide as claimed in any one of claims 5 to 8.

15

13. The vector as claimed in claim 12, characterized in that it comprises the elements which allow the expression, optionally the secretion, of said polypeptide in a host cell.

20

14. The vector as claimed in any one of claims 12 to 13, characterized in that the elements which allow the expression of said polypeptide are chosen from:

25 a) the isolated polynucleotide of sequence SEQ ID No. 15 and SEQ ID No. 16;

30 b) a polynucleotide, the sequence of which is complementary to the sequence of the polynucleotide defined in a);

c) a polynucleotide, the sequence of which comprises at least 80% identity with a polynucleotide defined in a) or in b);

35

d) a polynucleotide which hybridizes, under conditions of high stringency, with a sequence of the polynucleotide defined in a), b) or c).

15. The vector as claimed in claims 13 and 14, for expression in eukaryotic cells, selected from viral DNA and naked DNA.

5 16. A host cell, characterized in that it is transformed with a vector as claimed in one of claims 12 to 15.

10 17. A process for preparing a recombinant polypeptide, characterized in that a host cell as claimed in claim 16 is cultured under conditions which allow the expression and, optionally, the secretion of said recombinant polypeptide, and in that said recombinant polypeptide is recovered.

15 18. A recombinant polypeptide which can be obtained using a process as claimed in claim 17.

20 19. The use of a polypeptide chosen from a polypeptide as claimed in any one of claims 1 to 4 and 18, or a fragment thereof, as a protein which binds to a hydrophobic ligand, preferably an odorous molecule.

25 20. The use of a polypeptide as claimed in any one of claims 1 to 4 and 18, or of the polypeptide hOBPII_{ba} of sequence SEQ ID No. 10, a polypeptide which is a variant of said polypeptide hOBPII_{ba}, a polypeptide homologous to said polypeptide hOBPII_{ba} comprising at 30 least 90% identity with said polypeptide hOBPII_{ba} or a fragment thereof, as a competitive inhibitor, as an agonist or as an antagonist of the cellular receptors for lipocalins.

35 21. A monoclonal or polyclonal antibody, and fragments thereof, characterized in that it is specifically against an isolated polypeptide as claimed in one of claims 1 to 4 and 18.

22. The use of an antibody as claimed in claim 21, for demonstrating the presence of a polypeptide as claimed in one of claims 1 to 4 and 18 in a biological sample.

5

23. A process for detecting an antibody against hOBPII in human serum from an allergic and/or asthmatic patient, using an hOBPII polypeptide.

10 24. A process for controlling the volatilization of an odorant, characterized in that it comprises a step of binding of said odorant with a polypeptide as claimed in any one of claims 1 to 4 and 18, or with the polypeptide hOBPII_{ba} of sequence SEQ ID No. 10, a polypeptide

15 which is a variant of said polypeptide hOBPII_{ba} or a polypeptide homologous to said polypeptide hOBPII_{ba} comprising at least 90% identity with said polypeptide hOBPII_{ba}.

20 25. The process as claimed in claim 24, characterized in that the polypeptide is bound to a solid support.

26. The process as claimed in claim 24, characterized in that the polypeptide is in a liquid composition.

25

27. The process as claimed in claim 26, characterized in that said composition is a fragranced composition for the skin.

30 28. A process for screening a molecule, preferably odorants or flavors, which comprises passing the molecule over a substrate which comprises a polypeptide as claimed in any one of claims 1 to 4 and 18, or the

35 polypeptide hOBPII_{ba} of sequence SEQ ID No. 10, a polypeptide which is a variant of said polypeptide hOBPII_{ba} or a polypeptide homologous to said polypeptide hOBPII_{ba} comprising at least 90% identity with said polypeptide hOBPII_{ba}, bound to said substrate, said polypeptide

binding said odorant or flavor, and recovering said odorant or flavor from the polypeptide if necessary.

29. The process as claimed in claim 28, characterized
5 in that the molecules are human pheromones.

30. A process for solubilizing lipophilic molecules, characterized in that it comprises binding said molecule to a polypeptide as claimed in any one of
10 claims 1 to 4 and 18, or to the polypeptide hOBPII_{ba} of sequence SEQ ID No. 10, a polypeptide which is a variant of said polypeptide hOBPII_{ba} or a polypeptide homologous to said polypeptide hOBPII_{ba} comprising at least 90% identity with said polypeptide hOBPII_{ba}.
15

31. The application of the polypeptides as claimed in one of claims 1 to 4 and 18, or of the polypeptide hOBPII_{ba} of sequence SEQ ID No. 10, of a polypeptide which is a variant of said polypeptide hOBPII_{ba} or of a
20 polypeptide homologous to said polypeptide hOBPII_{ba} comprising at least 90% identity with said polypeptide hOBPII_{ba}, in combination with dietary fatty acids, as a food supplement.

25 32. The application as claimed in claim 31, for preparing a medicinal product intended for the treatment of hyperlipidemias and obesity.

30 33. The application as claimed in claim 31, for supplementing nonmaternal milks.

35 34. The polypeptide as claimed in any one of claims 1 to 4 and 18, or the polypeptide hOBPII_{ba} of sequence SEQ ID No. 10, a polypeptide which is variant of said polypeptide hOBPII_{ba} or a polypeptide homologous to said polypeptide hOBPII_{ba} comprising at least 90% identity with said polypeptide hOBPII_{ba}, as an agent for targeting a pharmaceutical compound.

35. The polypeptide as claimed in claim 34, characterized in that said polypeptide is expressed in the form of a protein from fusion with a protein which 5 allows specific cellular addressing.

36. The polypeptide as claimed in claim 35, characterized in that said protein which allows specific cellular addressing is chosen from the group composed 10 of interleukins, of cytokines, of lymphokines, of interferons, of growth factors, of hormones and of antibodies.

37. The polypeptide as claimed in claim 34, characterized in that said polypeptide is combined with a 15 molecule which allows specific cellular addressing.

38. The polypeptide as claimed in claim 37, characterized in that said molecule which allows specific cellular addressing is chosen from the group composed 20 of steroids, of interleukins, of cytokines, of lymphokines, of interferons, of growth factors, of hormones and of antibodies.

25 39. The polypeptide as claimed in any one of claims 1 to 4 and 18, or the polypeptide hOBPII_{ba} of sequence SEQ ID No. 10, a polypeptide which is a variant of said polypeptide hOBPII_{ba} or a polypeptide homologous to said polypeptide hOBPII_{ba} comprising at least 90% identity 30 with said polypeptide hOBPII_{ba}, as a pharmaceutical compound transporter.

40. A pharmaceutical composition comprising a pharmaceutical compound bound at least to a polypeptide as 35 claimed in one of claims 34 to 39, and a pharmaceutically acceptable vehicle.

41. The pharmaceutical composition as claimed in claim 40, characterized in that the pharmaceutical compound is chosen from the group of anticancer agents.

5 42. The pharmaceutical composition as claimed in claim 41, characterized in that said anticancer agent is a radioactive isotope chosen from the group: iodine¹³¹, yttrium⁹⁰, gold¹⁹⁹, palladium¹⁰⁰, copper⁶⁷, bismuth²¹⁷ and antimony²¹¹.

10 43. The pharmaceutical composition as claimed in any one of claims 40 to 42, characterized in that said polypeptide as claimed in any one of claims 34 to 39 constitutes a delayed form of delivery of said pharmaceutical compound in the body.

15 44. A pharmaceutical composition comprising an expression vector as claimed in claim 12 or 13, and a pharmaceutically acceptable vehicle.

20 45. The pharmaceutical composition as claimed in any one of claims 40 to 44, for treating cancer preferably chosen from breast cancer, uterine cancer, prostate cancer, liver cancer and pulmonary epithelial cell carcinoma.

25 46. The use of a polypeptide chosen from the polypeptide hOBPII_{ba} of sequence SEQ ID No. 10, a polypeptide which is a variant of said polypeptide hOBPII_{ba} and a polypeptide homologous to said polypeptide hOBPII_{ba} comprising at least 90% identity with said polypeptide hOBPII_{ba}, for preparing a medicinal product intended for the treatment of uterine cancer, prostate cancer, liver cancer and pulmonary epithelial cell cancer.

30 47. The use of the polypeptide as claimed in any one of claims 1 to 4 and 18, or the polypeptide hOBPII_{ba} of

sequence SEQ ID No. 10, or a polypeptide which is a variant of said polypeptide hOBPII_{ba} or a polypeptide homologous to said polypeptide hOBPII_{ba} comprising at least 90% identity with said polypeptide hOBPII_{ba}, for 5 preparing a medicinal product intended for the transport of a compound across the placental barrier.

48. The use as claimed in claim 47, characterized in that said transport is carried out from the gestating 10 mother to the fetus, and in that said compound is chosen from hormones, essential fatty acids, lipophilic medicinal products and vitamins.

49. The use as claimed in claim 47, characterized in 15 that said transport is carried out from the fetus to the mother and is intended for the detoxification of the fetus.

50. The polypeptide as claimed in claims 1 to 4 and 20 18, or the polypeptide hOBPII_{ba} of sequence SEQ ID No. 10, a polypeptide which is a variant of said polypeptide hOBPII_{ba} or a polypeptide homologous to said polypeptide hOBPII_{ba} comprising at least 90% identity with said polypeptide hOBPII_{ba}, as a pregnancy marker.

25 51. The polypeptide as claimed in claims 1 to 4 and 18, or the polypeptide hOBPII_{ba} of sequence SEQ ID No. 10, a polypeptide which is a variant of said polypeptide hOBPII_{ba} or a polypeptide homologous to said 30 polypeptide hOBPII_{ba} comprising at least 90% identity with said polypeptide hOBPII_{ba}, as a marker for a fetoplacental pathological condition.

(12) DEMANDE INTERNATIONALE PUBLIÉE EN VERTU DU TRAITÉ DE COOPÉRATION
EN MATIÈRE DE BREVETS (PCT)(19) Organisation Mondiale de la Propriété
Intellectuelle
Bureau international(43) Date de la publication internationale
22 février 2001 (22.02.2001)

PCT

(10) Numéro de publication internationale
WO 01/12806 A2(51) Classification internationale des brevets: C12N 15/12,
C07K 14/47, C12Q 1/68, C12N 15/11, 5/10, C07K 16/18,
G01N 33/68, A61K 7/32, 7/46, A23C 9/152, C07K 19/00
// A61P 3/04, 3/06, 35/00(21) Numéro de la demande internationale:
PCT/FR/00/02319

(22) Date de dépôt international: 11 août 2000 (11.08.2000)

(25) Langue de dépôt: français

(26) Langue de publication: français

(30) Données relatives à la priorité:
99/10439 12 août 1999 (12.08.1999) FR

(71) Déposant (pour tous les États désignés sauf US): UNIVERSITÉ D'AUVERGNE [FR/FR], 49, boulevard François-Mitterrand, F-63000 Clermont-Ferrand (FR).

(72) Déposant et
(72) Inventeur: PITIOT, Gilles [FR/FR], 151, rue du Chevalier, F-75013 Paris (FR).(72) Inventeur et
(75) Inventeur/Déposant (pour US seulement): LA-CAZETTE, Eric [FR/FR], Appartement 311, 66, boulevard La Fayette, F-63000 Clermont-Ferrand (FR).

GACHON, Françoise (FR/FR); 11, rue des Pailliards, F-63540 Romagnat (FR).

(74) Mandataires: MARTIN, Jean-Jacques etc.; Cabinet Regimbeau, 26, avenue Kléber, F-75116 Paris (FR).

(81) États désignés (national): AT, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CI, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, H, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JE, KE, KG, KP, KR, KZ, L, C, LK, LR, I, S, LT, LU, LV, MA, MD, MG, MN, MW, MX, MZ, NO, NZ, PT, RO, RU, SD, SI, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) États désignés (régional): brevet ARPO (GI, GM, KE, LS, MW, MZ, SD, SI, SZ, TZ, UG, ZW), brevet européen (AM, AZ, BY, KG, KZ, MD, RU, TI, TM), brevet européen (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, MC, NL, PT, SD), brevet OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Publiée:

— Sons rapport de recherche internationale, sera républiée dès réception de ce rapport

For ce qui concerne les codes à deux lettres et autres abréviations, se référer aux "Notes explicatives relatives aux codes et abréviations" figurant au début de chaque numéro ordinaire de la Gazette du PCT

(54) Title: ODORANT BINDING HUMAN PROTEINS FIXING HYDROPHOBIC LIGANDS: POLYPEPTIDES AND POLYNUCLEOTIDES CODING FOR SAID POLYPEPTIDES AND USES THEREOF

A2
(54) Titre: "ODORANT-BINDING" PROTÉINES HUMAINES FIXANT DES LIGANDS HYDROPHOBES: POLYPEPTIDES ET POLYNUCLEOTIDES CODANT LESDITS POLYPEPTIDES ET LEURS APPLICATIONS

(57) Abstract: The invention concerns novel polypeptides fixing hydrophobic ligands and in particular odours, called OPBII (Odorant Binding Protein), the polynucleotides coding for said polypeptides and specific antibodies directed against said polypeptides. The invention also concerns the uses of said molecules for personal hygiene, uses in agri-food system and nutritional and therapeutic uses.

WO 01/12806 A2
(57) Abrégé: L'invention concerne de nouveaux polypeptides fixant des ligands hydrophobes et notamment des odeurs, dénommés OPBII (Odorant Binding Protein), les polynucléotides codant pour lesdits polypeptides et des anticorps spécifiques dirigés contre cesdits polypeptides. L'invention concerne également les applications de ces molécules notamment pour l'hygiène corporelle, les applications agro-alimentaires, nutritionnelles et thérapeutiques.




Fig. 1

2 / 21




FIG. 2





FIG.4

FIG. 5

5/21

6 / 21

FIG. 6



7 / 21




FIG. 7

8 / 21




FIG. 8

9 / 21





FIG. 9

10 / 21



11 / 21




FIG. 11

12 / 21




FIGURE 12




FIGURE 13




FIGURE 14

WO 01/12806

PCT/FR00/02319

15 / 21




FIG. 15

WO 01/12806

PCT/FR00/02319

16 / 21








FIG. 16

17 / 21




FIG. 17

WO 01/12806

PCT/FR00/02319

18 / 21




FIG. 18

19 / 21




FIG. 19

20 / 21




FIG. 20

WO 01/12806

PCT/FR00/02319

21 / 21




FIG. 21

DECLARATION AND POWER OF ATTORNEY

As a below named inventor, I HEREBY DECLARE:

THAT my residence, post office address, and citizenship are as stated below next to my name;

THAT I believe I am the original, first, and sole inventor (if only one inventor is named below) or an original, first, and joint inventor (if plural inventors are named below or in an attached Declaration) of the subject matter which is claimed and for which a patent is sought on the invention entitled **ODORANT-BINDING HUMAN PROTEINS HYDROPHOBIC LIGANDS: POLYPEPTIDES AND POLYNUCLEOTIDES CODING FOR SAID POLYPEPTIDES AND USES THEREOF**

(Attorney Docket No. 065691-0260)

the specification of which (check one)

is attached hereto.

was filed on Aug. 11, 2000 as ~~XXXXXXXXXX~~ and was
PCT International Application Number PCT/FR00/02319 and was
amended on _____ (if applicable).

THAT I do not know and do not believe that the same invention was ever known or used by others in the United States of America, or was patented or described in any printed publication in any country, before I (we) invented it;

THAT I do not know and do not believe that the same invention was patented or described in any printed publication in any country, or in public use or on sale in the United States of America, for more than one year prior to the filing date of this United States application;

THAT I do not know and do not believe that the same invention was first patented or made the subject of an inventor's certificate that issued in any country foreign to the United States of America before the filing date of this United States application if the foreign application was filed by me (us), or by my (our) legal representatives or assigns, more than twelve months (six months for design patents) prior to the filing date of this United States application;

THAT I have reviewed and understand the contents of the above-identified specification, including the claim(s), as amended by any amendment specifically referred to above;

THAT I believe that the above-identified specification contains a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the invention, and sets forth the best mode contemplated by me of carrying out the invention; and

THAT I acknowledge the duty to disclose to the U.S. Patent and Trademark Office all information known to me to be material to patentability as defined in Title 37, Code of Federal Regulations, §1.56.

I HEREBY CLAIM foreign priority benefits under Title 35, United States Code § 119(a)-(d) or § 365(b) of any foreign application(s) for patent or inventor's certificate, or §365(a) of any PCT international application which designated at least one country other than the United States of America, listed below and have also identified below any foreign application for patent or inventor's certificate or of any PCT international application having a filing date before that of the application on which priority is claimed.

Prior Foreign Application Number	Country	Foreign Filing Date	Priority Claimed?	Certified Copy Attached?
99 10439	France	Aug. 12, 1999	yes	

I HEREBY CLAIM the benefit under Title 35, United States Code § 119(e) of any United States provisional application(s) listed below.

U.S. Provisional Application Number	Filing Date

I HEREBY CLAIM the benefit under Title 35, United States Code, § 120 of any United States application(s), or § 365(c) of any PCT international application designating the United States of America, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of Title 35, United States Code, § 112, I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations, § 1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application.

U.S. Parent Application Number	PCT Parent Application Number	Parent Filing Date	Parent Patent Number
	PCT/FR00/02319	August 11, 2000	

I HEREBY APPOINT the registered attorneys and agents at Customer Number 22428



22428

PATENT TRADEMARK OFFICE

to have full power to prosecute this application and any continuations, divisions, reissues, and reexaminations thereof, to receive the patent, and to transact all business in the United States Patent and Trademark Office connected therewith.

I request that all correspondence be directed to:

Stephen B. Maebius
FOLEY & LARDNER
Customer Number: 22428



22428

PATENT TRADEMARK OFFICE

Telephone: (202) 672-5569
Facsimile: (202) 672-5399

I UNDERSTAND AND AGREE THAT the foregoing attorneys and agents appointed by me to prosecute this application do not personally represent me or my legal interests, but instead represent the interests of the legal owner(s) of the invention described in this application.

I FURTHER DECLARE THAT all statements made herein of my own knowledge are true, and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Name of first inventor

PITIOT Gilles

Residence

151 rue du Chevaleret, 75013 Paris / France

Citizenship

French

Post Office Address

The same as residence

Inventor's signature

Date

June 13, 2002

Name of second inventor

LACAZETTE Eric

Residence

Appartement 221, 66 boulevard La Fayette, 63000 Clermont-Ferrand / France

Citizenship

French

Post Office Address

The same as residence

Inventor's signature

Date

June 13, 2002

Name of third inventor

Residence

Citizenship

Post Office Address

Inventor's signature

Date

300
CACHON Françoise

11 rue des Paillards, 63540 Romagnat / France

French

The same as residence

June 13, 2002

Françoise

Name of fourth inventor

Residence

Citizenship

Post Office Address

Inventor's signature

Date

SMALL ENTITY DECLARATION
 [37 CFR 1.9(c-f)]

Each undersigned declares that:

(1) the application attached hereto
 (2) U.S. Application Serial No. _____ filed _____
 (3) U.S. Patent No. _____ Issued _____

is entitled to the benefits of "small entity" status for paying reduced fees under 35 USC 41(a) and (b) to the Patent and Trademark Office by virtue of the following:

(4) Each undersigned declares that he/she qualifies as an independent inventor, or would qualify had he/she made the invention, as defined in 37 CFR 1.9(c).

(5) The undersigned declares that he/she is an official empowered to act on behalf of the concern identified below; that this concern qualifies as a small business concern as defined in 37 CFR 1.9(d).

(6) The undersigned declares the he/she is an official empowered to act on behalf of the organization identified below; that this organization qualifies as a nonprofit organization as defined in

(a) 37 CFR 1.9(e)(1)
 (b) 37 CFR 1.9(e)(2)
 (c) 37 CFR 1.9(e)(3)
 (d) 37 CFR 1.9(e)(4) State law of France

(7) Each person, concern or organization to which I/we have assigned, granted, conveyed or licensed, or am under an obligation under contract or law to assign, grant, convey, or license any rights in the invention is listed below:

(a) no such person, concern or organization
 (b) persons, concerns or organizations listed below

[a separate declaration is required from each named person, concern or organization having rights to this invention averring to their status as "small entities"]

Full Name PITIOT Gilles

Address 151 rue du Chevaleret, 75013 Paris / France

Individual Small Business Concern Nonprofit Organization

I/we acknowledge the duty to file, in this application or patent, notification of any change in status resulting in loss of entitlement of small entity status prior to paying, or at the time of paying, the earliest of the issue fee or any maintenance fee due after the date on which status as a small entity is no longer appropriate. (37 CFR 1.28(b))

I/we hereby declare all statements made herein of his/her own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application, any patent issued thereon or any patent to which this declaration is directed.

(8) PITIOT Gilles June 13, 2002
 Typed Name of Inventor Signature Date

Typed Name of Inventor Signature Date

(9) _____ Name of Small Business Concern or Nonprofit Organization
 Typed Name _____ By _____ Signature _____ Date

Title of Signatory _____

SEQUENCE LISTING

<110> UNIVERSITE D'AUVERGNE CLERMONT I

<120> HUMAN ODORANT-BINDING PROTEINS WHICH BIND HYDROPHOBIC LIGANDS: POLYPEPTIDES AND POLYNUCLEOTIDES ENCODING SAID POLYPEPTIDES, AND USES THEREOF

<130> D15947

<160> 16

<170> PatentIn Vers. 2.0

<210> 1

<211> 676

<212> DNA

<213> Homo sapiens

<220>

<221> CDS

<222> (43)..(552)

<223> cDNA396 (676) /g1 (hOBPIIa-alpha)

<400> 1

cgccccagtga	cctgcccggagg	tcggcagcàc	agagctctgg	ag	atg	aag	acc	ctg	54
					Met	Lys	Thr	Leu	
					1				

ttc	ctg	ggg	gtc	acg	ctc	ggc	ctg	gcc	gct	gcc	ctg	tcc	tcc	acc	ctg	102
Phe	Leu	Gly	Val	Thr	Leu	Gly	Leu	Ala	Ala	Ala	Leu	Ser	Phe	Thr	Leu	
5	10				15						20					

gag	gag	gag	gat	atc	aca	ggg	acc	tgg	tac	gtg	aag	gcc	atg	gtg	gtc	150
Glu	Glu	Glu	Asp	Ile	Thr	Gly	Thr	Tyr	Val	Lys	Ala	Met	Val	Val		
25	30				35											

gat	aag	gac	ttt	ccg	gag	gac	agg	agg	ccc	agg	aag	gtg	tcc	cca	gtg	198
Asp	Lys	Asp	Phe	Pro	Glu	Asp	Arg	Arg	Pro	Arg	Lys	Val	Ser	Pro	Val	
40	45								50							

aag	gtg	aca	gcc	ctg	ggc	ttt	ggg	aat	tgg	gaa	gcc	acg	tcc	acc	ttc	246
Lys	Val	Thr	Ala	Leu	Gly	Gly	Gly	Asn	Ile	Leu	Ala	Thr	Phe	Thr	Phe	
55	60								65							

atg	agg	gag	gat	cgg	tgc	atc	cag	aag	aaa	atc	ctg	atg	cgg	aag	acg	294
Met	Arg	Glu	Asp	Arg	Cys	Ile	Gln	Lys	Ile	Leu	Met	Arg	Lys	Thr		
70	75								80							

gag	gag	cct	ggc	aaa	ttc	agg	ggc	ttt	ggg	ggc	agg	aag	ctc	ata	tac	342
Glu	Glu	Pro	Gly	Lys	Phe	Ser	Ala	Tyr	Gly	Gly	Arg	Lys	Leu	Ile	Tyr	
85	90								95					100		

ctg	cag	gag	ctg	ccc	ggg	acg	gac	gac	tac	gtc	ttt	tac	tgc	aaa	gac	390
Leu	Gln	Glu	Leu	Pro	Gly	Thr	Asp	Asp	Tyr	Val	Phe	Tyr	Cys	Lys	Asp	
105									110					115		

cag cgc cgt ggg ggc ctg cgc tac atg gga aag ctt gtg ggt agg aat 438
 Gln Arg Arg Gly Gly Leu Arg Tyr Met Gly Lys Leu Val Gly Arg Asn
 120 125 130
 cct aat acc aac ctg gag gcc ctg gaa gaa ttt aag aaa ttg gtg cag 486
 Pro Asn Thr Asn Leu Glu Ala Leu Glu Glu Phe Lys Lys Leu Val Gln
 135 140 145
 cac aag gga ctc tcg gag gag gac att ttc atg ccc ctg cag acg gga 534
 His Lys Gly Leu Ser Glu Glu Asp Ile Phe Met Pro Leu Gln Thr Gly
 150 155 160
 agc tgc gtt ctc gaa cac taggcagcccc ccgggtctgc acctccagag 582
 Ser Cys Val Leu Glu His
 165 170
 cccacccatc caccagacac agagccccga ccacctggac ctaccctcca gccatgaccc 642
 ttccctgctc ccacccacct gactccaaat aaag 676

 <210> 2
 <211> 170
 <212> PRT
 <213> Homo sapiens

 <400> 2
 Met Lys Thr Leu Phe Leu Gly Val Thr Leu Gly Leu Ala Ala Ala Leu
 1 5 10 15
 Ser Phe Thr Leu Glu Glu Glu Asp Ile Thr Gly Thr Trp Tyr Val Lys
 20 25 30
 Ala Met Val Val Asp Lys Asp Phe Pro Glu Asp Arg Arg Pro Arg Lys
 35 40 45
 Val Ser Pro Val Lys Val Thr Ala Leu Gly Gly Asn Leu Glu Ala
 50 55 60
 Thr Phe Thr Phe Met Arg Glu Asp Arg Cys Ile Gln Lys Lys Ile Leu
 65 70 75 80
 Met Arg Lys Thr Glu Glu Pro Gly Lys Phe Ser Ala Tyr Gly Gly Arg
 85 90 95
 Lys Leu Ile Tyr Leu Gln Glu Leu Pro Gly Thr Asp Asp Tyr Val Phe
 100 105 110
 Tyr Cys Lys Asp Gln Arg Arg Gly Leu Arg Tyr Met Gly Lys Leu
 115 120 125
 Val Gly Arg Asn Pro Asn Thr Asn Leu Glu Ala Leu Glu Glu Phe Lys
 130 135 140
 Lys Leu Val Gln His Lys Gly Leu Ser Glu Glu Asp Ile Phe Met Pro
 145 150 155 160
 Leu Gln Thr Gly Ser Cys Val Leu Glu His

<210> 3
 <211> 725
 <212> DNA
 <213> Homo sapiens

<220>
 <221> CDS
 <222> (43)..(480)
 <223> cDNA396 (725) /SM12 (hOBPIIa-beta)

<400> 3
 cggcccaagtga cctggccgagg tggcagcac agagctctgg ag atg aag acc ctg
 Met Lys Thr Leu 54
 1

ttc ctg ggt gtc acg ctc ggc ctg gct gcc ctg tcc ttc acc ctg 102
 Phe Leu Gly Val Thr Leu Gly Leu Ala Ala Leu Ser Phe Thr Leu
 5 10 15 20

gag gag gag gat atc aca ggg acc tgg tac gtg aag gcc atg gtg gtc 150
 Glu Glu Glu Asp Ile Thr Gly Thr Trp Tyr Val Lys Ala Met Val Val
 25 30 35

gat aag gac ttt ccg gag gac agg agg ccc agg aag gtg tcc cca gtg 198
 Asp Lys Asp Phe Pro Glu Asp Arg Arg Pro Arg Lys Val Ser Pro Val
 40 45 50

aag gtg aca gcc ctg ggc ggt ggg aac ttg gaa gcc acg ttc acc ttc 246
 Lys Val Thr Ala Leu Gly Gly Asn Leu Glu Ala Thr Phe Thr Phe
 55 60 65

atg agg gag gat ccg tgc atc cag aag aaa atc ctg atg cgg aag acg 294
 Met Arg Glu Asp Arg Cys Ile Gln Lys Ile Leu Met Arg Lys Thr
 70 75 80

gag gag cct ggc aaa ttc agc gcc tat ggg ggc agg aag ctc ata tac 342
 Glu Glu Pro Gly Lys Phe Ser Ala Tyr Gly Arg Lys Leu Ile Tyr
 85 90 95 100

ctg cag gag ctg ccc ggg acg gac gac tac gtc ttt tac tgc aaa gac 390
 Leu Gln Glu Leu Pro Gly Thr Asp Asp Tyr Val Phe Tyr Cys Lys Asp
 105 110 115

gag cgc cgt ggg ggc ctg cgc tac atg gga aag ctt gtg ggg cgc tgc 438
 Gln Arg Arg Gly Leu Arg Tyr Met Gly Lys Leu Val Gly Pro Cys
 120 125 130

cgc tgt ccc cac gtc ggc tca cct ggc cac ctc acc tgc agg 480
 Arg Cys Pro His Val Gly Ser Pro Gly His Leu Thr Cys Arg
 135 140 145

taggaatccat aataccaaacc tggaggccctt ggaagaattt aagaaatttg tgcagcacaa 540
 gggactctcg gaggaggaca ttttcatgcc cctgcagcac ggaagctgcg ttctcgaaca 600

ctaggcagcc cccgggtctg cacccaga gcccacccctt ccaccagaca cagagcccg 660
 accacctgga cctaccctcc agccatgacc cttccctgtc cccaccacc tgactccaaa 720
 taaaag 725

<210> 4
 <211> 146
 <212> PRT
 <213> Homo sapiens

<400> 4
 Met Lys Thr Leu Phe Leu Gly Val Thr Leu Gly Leu Ala Ala Ala Leu
 1 5 10 15

Ser Phe Thr Leu Glu Glu Glu Asp Ile Thr Gly Thr Trp Tyr Val Lys
 20 25 30

Ala Met Val Val Asp Lys Asp Phe Pro Glu Asp Arg Arg Pro Arg Lys
 35 40 45

Val Ser Pro Val Lys Val Thr Ala Leu Gly Gly Asn Leu Glu Ala
 50 55 60

Thr Phe Thr Phe Met Arg Glu Asp Arg Cys Ile Gln Lys Lys Ile Leu
 65 70 75 80

Met Arg Lys Thr Glu Glu Pro Gly Lys Phe Ser Ala Tyr Gly Arg
 85 90 95

Lys Leu Ile Tyr Leu Gln Glu Leu Pro Gly Thr Asp Asp Tyr Val Phe
 100 105 110

Tyr Cys Lys Asp Gln Arg Arg Gly Leu Arg Tyr Met Gly Lys Leu
 115 120 125

Val Gly Pro Cys Arg Cys Pro His Val Gly Ser Pro Gly His Leu Thr
 130 135 140

Cys Arg
 145

<210> 5
 <211> 741
 <212> DNA
 <213> Homo sapiens

<220>
 <221> CDS
 <222> (43)..(726)
 <223> cDNA396 (741) /SM4 (hOBPIIa-gamma)

<400> 5
 cgcccgagtga cctggccgagg tcggcagcac agagctctgg ag atg aag acc ctg 54
 Met Lys Thr Leu
 1

ttc ctg ggt gtc acg ctc ggc ctg gcc gct gcc ctg tcc ttc acc ctg 102
 Phe Leu Gly Val Thr Leu Gly Leu Ala Ala Ala Leu Ser Phe Thr Leu
 5 10 15 20
 gag gag gag gat atc aca ggg acc tgg tac gtg aag gcc atg gtg gtc 150
 Glu Glu Glu Asp Ile Thr Gly Thr Trp Tyr Val Lys Ala Met Val Val
 25 30 35
 gat aag gac ttt ccg gag gac agg agg ccc agg aag gtg tcc cca gtg 198
 Asp Lys Asp Phe Pro Glu Asp Arg Arg Pro Arg Lys Val Ser Pro Val
 40 45 50
 aag gtg aca gcc ctg ggc ggt ggg aac ttg gaa gcc acg ttc acc ttc 246
 Lys Val Thr Ala Leu Gly Gly Asn Leu Glu Ala Thr Phe Thr Phe
 55 60 65
 atg agg gag gat cgg tgc atc cag aag aaa atc ctg atg cgg aag acg 294
 Met Arg Glu Asp Arg Cys Ile Gln Lys Ile Leu Met Arg Lys Thr
 70 75 80
 gag gag cct ggc aaa ttc aac gcc tat ggg ggc agg aag ctc ata tac 342
 Glu Glu Pro Gly Lys Ser Ala Tyr Gly Gly Arg Lys Leu Ile Tyr
 85 90 95 100
 ctg cag gag ctg ccc ggg acg gac gac tac gtc ttt tac tgc aaa gac 390
 Leu Gln Glu Leu Pro Gly Thr Asp Asp Tyr Val Phe Tyr Cys Lys Asp
 105 110 115
 cag cgc cgt ggg ggc ctg cgc tac atg gga aag ctt gtg gca tct gct 438
 Gln Arg Arg Gly Gly Leu Arg Tyr Met Gly Lys Leu Val Ala Ser Ala
 120 125 130
 ccc tgc agg ggc gtg cgc ctg tcc cca cgt cgg ctc acc tgg cca cct 486
 Pro Cys Arg Ala Val Pro Leu Ser Pro Arg Arg Leu Thr Trp Pro Pro
 135 140 145
 cac ctg cag gta gga atc cta ata cca acc tgg agg ccc tgg aag aat 534
 His Leu Gln Val Gly Ile Leu Ile Pro Thr Trp Arg Pro Trp Lys Asn
 150 155 160
 tta aga aat tgg tgc agc aca agg gac tct cgg agg agg aca ttt tca 582
 Leu Arg Asn Trp Cys Ser Thr Arg Asp Ser Arg Arg Arg Thr Phe Ser
 165 170 175 180
 tgc ccc tgc aga cgg gaa gct ggc ttc tgc aac act agg cag ccc ccc 630
 Cys Pro Cys Arg Glu Ala Ala Phe Ser Asn Thr Arg Gln Pro Pro
 185 190 195
 ggt ctg cac ctc cag agc cca ccc tac cac cag aca cag agc ccc gac 678
 Gly Leu His Leu Gln Ser Pro Pro Tyr His Gln Thr Gln Ser Pro Asp
 200 205 210
 cac ctg gac cta ccc tcc agc cat gac cct tcc ctg ctc cca ccc acc 726
 His Leu Asp Leu Pro Ser Ser His Asp Pro Ser Leu Leu Pro Pro Thr
 215 220 225
 tgactccaaat taaaag 741

<210> 6
<211> 228
<212> PRT
<213> Homo sapiens

<400> 6
Met Lys Thr Leu Phe Leu Gly Val Thr Leu Gly Leu Ala Ala Ala Leu
1 5 10 15
Ser Phe Thr Leu Glu Glu Asp Ile Thr Gly Thr Trp Tyr Val Lys
20 25 30
Ala Met Val Val Asp Lys Asp Phe Pro Glu Asp Arg Arg Pro Arg Lys
35 40 45
Val Ser Pro Val Lys Val Thr Ala Leu Gly Gly Asn Leu Glu Ala
50 55 60
Thr Phe Thr Phe Met Arg Glu Asp Arg Cys Ile Gln Lys Lys Ile Leu
65 70 75 80
Met Arg Lys Thr Glu Glu Pro Gly Lys Phe Ser Ala Tyr Gly Gly Arg
85 90 95
Lys Leu Ile Tyr Leu Gln Glu Leu Pro Gly Thr Asp Asp Tyr Val Phe
100 105 110
Tyr Cys Lys Asp Gln Arg Arg Gly Gly Leu Arg Tyr Met Gly Lys Leu
115 120 125
Val Ala Ser Ala Pro Cys Arg Ala Val Pro Leu Ser Pro Arg Arg Leu
130 135 140
Thr Trp Pro Pro His Leu Gln Val Gly Ile Leu Ile Pro Thr Trp Arg
145 150 155 160
Pro Trp Lys Asn Leu Arg Asn Trp Cys Ser Thr Arg Asp Ser Arg Arg
165 170 175
Arg Thr Phe Ser Cys Pro Cys Arg Arg Glu Ala Ala Phe Ser Asn Thr
180 185 190
Arg Gln Pro Pro Gly Leu His Leu Gln Ser Pro Pro Tyr His Gln Thr
195 200 205
Gln Ser Pro Asp His Leu Asp Leu Pro Ser Ser His Asp Pro Ser Leu
210 215 220
Leu Pro Pro Thr
225

<210> 7
<211> 607
<212> DNA
<213> Homo sapiens

```

<220>
<221> CDS
<222> (43)..(483)
<223> cDNA396 (607) - short form (hOBPIIa-delta)

<400> 7
cgcccatgta cctggcgagg tcggcagcac agagctctgg ag atg aag acc ctg      54
                                         Met Lys Thr Leu
                                         1

ttc ctg ggt gtc acg ctc ggc ctg gcc gct gcc ctg tcc ttc acc ctg      102
Phe Leu Gly Val Thr Leu Gly Leu Ala Ala Ala Leu Ser Phe Thr Leu
 5          10          15          20

gag gag gag gat gag gga gaa tgg ctg gtc cat ccc gaa gaa aat cct gat      150
Glu Glu Glu Asp Glu Gly Glu Ser Val His Pro Glu Glu Asn Pro Asp
 25          30          35

gct gaa gac gga gga gcc tgg caa att cag cgc cta tgg ggg cag gaa      198
Ala Glu Asp Gly Gly Ala Trp Gln Ile Gln Arg Leu Trp Gly Gln Glu
 40          45          50

gct cat ata cct gca gga gct gcc cgg gac gga cga cta ctt ctt tta      246
Ala His Ile Pro Ala Gly Ala Ala Arg Asp Gly Arg Leu Arg Leu Leu
 55          60          65

ctg caa aga cca gcg cgg tgg ggg cct gcg cta cat ggg aaa gct tgt      294
Leu Gln Arg Pro Ala Pro Trp Gly Pro Ala Ieu His Gly Lys Ala Cys
 70          75          80

ggc atc tgc tcc ctg cag ggc cgt gcc gct gtc ccc acc ttg gct cac      342
Gly Ile Cys Ser Leu Gln Gly Arg Ala Ala Val Pro Thr Leu Ala His
 85          90          95          100

ctg gcc acc tca cct gca ggt agg aat cct aat acc aac ctg gag gcc      390
Leu Ala Thr Ser Pro Ala Gly Arg Asn Pro Asn Thr Asn Leu Glu Ala
 105         110         115

ctg gaa gaa ttt aag aaa ttg ttg cag cgc aag gga ctc tcc gag gag      438
Leu Glu Phe Lys Ieu Val Gln Arg Lys Gly Leu Ser Glu Glu
 120         125         130

gac att ttc atg ccc ctg cag acg gga agc tgc gtt ctc gaa cac      483
Asp Ile Phe Met Pro Leu Gln Thr Gly Ser Cys Val Leu Glu His
 135         140         145

taggcagcccc cccgggtctgc acctccagag cccacccctac caccagacac agagcccgga 543
ccacccgtggac ctacccctca gccatgacc cttccctgttc ccacccacct gactccaaat 603
aaag                                     607

<210> 8
<211> 147
<212> PRT
<213> Homo sapiens

```

<400> 8
 Met Lys Thr Leu Phe Leu Gly Val Thr Leu Gly Leu Ala Ala Ala Leu
 1 5 10 15
 Ser Phe Thr Leu Glu Glu Asp Glu Gly Glu Ser Val His Pro Glu
 20 25 30
 Glu Asn Pro Asp Ala Glu Asp Gly Gly Ala Trp Gln Ile Gln Arg Leu
 35 40 45
 Trp Gly Gln Glu Ala His Ile Pro Ala Gly Ala Ala Arg Asp Gly Arg
 50 55 60
 Leu Arg Leu Leu Gln Arg Pro Ala Pro Trp Gly Pro Ala Leu His
 65 70 75 80
 Gly Lys Ala Cys Gly Ile Cys Ser Leu Gln Gly Arg Ala Ala Val Pro
 85 90 95
 Thr Leu Ala His Leu Ala Thr Ser Pro Ala Gly Arg Asn Pro Asn Thr
 100 105 110
 Asn Leu Glu Ala Leu Glu Glu Phe Lys Lys Leu Val Gln Arg Lys Gly
 115 120 125
 Leu Ser Glu Glu Asp Ile Phe Met Pro Leu Gln Thr Gly Ser Cys Val
 130 135 140
 Leu Glu His
 145

<210> 9
 <211> 676
 <212> DNA
 <213> Homo sapiens

<220>
 <221> CDS
 <222> (43)..(552)
 <223> cDNA2098 (676) - conventional form (hOBPIb-alpha)

<400> 9
 cgcggcgtga cctggcgagg tcggcagcac agagctctgg ag atg aag acc ctg 54
 Met Lys Thr Leu
 1

ttc ctg ggt gtc acg ctc ggc ctg gcc gct gcc ctg tcc ttc acc ctg 102
 Phe Leu Gly Val Thr Leu Gly Leu Ala Ala Ala Leu Ser Phe Thr Leu
 5 10 15 20

gag gag gag atc aca ggg acc tgg tac gtg aag gcc atg gtg gtc 150
 Glu Glu Glu Asp Ile Thr Gly Thr Trp Tyr Val Lys Ala Met Val Val
 25 30 35

gat aag gac ttt ccg gag gac agg aag ccc agg aag gtg tcc cca gtg 198
 Asp Lys Asp Phe Pro Glu Asp Arg Arg Pro Arg Lys Val Ser Pro Val

40	45	50	
aag gtg aca gcc ctg ggc ggt ggg aag ttg gaa gcc acg ttc acc ttc Lys Val Thr Ala Leu Gly Gly Gly Lys Leu Glu Ala Thr Phe Thr Phe	55	60	246
atg agg gag gat cgg tgc atc cag aag aaa atc ctg atg cgg aag acg Met Arg Glu Asp Arg Cys Ile Gln Lys Lys Ile Leu Met Arg Lys Thr	70	75	294
gag gag cct ggc aaa tac agc gcc tat ggg ggc agg aag ctc atg tac Glu Glu Pro Gly Lys Tyr Ser Ala Tyr Gly Gly Arg Lys Leu Met Tyr	85	90	342
ctg cag gag ctg ccc agg agg gac cac tac atc ttt tac tgc aaa gac Leu Gln Glu Leu Pro Arg Arg Asp His Tyr Ile Phe Tyr Cys Lys Asp	105	110	390
cag cac cat ggg ggc ctg ctc cac atg gga aag ctt gtg ggt agg aat Gln His His Gly Gly Leu Leu His Met Gly Lys Leu Val Gly Arg Asn	120	125	438
tct gat acc aac cgg gag gcc ctg gaa gaa ttt aag aaa ttg gtg cag Ser Asp Thr Asn Arg Glu Ala Leu Glu Glu Phe Lys Lys Leu Val Gln	135	140	486
cgc aag gga ctc tcg gag gag gac att ttc acg ccc ctg cag acg gga Arg Lys Gly Leu Ser Glu Glu Asp Ile Phe Thr Pro Leu Gln Thr Gly	150	155	534
agc tgc gtt ccc gaa cac taggcagccc cgggtctgc acctccagag Ser Cys Val Pro Glu His	165	170	582
cccaccc tac caccagacac agagcccgga ccacctggac ctaccctcca gccatgaccc ttccctgctc ccacccacct gactccaaat aaag			642
676			
<210> 10			
<211> 170			
<212> PRT			
<213> Homo sapiens			
<400> 10			
Met Lys Thr Leu Phe Leu Gly Val Thr Leu Gly Leu Ala Ala Ala Leu	1	5	10
Ser Phe Thr Leu Glu Glu Asp Ile Thr Gly Thr Trp Tyr Val Lys	20	25	30
Ala Met Val Val Asp Lys Asp Phe Pro Glu Asp Arg Arg Pro Arg Lys	35	40	45
Val Ser Pro Val Lys Val Thr Ala Leu Gly Gly Lys Leu Glu Ala	50	55	60
Thr Phe Thr Phe Met Arg Glu Asp Arg Cys Ile Gln Lys Lys Ile Leu			

10

65	70	75	80
Met Arg Lys Thr Glu Glu Pro Gly Lys Tyr Ser Ala Tyr Gly Gly Arg			
85	90	95	
Lys Leu Met Tyr Leu Gln Glu Leu Pro Arg Arg Asp His Tyr Ile Phe			
100	105	110	
Tyr Cys Lys Asp Gln His His Gly Gly Leu Leu His Met Gly Lys Leu			
115	120	125	
Val Gly Arg Asn Ser Asp Thr Asn Arg Glu Ala Leu Glu Glu Phe Lys			
130	135	140	
Lys Leu Val Gln Arg Lys Gly Leu Ser Glu Glu Asp Ile Phe Thr Pro			
145	150	155	160
Leu Gln Thr Gly Ser Cys Val Pro Glu His			
165	170		

<210> 11
 <211> 782
 <212> DNA
 <213> Homo sapiens

<220>
 <221> CDS
 <222> (1)...(537)
 <223> cDNA2098 (782) - long form (hOBPIIb-beta)

<400> 11				
cgc cca gtc acc tgc cga ggt cgg cag cac aga gca gct ctg gag atg aag	48			
Arg Pro Val Thr Cys Arg Gly Arg Gln His Arg Ala Leu Glu Met Lys				
1	5	10	15	
acc ctg ttc ctg ggt gtc acg ctc ggc ctg gcc gct gcc ctg tcc ttc	96			
Thr Leu Phe Leu Gly Val Thr Leu Gly Leu Ala Ala Leu Ser Phe				
20	25	30		
acc ctg gag gag gag gat atc aca ggg acc tgg tac gtc aag gcc atg	144			
Thr Leu Glu Glu Asp Ile Thr Gly Thr Trp Tyr Val Lys Ala Met				
35	40	45		
gtg gtc gat aag gac ttt ccg gag gac agg aag ccc agg aag gtc tcc	192			
Val Val Asp Lys Asp Phe Pro Glu Asp Arg Arg Pro Arg Lys Val Ser				
50	55	60		
cca gtc aag gtc aca gcc ctc ggc ggt ggg aag ttg gaa gcc acg ttc	240			
Pro Val Lys Val Thr Ala Leu Gly Gly Lys Leu Glu Ala Thr Phe				
65	70	75	80	
acc ttc atg agg gag gat cgg tgc atc cag aag aaa atc ctg atg cgg	288			
Thr Phe Met Arg Glu Asp Arg Cys Ile Gln Lys Ile Leu Met Arg				
85	90	95		
aag acg gag gag cct ggc aag tac acg gcc tgc ttg tcc gca gtc gag	336			
Lys Thr Glu Glu Pro Gly Lys Tyr Ser Ala Cys Leu Ser Ala Val Glu				

WO 01/12806

PCT/FR00/02319

11

100

105

110

atg gac cag atc acg cct gcc ctc tgg gag gac cta gcc att gac aca 384
 Met Asp Gln Ile Thr Pro Ala Leu Trp Glu Ala Leu Ala Ile Asp Thr
 115 120 125

ttg agg aag ctg agg att ggg aca agg cca agg att aga tgg ggg 432
 Leu Arg Lys Leu Arg Ile Gly Thr Arg Arg Pro Arg Ile Arg Trp Gly
 130 135 140

cag gaa gct cat gta cct gca gga gct gcc cag gag gga cca cta cat 480
 Gln Glu Ala His Val Pro Ala Gly Ala Ala Gln Glu Gly Pro Leu His
 145 150 155 160

ctt tta ctg caa aca cca gca cca tgg ggg cct gct cca cat ggg aaa 528
 Leu Leu Leu Gln Arg Pro Ala Pro Trp Gly Pro Ala Pro His Gly Lys
 165 170 175

gct tgt ggg taggaaatctt gataccaaacc gggaggccctt ggaagaattt 577
 Ala Cys Gly

aaaaatgg ttcagcgc aa gggactctcg gaggaggaca ttttcacgc cctgcagacg 637

ggaagctcg ttcccgaaaca cttaggcgac cccgggtctg cacttcaca gcccacccctt 697

ccaccagaca cagagccccgg accaccttgg a ctttttttttccatggcc accatggcc ttccctgtttt 757
 cccacccacc ttgactccaaa taaag 782

<210> 12

<211> 179

<212> PRT

<213> Homo sapiens

<400> 12

Arg Pro Val Thr Cys Arg Gly Arg Gln His Arg Ala Leu Glu Met Lys
 1 5 10 15

Thr Leu Phe Leu Gly Val Thr Leu Gly Leu Ala Ala Ala Leu Ser Phe
 20 25 30

Thr Leu Glu Glu Glu Asp Ile Thr Gly Thr Trp Tyr Val Lys Ala Met
 35 40 45

Val Val Asp Lys Asp Phe Pro Glu Asp Arg Arg Pro Arg Lys Val Ser
 50 55 60

Pro Val Lys Val Thr Ala Leu Gly Gly Lys Leu Glu Ala Thr Phe
 65 70 75 80

Thr Phe Met Arg Glu Asp Arg Cys Ile Gln Lys Lys Ile Leu Met Arg
 85 90 95

Lys Thr Glu Glu Pro Gly Lys Tyr Ser Ala Cys Leu Ser Ala Val Glu
 100 105 110

Met Asp Gln Ile Thr Pro Ala Leu Trp Glu Ala Leu Ala Ile Asp Thr

115

120

125

Leu Arg Lys Leu Arg Ile Gly Thr Arg Arg Pro Arg Ile Arg Trp Gly
 130 135

Gln Glu Ala His Val Pro Ala Gly Ala Ala Gln Glu Gly Pro Leu His
 145 150 155 160

Leu Leu Leu Gln Arg Pro Ala Pro Trp Gly Pro Ala Pro His Gly Lys
 165 170 175

Ala Cys Gly

<210> 13

<211> 542

<212> DNA

<213> Homo sapiens

<220>

<221> CDS

<222> (43)..(297)

<223> cDNA2098 (542) - short form (OBPIIb-gamma)

<400> 13

cgtccaggatgtatccggcgagg tccggcagcac agagctctgg ag atg aag acc ctg 54
 Met Lys Thr Leu
 1

ttc ctg ggt gtc acg ctc ggc ctg gcc gct gcc ctg tcc ttc acc ctg 102
 Phe Leu Gly Val Thr Leu Gly Leu Ala Ala Leu Ser Phe Thr Leu
 5 10 15 20

gag gag gag gat gag gga gga tcg gtg cat cca gaa gaa aat cct gat 150
 Glu Glu Glu Asp Glu Gly Gly Ser Val His Pro Glu Glu Asn Pro Asp
 25 30 35

gct gaa gac gga gga gcc tgg caa att cag cgc cta tgg ggg cag gaa 198
 Ala Glu Asp Gly Ala Trp Gln Ile Gln Arg Leu Trp Gly Gln Glu
 40 45 50

gct cat ata cct gca gga gct gcc cag gag gga cca cta cat ctt tta 246
 Ala His Ile Pro Ala Gly Ala Ala Gln Glu Gly Pro Leu His Leu Leu
 55 60 65

ctg caa aga cca gca cca tgg ggg cct gct cca cat ggg aaa gct tgt 294
 Leu Gln Arg Pro Ala Pro Trp Gly Pro Ala Pro His Gly Lys Ala Cys
 70 75 80

ggg taggaaattct gataccaaacc gggaggccct ggaagaattt aagaaaattgg 347
 Gly
 85

tgcagcgcaga gggactctcg gaggaggaca ttttacgccc cctgcagacg ggaagctgcg 407
 ttcccgaaaca ctaggcagcc cccgggtctg cacctccaga gcccacccctt ccaccagaca 467

cagagccccgg accacaccttga cctaccctcc agccatgacc ctteccctgtct cccacccacc 527
tgactccaaat taaaat 542

<210> 14
<211> 85
<212> PRT
<213> *Homo sapiens*

<400> 14
Met Lys Thr Leu Phe Leu Gly Val Thr Leu Gly Leu Ala Ala Ala Leu
1 5 10 15

Ser Phe Thr Leu Glu Glu Glu Asp Glu Gly Gly Ser Val His Pro Glu
 20 25 30

Glu Asn Pro Asp Ala Glu Asp Gly Gly Ala Trp Gln Ile Gln Arg Leu
35 40 45

Trp Gly Gln Glu Ala His Ile Pro Ala Gly Ala Ala Gln Glu Gly Pro
50 55 60

Leu His Leu Leu Leu Gln Arg Pro Ala Pro Trp Gly Pro Ala Pro His
65 70 75 80

Gly Lys Ala Cys Gly
85

<210> 15
<211> 10664
<212> DNA
<213> *Homo sapiens*

<220>
<223> hOBPIIa Gene

```
<400> 15
cttcgttctt atatccggcc tccaaaatctg tgctcaatgc agcaactgga gtgacccccc 60
aaatacgtaa gtcacagcgtt gcctttgtca gagctatcca gggtttttca ctcagagcag 120
aagctgaagt ccttcgtggc gtccatatac cttacatggc cgtttccaccc actcccccage 180
ctcatgtgtg gccgggttccctt ctggatcatt tgctgtggct gctctggct gtgttccgg 240
aaactggccag cgttctccca cttctgggct ggcactgtgat gtccctgcac cttggactcc 300
ttttccagct gacgagctca tggcttgcctt cttcatgttc tttaaattccg tgggttgaatg 360
ccacccatggc gaggggttcc tctatcaatt catgtaaaagg acaaataaacc ctttgcgttgc 420
ccactccctgt ccaacttgtc cactttgtttt ccatccatgc actgtatccacc attttaaaata 480
atgtatgaac cagtgaccca tcagtgcacca gagacagtagt atgaaacagg tattgttgc 540
acatgtaaaca atcagctcta gaggtttaaa gagaaccacca aagaatggct caggattgtca 600
```


tctttggctt gtctttttat tctgttaaca gggctcttta cagagcaaaa gggtttttatt 2400
ttgatagaat ctatTTTaaC aatttttctt ttatggatc atattttgg caacaatct 2460
aaaaccccttT gaccCagTC cataTgtca aagTTTCTT gTTTCTTaa agTTTatag 2520
tttaaagtTT tatgttgaag tctatgtatcc aTTTigagt aTTTTCata cagggtgtga 2580
gaccAaggTT gtggTTCTTC ttttCTTtg gggTTTgt ctgtggatgt ccagTTgtc 2640
cagccccattt gctacaaaag ctatTTTCC tccactgaat tactTTTgca tctttgtaa 2700
aatgttaattt ggtgtatTT tacaggTctg tttgaggatt ctttatttgc tggccatTT 2760
atctatgtat ctggccatgt gctactata taagtcttga aagggttagcc tggactctgg 2820
tggTggggcg aqaggcctgtat atccccatca ttcgggaagt ggaggcaggA gaatcgatt 2880
aaccggagg gtggagggtg cagttagtca agatcgTcc actgcactcc acgtcggtg 2940
acagagtggaa ctccatataa aaaaataaaa aaaaaataaa agtagcgTga ttTcccac 3000
cttattttt tttaaaaaaag ttttagtcat tccagTTCTT ttgcTTTCC atataaaattt 3060
tagaataatc ttgtctatAT ctaccacat ttttcttggA atTTTgatag aatTTTgtt 3120
acatctttat attatttgg agaaaatgata ttttactat gttgagtctt ctaatccatg 3180
gatataaacgt ctcccatTT gtttagatct ttttgattt atTTTataa cattgtatg 3240
ttttcagcat acaaattccag catatgggtt gtttagactta tgccTtagca ttcattttt 3300
ttagccatta taaaatgtac tggTTTTA agTTTgggt ccattactag tatgttagaca 3360
cacaattgtat ctttggatata ttaatcttgc tccTgcAACc ttgtgaaat cactactag 3420
ttcttagggg tggatTTTTT ttttttttgg ttttttttgg ttttttttgg ttttttttgg 3480
agataataat gtcatctgca gatgcagtTT tccTccTcc ttttcaattt gtatgtctt 3540
aattttccTTT ttttttttttgg ttttttttgg ttttttttgg ttttttttgg ttttttttgg 3600
caagttggtag agtggacatc ctggccTgt ccttgatgtt aaagagaag catttgcata 3660
tgagtatccc agccTcaaaa tggTgttaaa aacttttttcc ttttttttgg ttttttttgg 3720
aaacatattt cggaaactttt tttttccccc tttccacca ggcacttccg tgagcagtgc 3780
tcgcTTatct aattatgtgc ttacttagaa attcggggg ccaatTTTgtt aacaaaccag 3840
gcagagagac ccagctgcag aatctccctt cttagggggg gttacaggtt gcttacact 3900
tcccccgtga aatcaggatg acgcaaaacca gacccTccgg aacacgttgg atgactcaca 3960
ataaccatca gaacaagatg cagaccaaca tccTccTgc ccatTTccac atatttccca 4020
cacTTTcc tccTTaaacc cttccgctca gttccggggg ttttttttgg ttttttttgg 4080

tactgaccctt gagccacaca atatgtgcctc tctctgtcccc taggaagctc gagggtgcagg 5880
tccagggtggg gaaaatcaat gcagagtggg tccccagatg ggcggaaatctggggctctag 5940
ggcggtgcggg actcagctgg cagcagcccc acatctctat ggttctaaag cccagttccat 6000
ttctgtcttag caggggatg gccagttccc cagaggactt gcccagggttc ccaggctgg 6060
ccctggggagg gctcagggtt gaggaggaga gaattcccgag ccgtggggccc tccctctgtg 6120
gctcgggggtg cagacgtca ctaccctggc ctgtctctg gagtctctcg ggctcatcca 6180
agtggggcga tttgggtgc aaccctggac agcatactgt gtctttctt ctctgggtgg 6240
cactgaatgt ctgttccatca gatggccagca atggggacac tccccctccc ggatgtcaggaa 6300
ctgggttgcaca ccatggggag ggggtgcaccc tgccacgttc tccaggacca ctggccagg 6360
ggctataaag aacatctcgaa gaggagccag cacagccctt ttcagacgccc cagtgtaccc 6420
ccgagggtcg cagcacacag ctctggagat gaagaccctt ttctgggtg tcaacgtcg 6480
cctggccgtt gcccctgttcc tcaaccctggaa ggaggaggat gtgagctggg ttgggtggg 6540
cggtatggagg agccagggtgg actctctggc agggggcagt gccaggggcc ctgtttagg 6600
.agggttcaat taaggctggg gtgggtgggg aggggtctca ttgttcttc agcagacaaat 6660
gtctcccaatg agggccagggg ccggagcagg ctggctca gggttcttc tgcactgtac 6720
cctgttgcggccaa gaagggttcg cagggtgggg ccctgtgggg ggagggttc tctgggtctg 6780
ggggccggggg gtccatgggg tgccagatcg ccctcttc actgggggtt gggagccctg 6840
agcagggggc tgggtctaaac tcaactccatcg tgagcttaa ctaagggtca ggaaccaccc 6900
ctggcttttag ggggtgcagc cgggcacccat ggggtgttgg ttatagctgc aggctttagt 6960
gcccagggtca gagtagaaatc tggggccaccc atgggtgggtt caccggcttc tgcctgttca 7020
gatcacacaggg acctgttcaatc tgaaggccat ggtgggtcat aaggactttc cggaggacac 7080
gaggcccaagg aagggttccc cagtgttgc gatggccctg ggcgggtgggg acttggaaac 7140
caatgttccatc ttcatgttgc tgggttgcaccc tgccagggtcc ctcaggccatc ttctggctcc 7200
cgccccacag ccacccatggg cccattgtcc catccacatt tgggtgttgg ggaagatgtca 7260
ccccctgtctt tggggggaaa cagccagggttcc atctctgttgc tgggtgggtt gggggggcc 7320
tggaaatttc aggttgcggg gtccagggttgc tgccacccat gatgttgc ggggttgcagg 7380
gtgttgcggg agccgttgc cgggtgttgc tgggttgc tgggtgggtt ggggttgcagg 7440
cagaagaaaa tccatgttgc gaaagccagg gacccatggca aatacagccgc ctgttgcaggcc 7500
ctcccccaatc ccccaactccc catggccatcc cccggatgtca ccaggccatc tgcacatgtca 7560

gagtggccca gccacacattc tgcagggttc ccagccctgc ccacactcca ggaggggctg 7620
gcctcttcctt cctggggggc tggggccctt gacatcagac accaggtgt acagggttg 7680
ccacagtaga gatggccacg atcaagcttg cctctggaa ggccttagcc attgacatc 7740
tgaggaaatcc gagtgttagg gaccaggagg ccgagggtta gggatggaa gccaaggctg 7800
agggtttggg atcaggaaatc cgagggttag ggacaggaa gttggggcagg agcagctgt 7860
ggagctggaa aggccggact ctatgtctgg acgtgtctgg gccttgcgc tccattact 7920
gcattggac ctcccgagag gaggctctg cttccgttc cgggtccatg ctgtgcggag 7980
cagccaggcc tggctcaggc tgccaggc acctgggtga ccactgaaac attcctgagt 8040
gtttcttgtt gtggccctga gtgtcttc cgggtatgt ggcactgtgg accccatctc 8100
tctgtcatct acagatgggg gcaggaaatc catatactgg caggagctgc cggggacgg 8160
cgactaegtc ttttactgtca aagaccaggc cccgtggggc ctgcgttaca tgggaaatg 8220
tgtgggttag gggccctgtt gggccgtat gtcttgcggcc atggctctgg cttccaaag 8280
ccagttggaaac caccatcata acgccttgc acggggggaa aaggaaatccc cttgcggcc 8340
.cccttcgtgtg cttaggcacca agcgtgtccc tggatggctg gtccaaatgc ctgaatgtgg 8400
agtgggggtgg gccaggcagg gacagacacg gccttcgggt acgtgtaccc gccaaggccc 8460
gtcttggggg tctcagggtt agggggctca ctttaaggggg gaggtaatcat cttaacagag 8520
cttcctatgg ggcagggtact ctccagggtgc gcagggtcgc cagtgcctt gggacacaaag 8580
gtccctccag gtgggggttg tgaccctgtca gagttgtttt gggagctgtcc cagggtcccc 8640
tgggggtgtt gatgtgttgc gacccgttca ctgtccctt tcttggggac ctctcaccatg 8700
ggcggtggcc gtctccctgtg tccccatgtcc caccctgtag ctcttgcata ttctcaggcc 8760
tctcttcccc cttagcgtgtt gctggacatgt tgccatcttct tcttccccca gcccccccc 8820
tgagctctga tccactcttcg ggccttcctt cccgttgcgtat gtcggggctg ggtgtctcc 8880
ttttagcata tgctccctgtc agggccgtgc cgtgtcccc acgtgtccctc acctggccac 8940
ctcacctgtca ggttagaaatc ctaataccaa cttggggggc ctggaaatgt ttaagaattt 9000
ggtgtcagcac aaggggactt cggaggaggaa cattttcagc cccctgtcaga cgggtggaga 9060
ccgggtgtcc cagtagcccttgg tttccctgtg tgcgttgcgtg tgatctccag tgcggggcc 9120
cccttcgtgtc ctcccatgtc ccccgatcc cccatgtgtcc cccgtatgtcc tgcggggcc 9180
tctggggctt gcttagcata ctgcgtgtt gagggtgtgc acttgggtt gcgatgggg 9240
cttaggtttcc acgtgttctggg cttaggtatgtc gtttggggctt ccgggtgtcc ggtgtatgtc 9300

gggctctgggg ctcccgccctc tggggctgcga tggggctctgg ggtctccgcgc tctgggctgc 9360
 gatggggctctt ggggctccgc gctctgggctt gcgatggggctt ctggggctcc ggtctctggg 9420
 ctgcgtatggg gtcgtgggctt ccgcgtctcg ggctcgatgtt gggctctgggg ctcccgccctc 9480
 tggggctgcga tggggctctgg ggctccgcgc tctgggctgc gatggggctt ggggctctga 9540
 gctctgggctt gcgatggggctt ctggggccctg gtcgtggggctt ccttctataatc cctggggtttt 9600
 tcttggtctc tgcaggaaagc tgcgttctcg aacactaggg ttagtgagcc ttttaggaggg 9660
 cactggacaa gcccaggatc ctgggttcccc ggggttcag ggtacatctg ctctggccct 9720
 tcccatccccca cacaggcagg gagacccccc cagggtcagg cacagggttg gcaacctcaga 9780
 gtctggccac cc当地atcc tggggatctt gggaaatctt ttgttttacc attcctgcac 9840
 ctggccggcc gagtggggctt ctctctcgcc ct当地ccacag cgaggccctcc ctccggctcc 9900
 ctcaagggtgtc agctcgccccc atcccccctt gcaacctgtcc ctactcggtc tactcccccc 9960
 caccactca ccaaggatgc tcaagggttcc gcccaggatc tggaggagatc gagggtgtc 10020
 tggagccccc aggtgtccca gcaagggttcc gatgtggaaatc tgcaggatctt gggggaggag 10080
 ctctggggctt ggc当地ctcgcc ct当地ccatcga gctctccatgca ctctctgtcc tcttccca 10140
 acageagecccc cggggctgtc acetccagag cccacccatc caccagacac agagccccgg 10200
 cc当地ctggac ct当地ccatcga gcatgaccc ttc当地ctgtcc cc当地ccatc gactccaaat 10260
 aaagagcttc tccccccatc gtc当地ccatc gatgtggggatc ggacggaggag gctcgaccc 10320
 gtc当地ctggggatc ggccctgtctt gggggggggatc cc当地ccatc gatgtggggatc 10380
 tagcaagggttcc caaaccacaa gaggcaacatg gtc当地ccatc gatgtggggatc ggccgtatgtc 10440
 ctggaggggcc ctccggaaatc gccc当地ccatc gatctcgatgtc tcaaggatgttcc 10500
 ctctggggatc gaggacttggaaatc gaggccacttgg gggggccggatc agtggggatc cggccgtatgtc 10560
 cctgcatcag tggggatccatc acagggttccatc cggcccccggatc gtc当地ccatc gatctccatc 10620
 gggggatccatc ttttccatc tggggatccatc gggccgtatgtc gatctccatc 10664

<210> 16
 <211> 13591
 <212> DNA
 <213> Homo sapiens

<220>
 <223> hOBP11b Gen

<400> 16
 tctctgttttccatc tatattcgcc ctccaaatctt gtc当地ccatc gaggacttggatc agtggggatc 60

taataacgt a gtcacagct tgcctttgtc agagcttcg agggttttc acttcagacg 120
gaagctgaag tccctgtgtt ggctcttaat ccttacatgg cagttccacc cactcccc 180
cctcatgtgt ggccgggttc cttggatcat ttgtgtgtc tgctctgtc tgggttttt 240
gaaactgcca gatcttcccc accttccatgg tggactgtt tgctctgtcc acctggactc 300
ctcttccagc tgacgagtc atggcttgc tccctatgt cttaaattcg gtgtttgtaa 360
qccacccctgg cggggctgtt cttcatcaat tcattttaaag gacaataaac cccttgcct 420
gacactctgt tccaaacttgtt ccaactttgtt tttccatag cactgtatca cattttaaat 480
aaegtatgaa ccagtgtaccc atcaggatcc agagacaata gtttgcacag ggatgttgc 540
cacatgttac aatctgttctt agagggtttaa agagaccac aaagatggc tcaggatgtc 600
acggggcag ttaaggaa aataaacagg ggttttttttttccatggatccaa tgctgggttc 660
agacccatgtg ggagaagggtg tgggttttttttccatggatccaa tgctgggttgc 720
cccagccaca gctggccccc ggttgggtca gaggccagca ggcaggggaa tgtaggtttgc 780
gtctggcaag caggaaatcttccatggatccaa tgctgggttgc 840
tgcagatgc actggatccaa cccatgttgc tgatggatccaa tgctgggttgc 900
tgggggggtt cccatgttgc ttttttttttccatggatccaa tgctgggttgc 960
ctggcatttgc catggaa gaaagaaaaa ggaagaaatg gaagcatgtc gaaccatgtc 1020
tcttggatccatgttgc ttttttttttccatggatccaa tgctgggttgc 1080
caccagggttc acaaggaaatg cccatgttgc ttttttttttccatggatccaa tgctgggttgc 1140
gaagggttgc ttttttttttccatggatccaa tgctgggttgc 1200
tattttgttgc ttttttttttccatggatccaa tgctgggttgc 1260
tgggttttttccatggatccaa tgctgggttgc 1320
caaaaaatcaa acataaaaat gaaatgttgc ttttttttttccatggatccaa tgctgggttgc 1380
ggcatttccatggatccaa tgctgggttgc 1440
tatctgttgc ttttttttttccatggatccaa tgctgggttgc 1500
tttttttttccatggatccaa tgctgggttgc 1560
gatccccatgttgc ttttttttttccatggatccaa tgctgggttgc 1620
cttcagcccccc aaccccttccatggatccaa tgctgggttgc 1680
agaatgttgc ttttttttttccatggatccaa tgctgggttgc 1740
catcatttccatggatccaa tgctgggttgc 1800

tctggatgt gctctatggt atggatgtac cacatgtgt ttaactattc acctgttgga 1860
ggatgtctgt gtttatagat ttgggctatg acacatgtac aggttttgc atggacatca 1920
gttttcattt ttctgggaca aaggcccagg ggttctattg cggggctcta tgctgttgc 1980
agggtttttt tttttaaacc tgtaagcca tttccagaa actgttccagt ttccatgtcat 2040
cctcaccagg cttcagttatg atcactatga tcttatctca gccacctta taggtatgta 2100
ctgatatac atggcttttta ttgcatttc actgtatgact aatgggttg agetctttt 2160
catgtgttta ttgcacatc gtatatctc tctgtcaag tgccttctca tgctttttgt 2220
ttacatctca ttttgaac tggtgatgt tgaaaaattc ttatataagt atagaacata 2280
atctttgtt gaatatgtatg ttgtcata tttttttca gcttttggc tgctttttta 2340
ttctgttaac agggctcttt acagagcaaa aggtttttat ttgtatgaa tctatttta 2400
caatttttcc ttttatggat catattttg gtacacatc taaaatctc tgaccacagt 2460
ccatatccca aagatttct ttctgttttca aaaaatctt atagttttaa gttttatgtt 2520
taagtctatg atccattttt agttatttt ctgcagggt gtgagaccaa gtttgggtt 2580
cttttttttgg ttgggtgtt ttgtctgtt atgtccagtt aatccagccc atltgtaca 2640
aaagctatct tccattgaat tgcttttgc tcttgtaaa aacttaactg ggtatatgtc 2700
tgcaaggctg tttgaggatt ctattatgtc tgccctatg atctatgtcat ctgtccatct 2760
gctatgtata taatgtatgtc taaaagggtt gcttgcgtatg ggttgcgtt gtgtgcatact 2820
gtaatccca ctacttggga ggcggggca ggagaatcac ttgaatctgg gaggtggagg 2880
ttgcaatgtg tgcaaggatgt gctactgtc tccagccctgg gtgacagage aagactctgt 2940
ctctaaaaaa aagaaaagaag aagaaaagga aagaaagggt agetctgtt ctcccaatct 3000
attctaaaaaa aaaaaagtt tagttatctt agtttcttgc cttttccata taaaatgttag 3060
aataatcttg tctatgtctca caaaaatcc ttcgttggaaatt ttgtatgaaa ttgtttaaa 3120
tctttatattt atttgagaga aatgaatgtt ttatgtgtt ggttgcata atccatgtat 3180
atagacatc tcccaatgtt tttagatctt ctgttgcattt ttttataatc attgtatctt 3240
tttcagcata caaatccatc atatgggtt taaaacttgc gcttgcgtt ctttttttt 3300
tagccactat aagtagtattt gtttttttgc gtttgcgtt ctttttttttgc gtttgcgtt 3360
acaattgtatc ttgtatattt atcttgcattt ctttgcatttgc gtttgcgtt ctttttttttgc gtttgcgtt 3420
ttcttagggat gtatgtttt ctgttgcattt gtttttttgc gtttgcgtt ctttttttttgc gtttgcgtt 3480
gaaatcatg tcatgtcag atgcagacatc ttttttttttgc gtttgcgtt ctttttttttgc gtttgcgtt 3540

ttaatttcc ttttaaaaaa accttttattt cctctgactag aacttttctgt actatgttaa 3600
atacaagtgg tgaaagtggaa catccctggcc ttgtccctgaa tgtaaggag aaagcggtt 3660
taactgagta tcccaagcttcc aaaaatgtct taaaaactttt ttcttcttct tgccttcage 3720
cttggaaacat acttgcggaaatctttttcc accaggactt tctgtgagca 3780
gtgcgtcgctt atcttaattat gtgcgttactt agaaatttcca ggggccaattt tgaaacaaa 3840
ccaggccagag agacccagctt gcaaaatctt cccttctttagg gggagttaca ggttagccctac 3900
cacttcccggtt gtaaaatcgat gatgacttacc accagaccc tggacagacg attaaatgact 3960
catgataaaccat ttttgcggaaatccatcc tgcacccatcc ccacatattt 4020
cccacacccctt ttcttcttta aacccttcc tctcgttccatcc aaagtttggaa tggctttttt 4080
aaggcatggggccatcc tcttcttacttgc tctgatggaa aataatgttgc ctttttttt 4140
accacacccatcttccatcc ttttgcggaaatccatcc tggcggccatcc ttggcggccat 4200
tacacatcgat ttttccatcc tggatggaaatccatcc tggatggatcc aggtttttttt tagatgtct 4260
ttgtcaaggat ttttgcggatcc ttttccatcc ttttgcggatcc ttttgcggatcc ttttgcggatcc 4320
cgtgtatgtat ttttgcggatcc ttttgcggatcc ttttgcggatcc ttttgcggatcc ttttgcggatcc 4380
tctttaacata ttttgcggatcc ttttgcggatcc ttttgcggatcc ttttgcggatcc ttttgcggatcc 4440
aactgttttgcggatcc ttttgcggatcc ttttgcggatcc ttttgcggatcc ttttgcggatcc 4500
aaaggatccatcc ttttgcggatcc ttttgcggatcc ttttgcggatcc ttttgcggatcc ttttgcggatcc 4560
gtcagggttttgcggatcc ttttgcggatcc ttttgcggatcc ttttgcggatcc ttttgcggatcc 4620
ttattttttgcggatcc ttttgcggatcc ttttgcggatcc ttttgcggatcc ttttgcggatcc 4680
tttggaaatccatcc ttttgcggatcc ttttgcggatcc ttttgcggatcc ttttgcggatcc ttttgcggatcc 4740
tatcttataatcc ttttgcggatcc ttttgcggatcc ttttgcggatcc ttttgcggatcc ttttgcggatcc 4800
atatgtggatcc ttttgcggatcc ttttgcggatcc ttttgcggatcc ttttgcggatcc ttttgcggatcc 4860
tagtgcgtatcc ttttgcggatcc ttttgcggatcc ttttgcggatcc ttttgcggatcc ttttgcggatcc 4920
tttgcgtatcc ttttgcggatcc ttttgcggatcc ttttgcggatcc ttttgcggatcc ttttgcggatcc 4980
tttgcgtatcc ttttgcggatcc ttttgcggatcc ttttgcggatcc ttttgcggatcc ttttgcggatcc 5040
tttgcgtatcc ttttgcggatcc ttttgcggatcc ttttgcggatcc ttttgcggatcc ttttgcggatcc 5100
tttgcgtatcc ttttgcggatcc ttttgcggatcc ttttgcggatcc ttttgcggatcc ttttgcggatcc 5160
ctaatatatcc ttttgcggatcc ttttgcggatcc ttttgcggatcc ttttgcggatcc ttttgcggatcc 5220
tgcgtatcc ttttgcggatcc ttttgcggatcc ttttgcggatcc ttttgcggatcc ttttgcggatcc 5280

ttggcactate ttggctcaact gcaacactcca cctctctgggt tgaagtaatt ctctctgttc 5340
agccccctaa ttagctggaa ttacaggtat acggccacat gcccagcaat ttatcttattt 5400
atttatctttt gtatcttttag tagagatgag gttttgtcat gctgtccagg ctggctctcg 5460
actctgtacc tcaagtgtac tggccacgtg gggctccaaa gcaactgagat tataaggcata 5520
agccactgtg cccagcctgt ttttgggtt tttgagatgg agtcttgcctc tgcaccccg 5580
gtctggatgtc agtggcatga tagcccaactg caacccctccgc ctccccgggtt caagtgtttc 5640
tcctgtccca gcccctccgtat tagctgggtt tacaggctgtg caccacacata ctcaagctgt 5700
ttttgcattt ttggtagaga tgggttttcg ccatgttgc caggctggc tcgaatttct 5760
gatcgcaagt gatccacccg cctggggctc ccaaagtgtt ggaattatag gcacaagcc 5820
tcacgcccacatgtt gtatcttcat ttcatccatg cctagttatata tttaaaatattt 5880
accttcaggc ttccctcttg acctgtggat tatttcacagg tgggtttttt ccaaggcatct 5940
gaagaagat ttccattat ctttctggca ttgtatataa gttagattcc atgtggtag 6000
agactaccct ctatatcatt taaatttttttaaaaatccctt gaggcttattt ttctcatcca 6060
ggatgtgtc tattttggta latattctgg tgcatttgaa aagaatgtt gtatgtgtt 6120
tggcagggtgg tgggttctac aaatgtcaat tggattatgtt taattgtatgg gggccggagt 6180
tctttgtatgtt cctctgtgtt tttctgtctca gttgtctgaa gagaagggtt ttgaagtc 6240
caactataat ttgtgtctttt taaatcttctc ctttcagttc ttgtttgtt cacatattgt 6300
gcagctaatgtt ttgtgtgcac acacgtttag gattactatg tcttcttgc agaatggccc 6360
acatttattt gtataatttc cctctctgtt aattgttctt tgggttctaaag tctatcttac 6420
ctgttattgtt aataatgtttt ctgttcttctt ttgttattatgtt ttttttcatg 6480
tttttactttt caacctgtctt ctattgttac atttgaagta agtttcttgc agacggcata 6540
tagttgtata atgttatttta atttacttgc acacgtttagt cttttttatata tttaaaacat 6600
tttacatttaa tataatttttta aacatgttagt agtttgcattt atttttatag ggttgcata 6660
acaaaatactt accaactggg tggctttagaa caaaaatitaa ttttctcaca ttctgggtggc 6720
cagaaggctgtg agatctgtg agatctgttgc ggttagaaaaa ccaacaaaat atgttataatgt 6780
tggtaaccattt gtggcaactt gggactctgtt ctttctgttgc gccatctgtgaa atatagggtt 6840
gaacccatattt tgattgttcc actttagaaagg aagagtccatg accattttatc ccatcgtt 6900
ctatccctac agactgagga tgcgttgcattt cttgcacatc ttgggttcatc cagttgtcagg 6960
ggaaaggcagac aagaaaaagggtt gcaaggactt aagggtggaa gctgtgataa cgtccctgtca 7020

ctggggcccc tgacatcaga caccgggtgt gacaggcttg tccgcagtcg agatggacca 10560
gatcacgctt gcctctggg aggccttgc cattgacaca ttgaggaaagc tgaggatgg 10620
gacaaggagg ccaaggatta ggtacgggga ggctgggggt tagggatggg gaagctgagg 10680
gttaaggatg gggaaagctga gggttaaagga tgggggggtt gagggtttagg gacggggggcc 10740
aagggtttagg gatcgggaa ctgagggtta gggatgaggaa ggccgggggt tagggatggg 10800
ggggccgagg gttagtgcgta cggaaagctga ggattagaga tgggggggtt gaggggaaag 10860
atgggggtta gggcaggaga agtggggcag gaggcagtcg tggagctggg aaggccggac 10920
tctagtcctg gacgtgtctt ggcttggg ctccattact tgcattggg ccttcctgtag 10980
aggaggctcc tgcctccgtg tccgggtcca cactgtgcgg agcagccagg cctggctcag 11040
gctgtccagg gcacccgggtt gacegtgaa acatcccgaa tggtttcttc atgtggcccc 11100
gatgtgttctc tctggaaatg acccattttc tctgtcatct acatggggg gcaggaaagct 11160
crtgtacctg caggagctgc ccaggaggaa ccaactacatc tttactgca aagaccagca 11220
ccatggggcc ctgtccaca tggaaagct tgggggttagg gggcttgcgt gggctctgt 11280
gtccgtccccc acgggtctgtg cctctggaaag cccggtaaagc cagcaccacc atgcccgtgc 11340
atgggggaaaggaa aggaagcccc ctgtggccgc tttcatgtgc cgggcacccgc tgggcacccg 11400
gtccaaagtac ctgaaagtggg aatggggatgg gccaggcagg gacagacatg gccctcgtg 11460
acatgaacct gccaaggccc acttctgggg tctcgggtt aggagggtca ccttaagggg 11520
gagggtcacc ttaagcgtcc taagagactt ctcatgggg cagggacccct ccagggcagg 11580
agggtggccg gtgcctctgg gagacaaggctt ccctccagggtt gagggtctgtg accctcgagg 11640
gtggcatgg gagctccca ggtcccttgg ggttgcggag tggcttggag agtccccggcc 11700
actgtccccctt ttcctgggg aactctcatct gggcagtgc tgccttcctt gtcccccgtc 11760
ccacccctga gctctcatcc attctcaagt ctctcttctt gctgtccgg tgcgtggctca 11820
tgcccatctc ttctgtcccccc ggcacccacc cagagctctg gtccacttcc ggttcttc 11880
ccttgcctg gtgtggccatctt cctctgtcccccc cagcccccacc cccggagctctt 11940
gatccactctc caggccatctc cccctgtctt ggtgtggccatctt cgtggcgttc tcccttcggc 12000
atctgtcccccc tgcaggcccg tgcgtgttc cccacgtccgg ctcaactggc caccatccatctt 12060
gcagggttaga attctgtatac caacccgggg gccctggaaag aatctaagaa attgggtcag 12120
cccaaggacatctt tctcggagga ggcacatctt cagcccccgtc agacgggtga ggatgggtgt 12180
gcccaggatctt ctgtgtccccctt ctgtgtgtc tgcgtgtat ctccaggatgtc ccatgacccccc 12240

catgtccctcc catgtcccccc gatattccca tggccccca gtcctcccg agggggctccc 12300
gggcctcggtt tagegtccctc ctcatggag gtcctgtgt ctgggctcg agtgggtctg 12360
gggcctcgcg ctctggctg cgtggggc tggggctccg cactctggc tgcgatggg 12420
tctggggctc cgcgcgtctg gtcgcgttg gtcctggggc tctgagctct gggtctgtat 12480
ggggctcggg ccctgttcta gggcccttc taatccctgg gttttcttg gtctctgcag 12540
gaagctcgctt tcccaaacac tagggtgagt gaggctttag gagggcactg gacaaagccca 12600
gaggtctggg ttcccggggt tgcagggtat atctgtctg gcccctccca tcccacacag 12660
ccaggagac ccccccaggg tcaggcacga ggttggcacc tcagactctg cccacccaca 12720
gttcttggaa catttggaa gtccttgtt ttatcatcc tgcacccctgc agcccgagtg 12780
agggtctcc tgggccttc cacagegagg ccccccctcg gtcctcttag gtgtcagtc 12840
accccategc cccctgcacc tgcattccacg cggtccactc cccacccatc accccaccaag 12900
gatgtcaga ggcctgcca gtcatttggag gagctgagggt cgctctggag ccccgagggt 12960
gcccgacgtt ggcctgttg gggctcgac agccctggga gggagctctg gcccctggct 13020
ctggccatcc ctgcgcgttc cctgcgttctt gtcctcttc ccagcacacg agccccggg 13080
tctgcacccctc cagagccac cttaccacca gacacagacg cgggaccacc tggacccatcc 13140
ctccagccat gacccttccc tgcattccacc cacctgactc caaataaaagt ctttctccccc 13200
cagctctggg caggcctata tgcattggaca gaggggcttg cacccgttcc ctgggagggtc 13260
tgcgtggagg gggagccaca agggaaatgtt gggagatgtt gacccatgtca agggccaaac 13320
cacaagggc acgtatgtcca acaggcctgtt ggggtcggt gtgtccctgg aggggcctcc 13380
ggaagagccg ccctcagggtc tcaagggttca cttaggacag ccaggccctt gggcaggagc 13440
gtttggaaat ccactggggaa ggacaggagc ggggacacgg cgtcagggtt gcaaggatgg 13500
ggccacccgca gggctcccgcc tcaagggttca ctagagggtt cttccaaatctt 13560
agcagctgg gtcagtgcc agcactggag a 13591

United States Patent & Trademark Office
Office of Initial Patent Examination -- Scanning Division



Application deficiencies found during scanning:

Page(s) _____ of _____ were not present
for scanning. (Document title)

Page(s) _____ of _____ were not present
for scanning. (Document title)

Scanned copy is best available. *Some of the images are
Very Dark & Some are
faded*